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1. Asthma
Asthma is characterized by pulmonary inflammation and episodic reversible airway
obstruction along with increased reactivity of airway smooth muscle to a wide variety of
chemical, pharmacological or physical stimuli. It is currently accepted that asthma can be
subdivided into two categories, although the two forms are not always strictly seperated.
In the first category asthma is associated with atopy, the second category comprises the
non-atopic asthmatics. The majority of patients suffer from atopic asthma, although the
number of non-atopic patients is increasing. The most striking difference between atopic
and non-atopic asthma is the serum IgE, which is increased in allergic asthma (1) whereas
no elevated IgE levels can be detected in non-atopic asthma (2, 3). Amin and coworkers
recently showed that besides the difference in serum IgE levels, atopic and non-atopic
patients had different pathological changes present in their airways despite their similar
clinical respiratory symptoms (4). Atopic patients have increased numbers of eosinophils
in their airway tissue, whereas non-atopic asthma is dominated by the infiltration of
neutrophils. A common feature observed in both groups is a significant involvement of
inflammatory cells, either pulmonary resident, such as macrophages and mast cells, or
infiltrated inflammatory cells, such as eosinophils, neutrophils and lymphocytes. In addition,
tissue resident structural cells including endothelial cells, epithelial cells, fibroblasts and
smooth muscle cells may also be an important source of inflammatory mediators in asthma
(5).
2. Autonomic regulation of the airways
Inhibitory NANC nervous system
Inhibitory NANC nerves contain vasoactive intestinal peptide (VIP) and nitric oxide (NO).
VIP is a potent relaxant of the airways. VIP and NO seem to counteract the
bronchoconstriction. VIP also has been suggested to inhibit mediator release from mast
cells by elevating the level of intracellular cyclic AMP (14). Undem and coworkers (15)
reported that VIP inhibited antigen-induced histamine release. In cats, Miura and coworkers
(16) demonstrated that NANC inhibitory electrical nerve stimulation inhibited antigen-
induced bronchoconstriction and histamine secretion from histamine containing cells.
Although dysfunction of inhibitory NANC nerves has also been proposed in asthma, no
differences in inhibitory NANC responses have been found between asthmatics and healthy
subjects (13, 17).
Excitatory NANC nervous system
In addition to inhibitory NANC efferent systems in the airways, there is a NANC afferent
nervous system that protects the airways against inhaled irritants and chemical particles
(6, 13, 17) . These excitatory NANC nerves play a regulatory role in airways. Their activation
results in maintenance of pulmonary homeostasis via reflex pathways such as
bronchoconstriction, mucus secretion, and cough. Excitatory NANC nerves innervate the
airways of humans and other mammalian species (18).
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Excitatory NANC nerves or so called sensory nerves are mainly localized between
and beneath the airway epithelium. These sensory nerve fibers are also present in the
vicinity of blood vessels and submucosal glands, and make direct contact with the smooth
muscle layer and local tracheobronchial ganglion cells (19-21). The excitatory NANC nerves
can be activated by different stimuli, that affect the chemosensitive C-fiber afferents in
the airways and can lead to the local release of neuropeptides via axon reflex mechanisms
(22). The tachykinins and calcitonin gene-related peptide (CGRP) are the predominant
excitatory NANC-neuropeptides in the airways (23). These neuropeptides contract airway
smooth muscle, dilate bronchial arteries, increase vascular permeability, increase mucus
production and modulate ganglionic transmission. In addition, they are certain to influence
the recruitment, proliferation and activation of inflammatory cells such as mast cells.
The effects of tachykinins result from signal transduction initiated by the interaction
of tachykinins with specific receptors on effector cells. Three distinct subtypes of mammalian
receptors have been identified and denoted as neurokinin 1 (NK-1), neurokinin 2 (NK-2)
and neurokinin 3 (NK-3), which have the highest affinity for substance P, Neurokinin A en
B, respectively (18, 23, 24). The tachykinin NK-3 receptors are predominantly present in
the central and peripheral nervous system (25). Tachykinin NK-1 receptors are localized
on smooth muscle cells, submucosal glands, blood vessels and inflammatory cells (24,
26). The NK-2 receptor is also found on smooth muscle. Animal studies have shown that
the NK-2 receptors are involved in bronchoconstriction, whereas activation of tachykinin
NK-1 receptors leads to neurogenic inflammation (27, 28).
3. Neurogenic inflammation
Neurogenic inflammation has been shown to occur in different tissues, including the skin,
urinary tract, the digestive system and airways (19, 26, 29, 30). Neurogenic inflammation
involves a change in function of sensory neurons due to inflammatory mediators, inducing
an enhanced release of neuropeptides from the sensory nerve endings (31, 32). With the
close proximity of mast cells and nerves to blood vessels in most tissues, these three
components may be considered as an important functional unit in neurogenic inflammation
(33).
Sensory neurons are characterized by their expression of a certain group of
neuropeptides, the tachykinins such as substance P and neurokinin A. Tachykinins released
from sensory nerves induce a wide range of inflammatory reactions including vasodilatation,
increased vascular permeability, bronchoconstriction and adherence of inflammatory cells
to the endothelium thereby facilitating cellular infiltration (18, 28). The effects produced
by tachykinins (substance P, neurokinin A and neurokinin B) and CGRP released from
peripheral endings of capsaicin-sensitive primary sensory neurons, are collectively referred
to as neurogenic inflammation (34)(figure 1). Several studies have shown a role for
neurogenic inflammation in the induction of airway hyperresponsiveness in animal models
(35-37).
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 4. Tachykinins and asthma
Substance P, neurokinin A and CGRP are present in airways of various mammals including
man (19, 20). Both animal and human data strongly suggest a role for tachykinins in the
pathogenesis of asthma. The role of excitatory NANC nerves, especially the tachykinins,
has been described in animal models for atopic and non-atopic asthma (13, 17, 35, 38).
Exposure of guinea pigs to an aerosol of either capsaicin or substance P elicited
airway hyperresponsiveness to bronchoconstrictor agents (37, 39-41). Recently, Ricciardolo
and coworkers (42) have demonstrated that aerosolised neurokinin A caused a profound
increase in total pulmonary resistance in guinea pigs, that was abolished by the combination
of a NK-1- and a NK-2-receptor antagonist. Many more animal studies show that capsaicin-
induced depletion of excitatory NANC neuropeptides or treatment with tachykinin receptor
antagonists prevent airway responsiveness and pulmonary inflammation. For instance,
airway hyperresponsiveness induced by ovalbumin (39), platelet-activating factor (43),
toluene diisocyanate (44), dinitrofluorobenzene (35) or respiratory viral infection (39) can
be attenuated by interruption or blockade of the excitatory NANC system. These data
support the concept that excitatory NANC nerves are an important factor in the pathway
leading to characteristics as hyperresponsiveness and inflammation as seen in asthma.
Immunohistochemical studies of neuronal tachykinins in airways of asthmatics have
yielded conflicting results. While in some studies an increase in both the number and
Figure 1. Schematic drawing of neurogenic inflammation in the airway via the release of
neuropeptides from sensory nerve terminals.
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length of tachykinin-immunoreactive nerve fibres was found in the airways (45, 46), others
have detected significantly less substance P-like immunoreactivity in lung tissue from
asthmatic compared to non-asthmatic patients (47, 48). However, this latter finding may
reflect augmented release of substance P followed by degradation (48).
Studies on autopsy tissue (48), plasma levels (49), lung lavage fluid (46) and
sputum (50) suggest that tachykinins are present in increased amounts in asthmatic airways.
In addition, tachykinin levels can be elevated during exacerbations of asthma (51).
Substance P and neurokinin A elicit bronchoconstrictor effects of in asthmatic patients
(22). Neurokinin A causes bronchoconstriction not only in asthmatics, but also in normal
persons with the asthmatics being more sensitive than normal subjects (52, 53). Asthmatics
were found to be hyperresponsive to substance P and neurokinin A (54). Effects of
tachykinins on bronchial responsiveness in man are less well studied. Inhalation of substance
P was found to enhance the maximal airway narrowing to metacholine in patients with
asthma (55). This effect was observed 24 h after inhalation of substance P. An increase in
mRNA transcripts for both tachykinin NK1 and NK2 receptors has been observed and possible
changes in tachykinin receptor expression are found in asthma (56).
5. Mast cells
Mast cells are widely distributed throughout the body in connective tissues, particularly
around blood vessels and nerves (57). They are abundant in the submucosa of the digestive
tract (58), oral and nasal mucosa (59), respiratory mucosal surfaces (60) and skin (57,
61, 62).
Mast cells are involved in the regulation of their own overall tissue cell mass since
mast cell degranulation leads to an overall increase in mast cells (63). Many factors are
involved including generation and secretion by mast cells of factors such as GM-CSF, SCF
and NGF which are all known to promote mast cell growth (64, 65).
Mast cells can be divided into various subpopulations with distinct phenotypes.
There are two primary mast cell subtypes, the connective tissue mast cells (CTMC) and the
mucosal mast cells (MMC), who differ markedly in their phenotypical and functional
characteristics (66, 67). However, environmental factors such as cytokines, may induce
differentiation in many more phenotypically different subsets (68). CTMC and MMC are
considered to be derived from a common precursor in the bone marrow. Mast-cell progenitor
cells originate from the bone marrow as undifferentiated cells that enter specific tissues
and mature under microenvironmental influences. Their development and survival essentially
depends on stem cell factor (SCF) and its receptor c-kit (69). Besides SCF, cytokines such
as IL-3, IL-4 and IL-10 influence mast cell growth and differentiation (70), as does nerve
growth factor (NGF) (71).
Mast cells are versatile cells capable of synthesis of a large number of pro- and
anti-inflammatory mediators including cytokines, products of arachidonic acid metabolism,
serotonin, histamine and growth factors including NGF and SCF. These mediators are pre-
stored or can be newly synthesized upon stimulation. Pre-stored mediators, such as
histamine, serine proteases, proteoglycans, sulfatases and TNF-α, are released within
      Introduction      13
minutes after degranulation of the cell (72). After this primary response a second wave of
newly synthesized mediators are released and include PGD2, LTC4, LTD4 and LTE4.
Subsequently, cytokines like IL-4, IL-5, IL-6, IL-8, IL-13 and TNF-α are induced and secreted
(72).
Mast cells are best known for their involvement in type I hypersensitivity, allergic
or anaphylactic reactions involving the interaction with IgE (73).  However, mast cells also
play a prominent role in non-IgE mediated hypersensitivity reactions (74-76). It was shown
that upon skin sensitization, lymphocytes are induced to produce and release hapten-
specific factors recently recognized as immunoglobulin light chain (IgLC)(77). IgLC will
bind to mast cells and mediate an early and late phase of a pulmonary hypersensitivity
reaction (78, 79).
The sensitivity of mast cells to activation by non-immunological stimuli as polycationic
compounds, complement proteins, superoxide anions or neuropeptides is dependent on
the population of the mast cells examined (80). A major distinction between the classical
CTMC and MMC is their difference in responsiveness to non-immunological activators like
neuropeptides. It has been reported that mast cells of mucosal origin including BMMC are
not activated by neuropeptides (81), whereas CTMC were shown to respond significantly
to stimulation by these compounds (81, 82).
Mast cell activation by neuropeptides do not need to involve one of the known NK
receptor subtypes. Activation can be induced via direct interaction with pertussis toxin-
sensitive G proteins through the N-terminal domain located in the inner surface of the
plasma membrane (83, 84). Stimulation of G-proteins will activate a signal transduction
pathway eventually leading to mast cell mediator production and release. However, it has
been suggested that functional NK receptors are present on mast cells (85-87). Activation
of the neurokinin receptors is dependent on the C-terminal domain of the tachykinins. In
conclusion, activation of mast cells by tachykinins can either be receptor- or non-receptor-
mediated. This process is highly influenced by their microenvironment, which is affected
by pathological inflammatory conditions such as asthma.
6. Mast cell-nerve interaction
Histological studies reveal an intimate association between mast cells and neurons
in both the peripheral and central nervous system (88). A close anatomical relationship
between mast cells and substance P-containing sensory nerve endings has been reported
in various tissues including skin (62, 89), intestine (90), dura mater (91, 92) and airway
mucosa (61, 89). Other than an anatomical link, mast cells also form a functional link
between the immune and nervous systems and mast cells appear to act as bi-directional
carriers of information. Neuronal mechanisms are involved in mast cell activation and
mast cells act as principle transducers of information between peripheral nerves and local
inflammatory events (93). Peripheral nerves are highly populated with mast cells and
manipulation of these peripheral nerves causes changes in mast cell densities (94).
Sensory neurons play a role in neurogenic inflammation (31, 95). It has becoming
apparent that also the mast cell and its mediators are important in  neurogenic inflammation
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(33, 96). Association with the nervous system allows mast cells to act as sensory receptors
for a variety of potentially noxious and newly encountered substances (97). They are
therefore ideal to act in these ways to pass information on through afferent nerves to local
tissues by axon reflexes. In various studies, tissue mast cells invariably show ultrastructural
evidence of activation even in normal healthy conditions, suggesting that these cells are
constantly providing information to the nervous system (91). The fact that they are located
at sites under constant exposure to the external environment, such as the skin, respiratory
and gastro-intestinal tract, emphasizes the significance of these associations.
The most evident neuronal response to mast cells is mast cell mediator-induced
activation of sensory nerves causing the release of tachykinins such as substance P and
neurokinin A (32, 98). Aside from the generation of action potentials, the C-fiber terminal
is a secretory system, releasing tachykinins to cause neurogenic inflammation. Stimulation
of these C-fibers by a range of chemical and physical factors results in afferent neuronal
condition eliciting parasympathetic reflexes and antidromic impulses traveling along the
peripheral nerve terminal. Such communication from one nerve to another, without passing
through a cell body, is called the axon reflex and results in local release of tachykinins and
CGRP from C-fiber terminals (figure 2) (23). Axon reflexes account for many of the local
physiological responses to antigen for instance in sensitized lung (99, 100) and gut tissues
(101), and have long been recognized to be involved in local vasodilatation in the skin
(102). Antidromic stimulation of guinea pig vagal sensory fibers results in contractions of
the isolated airway smooth muscle mediated by tachykinins (103). Further studies indicate
that neuropeptide release can also be induced via direct depolarization of the terminal
(104).
Figure 2.  Representation of the involvement of the mast cell in the axon reflex. Stimuli activate
sensory nerve fibers inducing the release of neuropeptides from the nerve terminals. This
will induce mediator release from adjacent mast cells leading to further activation of other
sensory nerve endings.
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7. Mast cells and tachykinins
The relationship between mast cells and neurons seems to be bidirectional. Mediator release
from mast cells can on one hand be induced by tachykinins and, on the other hand, cause
the release of tachykinins from nerve endings (105).
Mediator release from mast cells can be induced by tachykinins like substance P
and neurokinin A (92, 106). Stimulation of nerve fibers of humans and mammals induces
mast cells to degranulate and release histamine and other mediators such as serotonin
(107) and TNF-α (87). Janiszewski and coworkers (108) reported that mast cells respond
electrophysiologically to very low concentrations of substance P without degranulation,
but that degranulation occurred after repeated doses. These data indicate that substance
P may act as a priming substance rather than a substance causing direct degranulation.
Many studies have shown that mast cell-derived mediators such as histamine,
serotonin and cytokines modulate NANC neurotransmission (105, 109, 110). Furthermore,
NANC nerve endings express receptors for histamine (H1 and H3) and serotonin (5-
HT2a)(111-113), and histamine H1 receptor expression at least is upregulated on primary
NANC nerves in inflammation (114). Mast cell mediators like TNF-α can sensitize afferent
C fibers by lowering their treshold (109, 115) but can also cause direct release of substance
P, neurokinin A and CGRP from unmyelinated fibers (105).
Priming may be a prominent aspect of nerve-mast cell interactions. Mast cells have
been reported to be primed by different cytokine growth factors for subsequent different
agonists (116). The concept of priming also applies to neurons. For instance, TNF-α may
exert a priming, rather than a direct stimulatory effect on sensory activity (115, 117,
118).
8. Aim and scope of this thesis
From the previous paragraphs, it is clear that both mast cells and sensory neurons may
play an important role in the development of atopic and non-atopic asthma. The goal of
this thesis is to study mast cell-nerve interactions in vitro using primary cultured mast
cells and neurons and in vivo, in a murine model for non-atopic asthma. Features of the
murine model for non-atopic asthma are described in chapter 2. Chapter 3 focusses on
the role of the tachykinin receptors in the development of non-atopic asthma using specific
NK-1 or NK-2 receptor antagonists and genetically NK-1 receptor-deficient animals. We
hypothesize a role for mast cells in the pathogenisis of non-atopic asthma. To explore this
role, we studied hypersensitivity reactions associated with non-atopic asthma in genetically
mast cell-deficient and congenic normal mice. TNF-α, a major mediator released from the
mast cell, is studied in chapter 5. The role of TNF-α in our model was investigated by
neutralizing anti-TNF-α antibodies. TNF-α receptor antibodies were used to identify which
receptor subtype is involved in DNFB-induced tracheal hyperreactivity. Previously, we and
other investigators have demonstrated that both TNF-α and substance P are involved in
the inflammatory process associated with airway diseases. These two mediators also form
a possible interaction between the neurologic and the immune system. Therefore, we
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explored the effects of TNF-α and substance P on tracheal hyperreactivity and cellular
accumulation in mice by intranasal application of TNF-α and substance P by itself or in
combination. To further examine the mast cell-nerve interaction, we continued our studies
in vitro. Primary mast cells were cultured (chapter 7) and sensitivity to substance P
stimulation was studied under different culture conditions. We analyzed NK-1 receptor
expression on these groups of primary mast cells and investigated the involvement of NK-
1 receptors as a possible activation pathway. An in vitro coculture system of mast cells and
neurites, to study direct interactions, is described in chapter 8. The main results obtained
in this thesis are summarized and discussed in the final chapter (chapter 9: summarizing
discussion).
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Abstract
 Asthma is characterized by episodic reversible airway obstruction along with bronchial
hyperresponsiveness and airway inflammation. The majority of the patients suffer from
atopic asthma, although the number of non-atopic asthmatics is increasing. The mechanisms
involved in non-atopic asthma are poorly defined. In this chapter we describe a murine
model for non-atopic asthma. Non-atopic asthma was induced in mice by skin sensitization
with dinitrofluorobenzene (DNFB) followed by intranasal challenge with dinitrobenzene
sulfonic acid (DNS). Features of the early phase pulmonary reaction included acute
bronchoconstriction and mast cell activation shortly after challenge. Acute
bronchoconstriction was observed in DNFB-sensitized mice immediately after DNS challenge
and reached its maximum at 5 min after challenge. PenH values, a dimensionless value to
monitor airway function, slowly returned to basal levels 15 min after the challenge. Mast
cell activation, as measured by increase in serum mast cell protease-1 (mMCP-1), was
observed in both early phase (0-3 h after challenge) and late phase responses (24-48 h
after challenge). The most prominent rise in mMCP-1 was observed 30 min after intranasal
hapten challenge. Tracheal hyperreactivity and mononuclear and neutrophilic cell infiltration
were observed 24 and 48 h after the challenge. At both time points significant increases
were seen in DNFB-sensitized mice compared to vehicle-sensitized animals. Although the
infiltration of cells was comparable at both time points, the difference in reactivity between
DNFB-sensitized animals and vehicle-sensitized mice was more profound at 48 h. Therefore,
this time point was chosen in following studies to assess late phase features such as
tracheal hyperreactivity and cellular accumulation.
Introduction
Delayed type hypersensitivity (DTH) or cell-mediated immunity plays a major role in the
pathology and chronic aspects of many inflammatory disorders. Cell-mediated reactions
are primarily investigated in the skin. It has become apparent that similar reactions can
also occur in the airways (1) and the intestine (2) of sensitized animals after local antigen
challenge. These reactions in the lung and the intestine are not mediated by IgE and will
be referred to as non-atopic reactions in this thesis.
The cell-mediated reactions can be divided into three major subsets (Th1, Th2 and
Th3) based on distinct cytokine profiles. Type I lymphocytes predominantly produce IL-2
and IFN-γ. Type II lymphocytes mainly produce IL-4/IL-5 whereas Type III lymphocytes
are characterized by the production of IL-4 and TGF-β (3, 4). Previous studies have
demonstrated that T helper-1 cells play a role in the induction of airway hyperresponsiveness
associated with non-atopic asthma (5).
Asthma can roughly be divided into two categories. In the first category asthma is
associated with atopy, the second category comprises the non-atopic asthmatics. The
majority of patients have atopic asthma, characterized by an elevation of total and allergen-
specific IgE in serum (6). The second category comprises the non-atopic asthmatics. Non-
atopic asthmatics are skin test negative to common allergens and there is no evidence of
allergen-specific serum IgE (7, 8). Amin and coworkers recently showed that besides the
difference in serum IgE levels, atopic and non-atopic patients had different pathological
changes present in their airways despite their similar clinical respiratory symptoms (9).
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Atopic patients had increased numbers of eosinophils in their airway tissue, whereas non-
atopic asthma is dominated by the infiltration of neutrophils. The number of mast cells
showed a similar increase in both of the groups.
Non-atopic asthma is an increasing problem in the developed world. The mechanism
involved in the induction and on-going respiratory impairments associated with non-atopic
asthma are poorly investigated. Mast cells and lymphocytes showed to play an important
role in non-atopic reactions in mouse skin, airway and intestine (2, 10, 11). It has been
hypothesized that upon skin sensitization, lymphocytes are induced to produce and release
hapten-specific factors recently recognized as immunoglobulin light chain (IgLC)(12). IgLC
will bind to mast cells and mediate an early and late phase of a pulmonary hypersensitivity
reaction (13, 14).
 Low molecular weight substances (<5000 Da) are the most common agents causing
non-atopic asthma (15). In the mouse, picrylchloride and toluene diisocyanate (TDI) have
been shown to induce pulmonary hypersensitivity reactions. In the present study, a
hypersensitivity reaction was elicited in the airways of mice with the low molecular weight
compound dinitrofluorobenzene (DNFB) as the contact sensitizing hapten followed by
intranasal challenge with dinitrobenzene sulphonic acid (DNS). We will describe this murine
model for non-atopic asthma and its characteristics. In the following chapters 3, 4 and 5
this model will be used to further clarify the mechanisms responsible for DNFB-induced
asthma.
Methods
Animals.  Male BALB/c mice were obtained from the Central Animal Laboratory (GDL),
Utrecht University, Utrecht, The Netherlands. All mice used were 6-8 weeks of age. The
mice were housed in groups not exceeding 10 per cage and maintained under standard
conditions. All experiments were conducted in accordance with the Animal Care Committee
of the Utrecht University (Utrecht, The Netherlands).
Sensitization and experimental procedure. Mice were sensitized on day 0 with either DNFB
(0.5% dissolved in acetone: olive oil [4:1] or vehicle control, both of which were applied
epicutaneously to the shaved thorax (50 µl) and all four paws (50 µl). On day 1, DNFB or
vehicle control (50 µl) was applied to the thorax alone. DNFB- and vehicle-sensitized mice
were intranasally challenged with dinitrobenzene sulphonic acid (DNS, 50 µl 0.6 % in PBS,
pH 7.2) on day 5. The sensitization and challenge were performed under light anesthesia
(pentobarbitone, 40 mg/kg i.p.).
Mast cell activation in vivo. Mouse mast cell protease 1 (mMCP-1) is a protease specific for
mouse mast cells, that appears in the blood after mast cell activation. To monitor mast cell
activation in time, blood samples of DNFB and vehicle sensitized mice were taken 10, 30
min and 3, 6, 24 and 48 h after intranasal DNS challenge. Blood samples were collected
and after centrifugation sera were stored at 70ºC until use. Levels of mMCP-1 were
measured using a commercially available ELISA assay. 96 Wells flat bottomed Nunc-
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immunoplates were coated with 50 µl sheep anti-mMCP-1 antibody (1 µg/ml in 0-1 M
carbonate buffer, pH 9.6) in a humid chamber at 4ºC for 24 h. Plates were washed 5 times
with PBS/Tween 20 (0.05% v/v) and were incubated for 30 min with 50 µl 1% BSA/PBS/
Tween 20 at 4ºC to block the residual binding sides. After 5 wash steps, plated were
loaded with 50 µl mMCP-1 standard (0-20 ng/ml) or 1:5 diluted samples and the plates
were incubated overnight at 4ºC. Subsequently, after washing the plates were incubated
with rabbit anti-mMCP-1-horse radish peroxidase conjugate (1:300, 50 µl) for 2 h at 4ºC.
Plates were washed again 5 times and were incubated for 30 min with 50 µl o-
phenylenediamine at room temperature (2.2 mM in 0.1 M citric/phosphate buffer, pH 5.0).
The reaction was stopped by adding 25 µl of 2.5 M H2SO4. The absorption was measured at
492 nm using a microplate reader. The mMCP-1 levels were obtained by comparison of
absorbance of samples with these of the calibration curve.
Acute bronchoconstriction. Bronchoconstriction was measured as reported previously (16).
In short, 5 min before intranasal DNS challenge, unrestrained conscious mice were placed
in a whole body plethysmographic chamber to analyze the respiratory wave forms and
obtain basal line. After 4 min and 30 sec, the mice were challenged under light anesthesia
(inhalation of halothane 3%) and placed back in the chamber where resistance in each
animal was measured over a 5 min period. Airway resistance is expressed as enhanced
pause (PenH) PenH = pause x PEP/PIP
where PEP stands for peak expiratory pressure and PIP for peak inspiratory pressure.
Pause is defined as (Te  Tr)/Tr, where Te stands for time of expiration and Tr stand for the
relaxation time -the time of pressure decay to 36% of the total expiratory pressure signal.
During bronchoconstriction, the changes in the box pressure during expiration are more
pronounced than during inspiration. Thus bronchoconstriction is reflected by an increase
in PenH, a dimensionless value to empirically monitor airway function. After intranasal
challenge, for each mouse maximal PenH readings were taken over 1 min time windows at
the following time points : 2 min 30 sec, 5 min, 10 and 15 min.
Leukocyte accumulation in bronchoalveolar lavage fluid. Bronchoalveolar lavages (BAL)
were performed in mice 24 and 48 h after the challenge. After sacrificing the animals, the
trachea was canulated. Saline (37ºC) was slowly injected into the lung and withdrawn in 4
x 1 ml aliquots. The aliquots were pooled and maintained at 4o C. The lavage fluids were
centrifuged (580 g, 5 min, 4ºC) to isolate the BAL cells. Total cells were counted using a
haemocytometer and expressed as cells/lung. The BAL cell preparations were analyzed
morphologically after centrifugation onto microscopic slides. Air dried preparations were
fixed and stained with hematoxylin and eosin to ascertain  the leukocyte populations.
Results are expressed as leukocytes/lung for neutrophils and mononuclear cells in the
airway lumen.
Tracheal reactivity in vitro.  Mice were killed with an overdose of pentobarbitone at 24 and
48 h after intranasal DNS challenge. The trachea, which was resected in toto, was carefully
cleaned of connective tissue using a binocular microscope as described before (1). A nine
ring piece of trachea (taken from just below the larynx) was then transferred to a 10 ml
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organ bath containing a modified oxygenated Krebs solution (118 mM NaCl, 4.7 mM KCl, 2.5
mM CaCl2, 0.5 mM MgCl2, 25 mM NaHCO3, 1 mM NaHPO4 and 11.1 mM glucose). The trachea
was directly slipped onto two supports, one coupled to the organ bath and the other
coupled to an isometric transducer. The solution was aerated (95% O2: 5% CO2) and
maintained at 37ºC. Isometric measurements were made using a force displacement
transducer and a two channel recorder and measurements were expressed as changes in
milligram (mg) force. An optimal preload, determined to be 1 g, was placed on the tissue
at the beginning of the experiment. The trachea was allowed to equilibrate for at least 1 h
before contractile effects were elicited. During this period, the bath fluid was exchanged
every 15 min. At the end of the equilibrium phase, tracheal contractile reactivity was
measured by recording cumulative concentration response-curves to carbachol (10-8 to 10-
4 M).
Histological examination. At 24 and 48 h after intranasal hapten challenge lungs were
removed from mice after lethal anesthesia with pentobarbitone. I. Lungs were removed
24 h after challenge and filled intratracheally with acetic acid formalin fixing solution
(0.8% formalin, 4% acetic acid). Lungs were fixed for at least 24 h in the fixative, dehydrated
and embedded in paraplast. Four ìm sections were stained with hematoxylin and eosin. II.
Due to optimized histological techniques, the lungs isolated 48 h after challenge were
fixed in 4% formaldehyde in PBS and routinely embedded in GMA (glycol methacrylate)(17).
Serial sections were cut at 3 µm and stained with hematoxylin in combination with eosin.
The parameters were scored according to the method described by Enander and coworkers
(18), as indicated in table 1.
Table 1. Histological score of cellular accumulation in the lung according to the method
  of Enander and coworkers (18).
Accumulation of
mononuclear  cells
0 1 2 3
Diffusely around
Bronchioli
No
Cells
< 10 cells
layers thick
> 10 cell
layers thick
Entirely surrounding
bronchiolus > 10 cell
layers thick
Around blood
Vessels
No cells ≤ 3 cell layers
thick
4-10 cell layers
thick
≥ 10 cell layers thick
Materials. DNFB and olive oil were purchased from Sigma Chemical Co., St. Louis, USA.
Hematoxylin and eosin were obtained from Sigma Aldrich, St.Louis, MO, USA. GMA came
from Merck, Darmstadt, Germany. Sodium pentobarbitone was obtained from Sanofi,
Maassluis, The Netherlands. Carbachol was purchased from Onderlinge Pharmaceutische
Groothandel, Utrecht, The Netherlands. The mMCP-1 ELISA was from Moredun Scientific
Ltd., Midlothian, UK. Maxisorp surface 96 well plates were purchased from Nunc Immuno
plate, Roskilde, Denmark. The whole body plethysmographic chamber (Buxco) was obtained
from Buxco Electronics, Inc. Shanon, CT. The force displacement transducer was purchased
from Harvard Bioscience, Boston, MA, USA and the two channel recorder (Servogar type
SE-120) from Plato BV, Diemen, the Netherlands.
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Statistical analyses. Data are expressed as mean and standard error of the mean (SEM).
EC50- and Emax-values for the carbachol-induced tracheal contractions were calculated
by non-linear least-squares regression analysis of the measured contractions versus
carbachol concentration using the sigmoid concentration-response relationship. The data
were analyzed by performing a two-way analysis of variance (ANOVA). Data on the cellular
accumulation in BAL fluid were processed by a distribution free Kruskal-Wallis ANOVA and
the non-parametric Wilcoxon rank test was used to determine the significance of differences
of histological scores. mMCP-1 data were analyzed by using a one-tailed unpaired  t-test.
Probability values of P<0.05 were considered significantly different. Analyses were performed
by the usage of Graphpad prism (version 2.01, San Diego, U.S.A).
mMCP-1 (ng/ml serum)
Time after challenge Vehicle DNFB
10 min 4.1 ± 0.5 9.1 ± 1.2*
30 min 5.4 ± 1.1 19.0 ± 3.8*
2 h 7.5 ± 2.1 15.7 ± 3.6*
3 h 4.1 ± 1.0 8.3 ± 1.4*
6 h 3.5 ± 0.7 5.3 ± 0.8
24 h 4.4 ± 0.4 10.7 ± 2.6*
48 h 3.9 ± 1.5 9.8 ± 1.8*
Table 2. mMCP-1 levels in serum of vehicle- and DNFB-
sensitized mice 10, 30 min and 2, 3, 24 and 48 h after intranasal
DNS challenge.
Results are expressed as mean (ng/ml serum) ± SEM, n=6-12
mice per group. Significant differences between the vehicle-
sensitized and the DNFB-sensitized group are denoted by (*)
for p<0.05.
Results
Mast cell activation in vivo.
The appearance of mMCP-1 in the
blood is indicative for the
activation of mast cells (19).
DNFB sensitization followed by
intranasal DNS challenge resulted
in a biphasic mast cell activation.
An early rise was found 10, 30
min and 3 h after challenge in
serum of DNFB-sensitized and
DNS-challenged mice compared to
vehicle-sensitized, DNS-
challenged mice (table 2). The
Figure 2. Acute bronchoconstriction is found in DNFB-sensitized BALB/c mice after intranasal DNS challenge.
Bronchoconstriction is characterized by increases in Penh values, which were recorded in vehicle- and DNFB-
sensitized mice 5 min before until 15 min after the challenge. For each mouse max PenH readings were taken
over 1 min time windows at 0, 2 min 30 sec, 5, 10 and 15 min. * p<0.05, n=6 mice per group.
Acute bronchoconstriction. Intranasal challenge
was accompanied by an acute bronchoconstriction
in DNFB-sensitized mice compared to vehicle-
sensitized mice, as monitored by an increase in
PenH values. Immediately after challenge Penh
values increased, reaching a maximum 5 min after
challenge. PenH values gradually returned to basal
levels 15 min after the challenge (figure 2).
most prominent rise in mMCP-1 was observed 30 min after intranasal hapten challenge. No
significant increase was found 6 h after challenge whereas in the late phase (24-48 h)
mMCP-1 levels were again significantly enhanced in DNFB-sensitized mice compared to
control animals.
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Tracheal reactivity.
The intranasal hapten application in DNFB-sensitized mice resulted in a tracheal
hyperreactivity reaction to carbachol 24 h and 48 h after the challenge (Emax 24 h; Con:
2020 mg ± 180 mg, DNFB: 2841 mg ± 201 mg. n=6; p<0.05. Emax 48 h; Con: 2095 mg
± 175 mg, DNFB: 3203 mg ± 133 mg. n=6; p<0.05)(figure 3). Because the increase in
reactivity was more profound at 48 h after challenge, this time point was chosen in
following studies to measure tracheal hyperreactivity.
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Figure 3. Mice were vehicle- or DNFB-sensitized and DNS challenged. Concentration-response curves were
measured in DNFB- (closed circles) or vehicle- (open circles) sensitized mice 24 (A) and 48 h (B) after DNS
challenge. Results are expressed as mean ± SEM (n=6). Significant differences between curves are denoted by
(*) or (**) for p<0.05 and p<0.01, respectively.
Sensitization Total cells mononuclear cells neutrophils
(x1000 cells/lung) (x1000 cells/lung)
24 h after challenge
    Vehicle 22.5 (21.0-31.5) 22.3 (20.1-29.4) 1.6 (0.9-2.0)
    DNFB 40.5 (37.5-52.5)* 36.1 (33.1-47.3)* 5.0 (3.6-5.7)*
48 h after challenge
    Vehicle 23.3 (16.5-31.5) 22.6 (15.5-31.0) 0.7 (0.5-1.5)
    DNFB 40.0 (33.0-46.5)* 35.1 (29.7-43.2)* 3.6 (2.8-5.4)*
Table 3. Total, mononuclear and neutrophil cell numbers in BAL fluid. Mice were skin-sensitized with DNFB or
vehicle and i.n. challenged with DNS. Cellular accumulation was studied studied 24 and 48 h after challenge.
Results are expressed as median (min-max) (n=6 animals/group). Significant differences between the vehicle-
sensitized and the DNFB-sensitized group are denoted by (*) for p<0.05.
DNFB-induced leukocyte accumulation in bronchial alveolar lavage fluid.
An increase in cellular accumulation was found in DNFB-sensitized, DNS-challenged mice 24
and 48 h after the challenge. The total cell counts from lung lavages from DNFB-sensitized
mice differed significantly from vehicle-sensitized mice at both time points (table 3). Broncho-
alveolar cells in these mice mainly consist of mononuclear cells and neutrophils. Both the
numbers of mononuclear cells and neutrophils showed to be significantly increased in DNFB-
sensitized animals compared to control mice at both 24 and 48 h after hapten challenge
(table 3).
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Histological analysis. Within one day after intranasal DNS challenge, an accumulation of
inflammatory cells around bronchioli and pulmonary blood vessels was induced in animals
sensitized with DNFB. On the other hand, in vehicle-sensitized mice, DNS challenge did
not result in cellular infiltration. Overall, a significant accumulation of inflammatory cells
was seen in DNFB-sensitized mice around the bronchioli and around the blood vessels
compared to vehicle-sensitized animals (table 4, figure 5 and 6). Differences between
sensitized and control mice were shown to be significant at both 24 and 48 h after DNS
challenge (table 4). No significant differences were observed between the two time points.
Accumulation of inflammatory cells
Treatment Around
bronchioli
Around
blood vessels
24 h Vehicle 0.53 ± 0.08 0.17 ± 0.06
DNFB 0.94 ± 0.04* 0.38 ± 0.02*
48 h Vehicle 0.49 ± 0.09 0.17 ± 0.12
DNFB 0.79 ± 0.10* 0.30 ± 0.17*
Table 4.  Cellular infiltration in the lung. Mice were
skin-sensitized with DNFB or vehicle and challenged
intranasally with DNS. 24 and 48 h after challenge
lungs were removed and studied for cellular
infiltration (see Methods). Results are expressed as
mean ± sem (4 mice/group). Significant differences
between the vehicle-sensitized and the DNFB-
sensitized group are denoted by (*) for (p<0.05).
A
A B
Figure 4. Lung of vehicle-sensitized mouse challenged with DNS. Specimen was taken 24 h after challenge. A.
Blood vessel (x25), B. Bronchiolus (x40). No cellular infiltrates are found.
Figure 5. Inflammatory response to DNFB-sensitized in mouse challenged with DNS. Specimen was taken 24
h after challenge. A. Blood vessel (x25), B. Bronchiolus (x25). Cellular infiltrates were observed.
B
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Discussion
In the present study, we describe a murine model for non-atopic asthma.
A pulmonary reaction was induced in contact sensitized and intranasally challenged mice.
This pulmonary reaction was characterized by an early (0-3 h) and late phase
hypersensitivity response (24-48 h after challenge). Features of the early pulmonary
hypersensitivity reaction included acute bronchoconstriction and mast cell activation. The
late phase was characterized by again mast cell activation, mononuclear and neutrophilic
cell infiltration into the airway lumen and tracheal hyperreactivity. These results support
data presented by previous studies performed in small intestine and airways in which
edema formation, leukocyte accumulation and hyperreactivity were present 24 h after
challenge (1, 20-22). Leukocyte accumulation was demonstrated 24 and 48 h after challenge
in sensitized mice and was dominated by the accumulation of neutrophils. The role of the
neutrophil in this model for non-atopic asthma will be further addressed elsewhere in this
thesis.
The lymphocyte and the mast cell are two of the key inflammatory cells in the non-
atopic response. Upon contact sensitization, lymphocytes are activated to produce hapten-
specific immunoglobulin kappa light chains (IgLC) (12). The hapten-specific IgLC can arm
mast cells (and possibly other cell types)(23). After a second encounter with the antigen
or hapten, the challenge phase, the hapten will multivalent crosslink IgLC bound to the
mast cell, causing activation and subsequent release of mediators. Vaso-active mediators
such as histamine, serotonin and TNF-α increase the micro-vascular permeability and
induce the infiltration of circulating hapten-specific effector cells, generated during the
sensitization. These effector T-cells can recognize antigen in the context of MHC class II on
antigen presenting cells after a second encounter with the hapten. The effector T-cells
are now triggered to produce cytokines leading to the inflammatory response (see figure
1).
Figure 1. Schematic representation of the proposed mechanism leading to hypersensitivity
    reactions in the airways.
hypersenstivity
reaction
mediators
cytokines
allergen/hapten
IgLC
Mast cell
 lymphocytes
APC
T-effector lymphocytes
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Both T lymphocytes and mast cells can be sensitive to sensory neuropeptides.
Since pretreatment of human or guinea pig skin with capsaicin enhanced the cell-mediated
reaction at the site of treatment, it was suggested that capsaicin-sensitive neurons modulate
the reaction via release of neuropeptides (24). It is reasonable to speculate that
neuropeptides, released from sensory nerve endings, play a role in the initiation and
maintenance of inflammatory responses. This will be extensively addressed in the following
chapters of this thesis.
 In summary, our study shows that our murine model for non-atopic asthma is
characterized by bronchoconstriction and mast cell activation in the early phase and mast
cell activation, cellular accumulation and tracheal hyperreactivity in the late phase reaction.
These characteristics bear marked similarity with those observed in non-atopic asthma in
man. Therefore, this model can be used to further study the mechanisms responsible for
the development of non-atopic asthma.
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Abstract
The mechanisms involved in non-atopic asthma are poorly defined. In particular, the
importance of mast cells in the development of non-atopic asthma is not clear. In the
mouse, pulmonary hypersensitivity reactions induced by skin sensitization with the low
molecular weight compound dinitrofluorobenzene (DNFB) followed by an intra-airway
application of the hapten have been featured as a model for non-atopic asthma. In the
present study, we employed this model to examine the role of mast cells in the pathogenesis
of non-atopic asthma. Firstly, the effect of DNFB sensitization and intra-airway challenge
with dinitrobenzene sulphonic acid (DNS) on mast cell activation was monitored during
the early phase of the response in BALB/c mice. Secondly, mast cell-deficient W/Wv, Sl/Sld
mice and their respective normal (+/+) littermate mice and mast cell-reconstituted W/Wv
mice (BMMC→ W/Wv) were used. Early phase mast cell activation was found, which was
maximal 30 min after DNS challenge in DNFB-sensitized BALB/c, +/+ mice, but not in
mast cell-deficient mice. An acute bronchoconstriction and increase in vascular permeability
accompanied the early phase mast cell activation. BALB/c, +/+ and BMMC→ W/Wv mice
sensitized with DNFB and DNS-challenged exhibited tracheal hyperreactivity 24 and 48 h
after the challenge when compared to vehicle-treated mice. Mucosal exudation and
infiltration of neutrophils in bronchoalveolar lavage fluid associated the late phase response.
Both mast cell-deficient strains failed to show any features of this hypersensitivity response.
Our findings show that mast cells play a key role in the regulation of pulmonary
hypersensitivity responses in this murine model for non-atopic asthma.
Introduction
Reversible airway obstruction, pulmonary inflammation and increased reactivity of airway
smooth muscle to various stimuli are prominent features of asthma (1, 2). The majority of
patients have atopic asthma, which starts during childhood and is characterized by an
elevation of total and allergen-specific IgE in the serum (3). It is currently accepted that a
subgroup of asthmatics is not demonstrably atopic (4). Non-atopic asthmatics are skin
test negative to common allergens and there is no evidence of allergen-specific serum IgE
(5, 6). Even total serum IgE levels are within the normal range. In addition, there is no
clinical or family history of allergy (5, 6).
Atopic asthma has been extensively investigated. Considerable less information is
available about the pathologic characteristics of non-atopic asthma (7). Very recently,
Amin and coworkers have compared the cellular pattern and structural changes in the
airways of atopic and non-atopic asthmatic patients (8). Both groups of asthmatics had
respiratory symptoms, peak flow variability and bronchial hyperresponsiveness of similar
severity. However, it was clearly demonstrated that in atopic asthmatics high numbers of
eosinophils, mast cells and T lymphocytes characterized the airway inflammation, whereas
non-atopic asthmatics mainly displayed high numbers of neutrophils and mast cells (8).
These findings suggest that there are differences in the extent of the immunopathologic
response of these two types of asthma.
The mechanisms involved in non-atopic asthma are poorly defined. In the mouse,
several investigators have characterized hapten-induced pulmonary hypersensitivity (also
referred to as delayed type hypersensitivity or type IV hypersensitivity) reactions induced
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by skin sensitization followed by an intra-airway application of low molecular weight
compounds such as picryl chloride, toluene diisocyanate and DNFB, as models for non-
atopic asthma (9-13). These pulmonary hypersensitivity reactions were not associated
with an elevated hapten-specific serum IgE (10, 13, 14). The features observed in these
murine models resemble those found in non-atopic asthma and are hapten-induced acute
bronchoconstriction, pulmonary edema, infiltration of neutrophils and mononuclear cells,
in vitro tracheal hyperresponsiveness and in vivo airway hyperresponsiveness. Both the
early (< 3 h) and the late (24 to 48 h) phases of the hapten-induced pulmonary reaction
were found to depend on the presence of T lymphocytes, since in athymic mice airway
hyperreactivity and cellular accumulation were suppressed (10, 12, 15).
Studies in mice contact-sensitized and locally challenged with low molecular weight
haptens suggest that the pulmonary hypersensitivity response consists of a sequence of
interactions between a variety of different cells rather than a direct T cell-mediated event.
The mast cell is an important immunological and regulatory cell involved in the early
mediation of tissue inflammation. Several human studies have suggested an important
role for mast cells in non-atopic asthma. Furthermore, a role of the mast cell in hapten-
induced pulmonary hypersensitivity reactions, the murine model of non-atopic asthma,
has also been suggested (16-18). We hypothesized that mast cells may be critical in the
development of non-atopic asthma.
Thus far no direct proof for the involvement of mast cells in hapten-induced pulmonary
hypersensitivity reaction in the mouse has been presented. Therefore, the present study
was undertaken to investigate the role of mast cells in DNFB-induced hypersensitivity
reaction in the mouse lung. Firstly, the effect of DNFB sensitization and intra-airway challenge
on mast cell activation was monitored during the early phase of the hypersensitivity reaction.
Using genetically mast cell-deficient and congenic normal mice, the role of the mast cell
was further established in this murine model for non-atopic asthma.
Methods
Animals. Male BALB/c mice were supplied by the central animal laboratory (GDL), Utrecht
University, Utrecht, The Netherlands. Male mast cell deficient mice (WBB6F1 W/W
v), their
respective normal littermates (WBB6F1 +/+), mast cell deficient mice (WCB6F1 Sl/Sl
d)
and their respective normal littermates (WCB6F1 +/+) were purchased from the Jackson
Laboratory (Bar Harbor, ME). All mice were used at 6-8 weeks of age, with the exception of
mast cell reconstituted W/Wv mice and age-matched +/+ and W/Wv mice that were used
at 40 weeks of age. All the mice were housed in groups of not exceeding 10 per cage and
maintained under standard conditions. The Animal Care Committee, Utrecht University,
Utrecht, the Netherlands approved all experiments.
Mast cell reconstitution. Selective reconstitution of mast cells in mast cell-deficient W/Wv
mice was carried out by the methods earlier described by Karimi and coworkers (19) and
Williams and coworkers (20) with several modifications. Bone marrow-derived mast cells
(BMMCs) were obtained from WBB6F1 +/+ mice. Bone marrow was aseptically flushed
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from femurs of +/+ mice and cultured for 4 to 5 weeks in complete RPMI (RPMI 1640
medium, which contained 10% FCS, 4 mM 1-glutamine, 0.5 µM β-mercaptoethanol, 1 mM
sodium pyruvate, 100 U/ml penicillin, 100 mg/ml streptomycin and 0.1 mM nonessential
aminoacids). Pokeweed mitogen-stimulated spleen cell conditioned medium (20% v/v)
was added to the culture medium as a source for IL-3. Medium was refreshed once a week.
By flow cytometry analysis (c-Kit) > 90% purity of the BMMC population was determined.
The culture contained a uniform cell population. Furthermore staining cells with toluidin
blue indicated that nearly 99% of the viable cells were mast cells after 4-5 weeks culture.
No stem-like cell was detected in the mast cell preparation. We suspect that the < 10% of
the c-kit negative cells are unmature mast cells. Mast cell-deficient W/Wv mice were injected
via the tail vein with 5 x 106 cultured BMMC cells and the recipients were studied 20 weeks
later. Age-matched mast cell-deficient W/Wv mice and congenic normal mice were used
when examining the BMMC-reconstituted W/Wv mice (BMMC→ W/Wv). BMMC→ W/Wv   mice
had 7.70 ± 1.33 mast cells/ mm trachea versus none or 8.04 ± 1.46 mast cells/ mm
trachea for W/Wv  or +/+ mice, respectively.
Preparation of tracheal tissue for histological examination. To establish the success of
reconstitution of mast cells, trachea of  +/+ and BMMC→ W/Wv mice were examined for
the presence and distribution of mast cells. After animals were sacrificed, trachea were
removed, fixed in 4% formaldehyde in PBS and routinely embedded in GMA (glycol
methacrylate)(21). Serial sections were cut at 3 µm and stained with Heaths aluminium-
Toluidin Blue (TB), or using chloro-acetate esterase (CAE) and peroxidase (PO) procedures,
respectively (22).
Immunization and airway challenge with the hapten. Mice were sensitized on day 0 with
either DNFB (0.5% dissolved in acetone: olive oil [4:1]) or vehicle control, both of which
were applied epicutaneously to the shaved thorax (50 µl) and all four paws (50 µl). On day
1, DNFB or vehicle control (50 µl) was applied to the thorax alone. DNFB- and vehicle-
sensitized mice were intranasally challenged with dinitrobenzene sulphonic acid (DNS, 50
µl 0.6 % in PBS, pH 7.2) on day 5.  The sensitization and challenge were performed under
light anesthesia (inhalation of halothane 3%). Acute bronchoconstriction was assessed in
conscious mice directly after the challenge (as described below). Thereafter, the mice
were sacrificed (sodium pentobarbitone, 0.3 ml, 60 mg/kg i.p.) at several time points after
the challenge to determine in vivo mast cell activation, tracheal vascular permeability,
mucosal exudation, in vitro tracheal reactivity and leukocyte accumulation in the
bronchoalveolar lavage fluid.
Measurement of acute bronchoconstriction. Bronchoconstriction was measured as reported
previously (23). In short, 5 min before intranasal DNS challenge, unrestrained conscious
mice were placed in a whole body plethysmographic chamber  to analyze the respiratory
wave forms and obtain basal line. After 4 min and 30 sec, the mice were intranasally
challenged and placed directly back in the chamber. Airway resistance in each animal was
measured over a 25 min period. The airway resistance is expressed as enhanced pause
(PenH). PenH = pause x PEP/PIP
where PEP stands for peak expiratory pressure and PIP for peak inspiratory pressure.
44 Chapter 3
Pause is defined as (Te  Tr)/Tr, where Te stands for time of expiration and Tr stand for the
relaxation time -the time of pressure decay to 36% of the total expiratory pressure signal.
During bronchoconstriction, the changes in the box pressure during expiration are more
pronounced than during inspiration. Thus bronchoconstriction is reflected by an increase
in PenH, a dimensionless value to empirically monitor airway function. After intranasal
challenge, for each mouse maximal PenH readings were taken over 1 min time windows at
the following time points: 2 min 30 sec, 5 min, 7 min 30 sec, 10, 15 and 20 min.
Mast cell activation in vivo.
a. Histamine radioimmunoassay in plasma
To monitor mast cell activation, blood samples were taken from DNFB- and vehicle-sensitized
mice 10 and 30 min after intranasal DNS challenge for measurement of histamine. Blood
samples were collected into chilled tubes containing EDTA and placed on ice immediately.
Plasma was obtained via centrifugation at 14000 rpm at 4ºC for 10 min. Supernatants
were separated and frozen at -70ºC until assay.  Histamine radioimmunoassay was
performed according to the manufactures instructions (Immunotech International). Resulting
counts per min from 0.5 to 150 nmol/L (assay standard enclosed with kit) and 0.1 to 50.0
ng/ml histamine standard solutions in plasma were used to construct standard curves.
Histamine values for unknown samples were determined from the standard curve.
b. Mouse mast cell protease 1 ELISA in serum and tissue samples
Mouse mast cell protease 1 (mMCP-1) is a protease specific for mouse mast cells and will
appear in the blood of mice after mast cell activation (24). To monitor mast cell activation
blood samples were taken from DNFB- and vehicle-sensitized BALB/c mice 10, 30, 120
and 180 min after intranasal DNS challenge for measurement of mMCP-1. Blood samples
were collected and after centrifugation sera were stored at -70o C until assay. In addition,
30 min after the challenge and after perfusing the mice with 5 ml PBS (37ºC) via the right
ventricle the lungs were isolated and homogenated in 1.5 M KCl at  4ºC. The lung
homogenates were centrifuged for 10 min at 10,000 g and the supernatant were stored at
-70ºC until assay. A commercially available mMCP-1 enzyme linked immunosorbent assay
was used for the measurements of mMCP-1 in the sera and tissue homogenates. Serum
and tissue homogenates supernatants were diluted 1:1 before assaying the samples using
two anti-mMCP1 antibodies. 96 Wells flat bottomed micro ELISA plates were coated with
sheep anti-mMCP-1 capture antibody (2 µg/ml) and kept for 24 h at 4ºC in a humid
chamber before use. The coated plates were wash 6 times before loading standard mMCP-
1 and samples for 24 h. After another wash step, plates were incubated with rabbit anti-
mMCP-1-HPO conjugate for 1.5 h at room temperature. HPO activity was assessed by
adding orthophenylenediamine/H2O2 (0.4 mg/ml). After stopping the reaction with 2.5 M
H2SO4, OD was measured at a wavelenghth of 490 nm using a microplate reader. Results
were expressed as ng mMCP-1 per ml serum or ng mMCP-1 per g tissue wet weight.
Determination of tracheal vascular permeability. Monastral blue pigment is a tracer to
localize leakage at postcapillary venules in the trachea (25). Monastral blue was injected
i.v. via the tail vein immediately before the challenge. 30 Min after the challenge mice
were sacrificed with an overdose of sodium pentobarbitone and were perfused transcardially
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for 5 min with PBS containing heparin (10 U/ml) followed by 1% paraformaldehyde for 10
min. Trachea were removed, opened longitudinally along the ventral midline and fixed in
4% paraformaldehyde overnight. Finally, they were hydrated in ethanol, cleared in xylene
and prepared as whole amounts.
Leukocyte accumulation in bronchoalveolar lavage fluid. Bronchoalveolar lavages (BAL)
were performed in separate groups of mice at 24 h after the challenge as previously
described (11). After sacrificing the animals, the trachea was cannulated. Saline (37ºC)
was slowly injected into the lung and withdrawn in 4 x 1 ml aliquots. After the collection of
1 + 3 ml BAL fluid samples per mouse, the samples were maintained at 4o C.  The lavage
fluids were centrifuged (1500 rpm, 580 g, 10 min, 4ºC) to isolate the BAL cells from the
supernatant. After measuring the volume of the first ml, the supernatant was used to
assess mucosal exudation. BAL cell pellets were pooled and resuspended in 150 µl for total
and differential counts. The total BAL leukocyte count was determined for each mouse,
using a hemocytometer. The BAL cell preparations were analyzed morphologically after
centrifugation on microscopic slides. Air-dried preparations were fixed and stained with
hematoxylin and eosin to ascertain the percentage of neutrophils, eosinophils and
mononuclear cells (lymphocytes, macrophages and monocytes) in the airway lumen. 100
Cells per cytospin were examined to determine cell differential counts. The total number of
the different leukocytes in the BAL fluid of each mouse was extrapolated from the data
collected. Results are expressed as number of cell per lung.
Mucosal exudation. Mucosal exudation was assessed as previously described (26). At time
of challenge or 22 h after the challenge, Evans blue dye (1.25%, 50 µl in sterile saline) was
injected i.v. into anesthetized mice. One and 24 h after the challenge the mice were
sacrificed and blood samples and BAL samples were taken as described above. The volumes
of the first ml of lavage fluid recovered were recorded for each mouse for measurement of
Evans blue content and for the calculation of mucosal exudation. No significant differences
were found in the volumes of BAL fluids of vehicle sensitized and DNFB-sensitized mice.
The extravasation of Evans blue dye-labeled macromolecules from the pulmonary
microcirculation to the bronchoalveolar spaces was quantified by measuring the OD of the
lavage and plasma samples at a wavelength of 595 nm with a microplate reader. The
amount of mucosal leakage in the lavage fluid (µl/lung) was determined by dividing the
Evans blue content in the total lavage fluid by the Evans blue content in 1 ml of plasma.
Tracheal reactivity in vitro. Determination of tracheal reactivity was assessed 48 h after
the challenge as described previously (11). The trachea, which was resected in toto, was
carefully cleaned of connective tissue under a binocular microscope. A nine-ring section of
the trachea (taken from just below the larynx) was then transferred to a 10 ml organ bath
containing a modified oxygenated Krebs solution (118 mM NaCl, 4.7 mM KCl, 2.5 mM
CaCl2, 0.5 mM MgCl2, 25 mM NaHCO3, 1 mM NaHPO4 and 11.1 mM glucose). The tracheal
section was slipped directly onto two supports of an organ bath, one of which was coupled
to the organ bath and the other to an isometric transducer. The solution was aerated (95%
O2: 5% CO2) at constant temperature (37ºC). Isometric measurements were made with a
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force displacement transducer and a two channel recorder and were expressed as changes
in milligram force. Optimal preload for the mouse trachea was determined to be 1 g. The
trachea was allowed to equilibrate for 1 h in Krebs solution. During equilibrium phase, the
fluid in the bath was changed every 15 min. To assess reactivity, cumulative concentration-
response curves for carbachol (concentration range: 10-8 to 10-4 M) were determined 24 or
48 h after the challenge of vehicle- or DNFB-sensitized mice.
Materials. DNFB, olive oil, carbachol, o-phenylenediamine dihydrochloride were purchased
from Sigma Chemical Co., St. Louis, MO. DNS was purchased from Eastman Kodak,
Rochester, NY.  Tween 20 was purchased from Janssen Pharmaceutica, Beerse, Belgium.
Sodium pentobarbitone was purchased from Sanofi, Maassluis, the Netherlands. RPMI
1640 medium was purchased from Life Technologies, Rockville, MD. Evans blue dye was
obtained from Fluka Chemie AG, Munchen, Germany and heparin from Leo Pharmaceutical
Products (Ballerup, Denmark). Monastral blue dye was a generous gift of Dr P. Baluk,
Cardiovascular Research Institute (University of California, San Francisco, USA). Hematoxylin
and eosin (Diff-Quik) were purchased from Merz & Dade A.G., Dubingen, Switzerland.
The histamine radioimmunoassay was purchased from Immunotech S.A., Marseilles, France.
The mMCP-1 enzyme linked immunosorbent assay was from Moredun Scientific Ltd.,
Midlothian, UK. Maxisorp surface 96 well plates were purchased from Nunc Immuno plate,
Roskilde, Denmark. The whole body plethysmographic chamber (Buxco) was obtained
from Buxco Electronics, Inc. Shanon, CT. The force displacement transducer was purchased
from Harvard Bioscience, Boston, MA, USA and the two channel recorder (Servogar type
SE-120) from Plato BV, Diemen, the Netherlands.
Statistical analysis. All experiments were designed as completely randomized multifactorials
with 4-14 mice per group. Emax values for the carbachol-induced tracheal contraction for
each experimental animal were calculated separately by nonlinear least-square regression
analysis (simplex minimalization) of the measured contractions versus carbachol
concentration, using the sigmoid concentration-response relationship and including a
theshold value. Histamine content in blood was analyzed using unpaired t-tests at the two
diffentent time points of sampling. The following data obtained from individual animals
were analyzed by two-way analysis of variance (ANOVA): mMCP-1 content in blood and
lung homogenates; mucosal exudation values; EC50 and Emax values for the carbachol-
induced tracheal contractility; followed by a post-hoc comparison between groups. In the
figures group means ± SEM are given and a difference was considered significant when
P<0.05. The cellular accumulation in BAL fluid was analyzed by using a distribution free
Kruksal Wallis one way ANOVA. The cell data are expressed as medians (minimum-
maximum). All data manipulation, non-linear fittings, unpaired t-test, ANOVA and post-
hoc comparisons were carried out with a commercially available statistical package (SYSTAT,
version 5.03; Wilkinson L. SYSTAT; The system for statistics. SYSTAT Inc. 1990, Evanston,
IL).
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Results
DNFB-induced pulmonary hypersensitivity reaction: early phase mast cell activation, acute
bronchoconstriction and vascular permeability changes in the trachea.
The appearance of histamine and mMCP-1 in the blood is indicative for the activation of
mast cells (24). An increase in histamine levels (± 150%) was found in the plasma of
DNFB-sensitized BALB/c mice 10 and 30 min after intranasal DNS challenge when compared
to vehicle-sensitized animals (10 min: vehicle/DNS: 158.4 ± 21.4 nM & DNFB/DNS: 240.1
± 20.3 nM, p<0.05, n=4 mice per group ; 30 min: vehicle/DNS: 98.4 ± 29.9 & DNFB/DNS:
171.4 ± 12.8 nM, p=0.07, n=4 mice per group). The hapten-induced rise in serum histamine
Figure 1. Mast cells are activated shortly after
intranasal DNS challenge in DNFB-sensitized BALB/c
mice. Mast cell proteases (mMCP-1) levels in serum
and in lung tissue of vehicle- and DNFB-sensitized
mice 10, 30, 120 and 180 min after intranasal DNS
challenge. Results are expressed as mean (ng mMCP-
1/ml serum or ng/g tissue wet weight) ± SEM, *
p<0.05, n=6-12 mice per group.
levels 30 min after the challenge was,
however, not statistically significantly
different, possibly due to the short half life
of histamine in serum. Moreover, mast cells
are not the only source for histamine;
therefore we have examined a more specific
marker for mast cell degranulation mMCP-1.
mMCP-1 was markedly enhanced in serum of
DNFB-sensitized and DNS-challenged BALB/
c mice 10, 30, 120 and 180 min after the
challenge (figure 1). The most prominent rise
in serum mMCP-1 was observed 30 min after
the intranasal challenge of DNFB-sensitized
mice. At this time point, a concomitant
reduction in lung tissue mMCP-1 levels was
found in DNFB-sensitized and DNS-challenged
BALB/c mice showing that the hapten-induced
rise in serum mMCP-1 was of pulmonary
origin. mMCP-1 levels in BAL fluid samples
from vehicle- and DNFB-sensitized BALB/c
mice were below the detection limit of the mMCP-1-ELISA.The early phase mast cell
activation was associated with an acute bronchoconstriction in DNFB-sensitized and DNS-
challenged BALB/c mice. As demonstrated by figure 2, intranasal DNS challenge in DNFB-
sensitized BALB/c mice resulted in an increase in PenH values when compared to vehicle-
sensitized mice (max PenH: saline/DNS=0.76 ± 0.07 and DNFB/DNS=2.92 ± 0.57, p<0.05,
n=6). The DNFB/DNS-induced bronchoconstriction was evident within 15 min after the
challenge. In addition, 30 min after the DNS challenge a significant increase in vascular
permeability was evident in trachea of DNBF-sensitized BALB/c mice compared to controls
(data not shown). Examination of Evans blue accumulation in BAL fluid 1 h after intranasal
challenge, showed a significant mucosal exudation in the airways of DNFB-sensitized BALB/
c mice when compared to vehicle-sensitized mice (table 1).
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Mouse               n      time(a)     DNFB         mucosal exudation
         (hrs)   sensitization (µl plasma/lung)
BALB/c 6 1 -    4.20 ± 1.12
6 1 +    8.51 ± 1.20*
+/+ 6 1 -    3.85 ± 1.37
6 1 +    8.65 ± 1.18*
W/Wv 6 1 -    4.00 ± 0.66
6 1 +    3.45 ± 0.59
+/+ 6 1 -    2.65 ± 0.18
6 1 +    5.55 ± 0.61*
Sl/Sld 6 1 -    2.75 ± 0.36
6 1 +    2.25 ± 0.29
BALB/c 6 24 -    3.17 ± 0.38
6 24 +    6.30 ± 0.46*
 ( b)+/+ 4 basal(c)    6.07 ± 0.81
8 24 -    6.58 ± 0.85
8 24 +    6.41 ± 0.33
W/Wv 7 24 -    5.51 ± 0.72
8 24 +    4.61 ± 0.77
BMMC > W/Wv 5 24  -    5.84 ± 1.02
6 24 +    4.95 ± 0.73
Table 1. Mucosal exudation in
the airway lumen 1 and 24 h after
DNS challenge of vehicle or DNFB-
sensitized BALB/c, W/Wv, Sl/Sld and
their respective normal littermate
control(+/+) and reconstituted
BMMC W/Wv mice(a). (a) Mucosal
exudation was determined in BAL
fluid of vehicle (-) or DNFB-
sensitized (+) mice 24 h after
intranasal DNS challenge. Results
are expressed as mean ml plasma/
lung ± SEM. Significant
differences between vehicle- and
DNFB-sensitized groups are
indicated (* p<0.05). (b) The
mice examined in these
experiments were age-matched
(40 weeks). (c) basal mucosal
exudation in airway of 40 weeks
old non-treated +/+ mice.
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Figure 2. Acute bronchoconstriction is found in DNFB-
sensitized BALB/c mice after intranasal DNS challenge.
Bronchoconstriction is characterized by increases in PenH
values, which were recorded in vehicle- and DNFB-
sensitized mice 5 min before until 20 min after the
challenge. For each mouse max PenH readings were
taken over 1 min time windows at -5 min, 0 min, 2 min
30 sec, 5, 10 and 15 min. * p<0.05, n=6 mice per group.
DNFB-induced pulmonary hypersensitivity reaction: late phase mucosal exudation, neutrophil
infiltration in BAL fluid and tracheal hyperreactivity.
Bronchoalveolar lavage studies were performed in BALB/c mice to examine mucosal leakage
and cellular infiltration 24 h after the challenge. Twenty-four hours after the intranasal
DNS challenge a significant mucosal exudation was evident in the lungs of DNFB-sensitized
BALB/c mice compared to controls (table 1). In addition, total cell numbers in BAL fluid of
DNFB- or vehicle-sensitized BALB/c mice were determined. An increase in total BAL cell
numbers recovered from DNFB-sensitized and DNS-challenged mice was found when
compared to vehicle-sensitized mice (table 2). The increase in total BAL fluid cells was
largely attributable to an increase in the number of neutrophils and mononuclear cells
(table 2). At 24 and 48 h BALB/c mice exhibit a marked and significant tracheal
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hyperreactivity to carbachol when DNFB-sensitized and DNS challenged (table 3).
However,the observed tracheal hyperreactivity was more pronounced and reproducible at
48 h after the challenge. Therefore, this time point was chosen in mast cell reconstitution
studies.
Table  2.   Leukocyte accumulation and differentiation (neutrophils, eosinophils and mononuclear cells) in the
lung air spaces 24 h after DNS challenge of vehicle or DNFB-sensitized BALB/c, W/Wv, Sl/Sld and their respective
normal littermate control(+/+) and reconstituted BMMC→W/Wv mice(a)
Mouse n DNFB           leukocyte accumulation in BAL (cells/lung x 104)
    total cells   neutrophils   eosinophils  mononuclear cells
BALB/c              6 -   2.25(1.05-2.78) 0.02(0.00-0.05) 0.00(0.00-0.11)   2.23(1.02-2.67)
6 +   4.72(3.45-5.77)* 0.67(0.21-1.16)* 0.02(0.00-0.12)   3.81(3.12-4.50)*
+/+ 8 -   2.10(1.35-2.78) 0.03(0.00-0.08) 0.00(0.00-0.01)   2.09(1.31-2.75)
7 +   3.97(2.03-4.58)* 0.40(0.24-0.82)* 0.02(0.00-0.80)   3.25(1.66-3.71)*
W/Wv 8 -   2.10(1.20-2.70) 0.05(0.00-0.13) 0.00(0.00-0.03)   2.07(1.18-2.56)
8 +   2.03(1.20-4.65) 0.05(0.02-0.06) 0.00(0.00-0.02)   1.97(1.16-4.19)
+/+ 8 -   1.85(1.65-2.93) 0.03(0.00-0.20) 0.00(0.00-0.01)   1.81(0.23-2.93)
8 +   2.93(1.98-5.40) 0.37(0.20-0.72)* 0.01(0.00-0.03)   2.54(1.30-5.02)*
Sl/Sld 8 -   2.02(0.83-4.28) 0.01(0.00-0.02) 0.00(0.00-0.01)   2.01(0.82-4.28)
7 +   1.97(0.98-4.13) 0.01(0.00-0.06) 0.00(0.00-0.02)   1.97(0.96-4.13)
(b)+/+ 4 B(c) 11.00(8.41-13.82) 0.03(0.00-0.14) 0.00(0.00-0.00) 10.99(8.41-13.75)
8 - 12.66(3.90-20.10) 0.13(0.00-0.41) 0.00(0.00-0.00) 12.53(3.90-19.99)
8 + 13.09(6.45-20.10) 0.89(0.29-1.58)* 0.04(0.00-0.13) 12.16(6.06-18.47)
W/Wv 7 - 12.41(5.10-18.90) 0.09(0.00-0.16) 0.03(0.00-0.15) 12.28(5.10-18.52)
8 + 10.53(4.50-17.70) 0.12(0.00-0.49) 0.01(0.00-0.06) 10.39(4.28-17.61)
BMMC→W/Wv 5 - 11.88(7.95-13.80) 0.04(0.00-0.11) 0.00(0.00-0.00) 11.83(7.91-13.80)
6 +   9.90(3.30-13.50) 0.58(0.27-0.90)* 0.06(0.00-0.27)   9.26(2.81-13.23)
(a) Leukocytes were determined in BAL fluid of vehicle (-) or DNFB-sensitized (+) mice 24 h after intranasal
DNS challenge. Mononuclear cells being lymphocytes, macrophages and monocytes Results are expressed as
median (minimum-maximum). Significant differences between vehicle- and DNFB-sensitized groups are indicated
(* p<0.05). (b) The mice examined in these experiments were age-matched (40 weeks). (c) B: basal; leukocyte
numbers of 40 weeks old non-treated +/+ mice.
Studies in two strains of mast cell deficient mice: the development of early and late phase
reactions of DNFB-induced pulmonary hypersensitivity.
In separate experiments, several features from the DNFB-induced pulmonary hypersensitivity
reaction were investigated in two strains of 8 weeks old mast cell-deficient mice (W/Wv
and Sl/Sld) and their respective normal (+/+) littermates. Figure  3a shows that in both
strains of normal (+/+) littermates DNFB/DNS-induced significant increases in mMCP-1
serum levels were found compared to vehicle sensitized animals. In both strains of mast
cell-deficient mice, no changes in mMCP-1 serum levels were observed 30 min after the
challenge of DNFB-sensitized mice compared to vehicle-sensitized animals (figure 3a).
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Moreover, no mucosal exudation response was found 1 h after intranasal DNS challenge in
DNFB-sensitized mast cell-deficient mice (table 1).To investigate the importance of the
mast cell in the development of late phase responses 24 and 48 h after the DNS challenge
in DNFB-sensitized mice, mucosal exudation, cellular infiltration into BAL fluid and tracheal
reactivity were examined in the two strains of mast cell-deficient mice and their respective
normal (+/+) littermates. In both strains of mast cell deficient mice no significant different
mucosal exudation or total BAL cell numbers were found after DNFB-sensitization and DNS
challenge when compared to vehicle-sensitized mice (tables 1 and 2). However, a significant
mucosal exudation response and increase in BAL fluid neutrophils and to a lesser extent of
mononuclear cells were demonstrated in the both normal (+/+) littermates 24 h after the
challenge of DNFB-sensitized mice. Tracheal preparations taken from DNFB-sensitized
congenic normal +/+ mice at 24 and 48 h after the DNS challenge exhibited a marked and
significant hyperreactivity to carbachol when compared with responses of trachea of vehicle-
sensitized mice (table 3). In both strains of mast cell deficient mice (W/Wv and Sl/Sld) no
carbachol were found in DNFB-sensitized and DNS-challenged mice compared to control
groups (table 3).
Mouse                  n            time(a) DNFB   Emax          pD2
     (hrs)  sensitization     (mg)
BALB/c 6 24 -   1928 ± 52         6.9 ± 0.1
6 24 +   2402 ± 28*         6.8 ± 0.0
+/+ 6 24 -   2277 ± 42         6.8 ± 0.1
6 24 +   3012 ± 45*         6.7 ± 0.1
W/Wv 6 24 -   2324 ± 53         6.8 ± 0.1
6 24 +   2488 ± 63         6.9 ± 0.1
+/+ 6 24 -   1372 ± 25         6.7 ± 0.1
6 24 +   2060 ± 41*         6.9 ± 0.1
Sl/Sld 6 24 -   1280 ± 33         6.7 ± 0.1
6 24 +   1253 ± 14         6.6 ± 0.0
BALB/c 6 48 -   2177 ± 32         6.8 ± 0.1
6 48 +   3116 ± 51*         6.8 ± 0.1
+/+ 6 48 -   2266 ± 48         6.8 ± 0.1
6 48 +   3091 ± 68*         6.7 ± 0.1
W/Wv 6 48 -   2042 ± 46         6.8 ± 0.1
6 48 +   2115 ± 47         6.9 ± 0.1
(b)+/+ 6 48 -   2347 ± 30         6.6 ± 0.0
5 48 +   3332 ± 54*         6.6 ± 0.1
W/Wv 6 48 -   2421 ± 27         6.5 ± 0.0
5 48 +   2616 ± 78         6.7 ± 0.1
BMMC→W/Wv 5        48 -   2480 ± 41         6.9 ± 0.1
5 48 +   3326 ± 51*         6.7 ± 0.1
(a) Tracheal reactivity to carbachol in vitro of vehicle (-) or DNFB-sensitized (+) mice was assessed 24 and 48
h after intranasal DNS challenge. Results are expressed as means ± SEM. Significant differences between
vehicle- and DNFB-sensitized groups are indicated (* p<0.05). (b) The mice examined in these experiments
were age-matched (40 weeks).  EC50: effective agonist concentration inducing 50% of the maximal response.
Table 3. Maximal tracheal reactivity (Emax) and pD2 (-log EC50) values derived from concentration response
curves to carbachol (10-8 to 10-4 M) 24 and 48 h after DNS challenge in vehicle or DNFB-sensitized BALB/c, W/
Wv, Sl/Sld and their respective normal littermate control(+/+) and reconstituted BMMC→W/Wv mice(a).
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Mast cells play a key role in the development of early and late phase reaction of DNFB-
induced pulmonary hypersensitivity.
To confirm that the lack of mast cells was responsible for the failure of the development of
the DNFB-induced pulmonary hypersensitivity reactions in the mast cell-deficient animals,
we have determined the effect of reconstitution of W/Wv mice with mast cells cultured
from bone marrow of  +/+ mice (BMMC→W/Wv). An age-matched study was performed
since the mast cell reconstitution took 20 weeks. To assess the establishment of mast cells
in mast cell-reconstituted mice, trachea of +/+, W/Wv and BMMC→W/Wv mice were
examined for the presence and distribution of mast cells. No mast cells were detected in
tissues obtained from mast cell-deficient W/Wv mice (data not shown).
Staining with TB, revealed the presence of mast cells in tracheal sections of  +/+ mice
(figure 4a). In trachea of mast cell-reconstituted mice, TB did not stain any mast cells
(figure 4d). Since CAE-staining is an accurate manner to identify mast cells in formalin
fixed and GMA embedded tissue, CAE was also used to detect mast cells in the tracheal
tissue. However, CAE staining not only detects mast cells but also some neutrophils.
Therefore, serial sections were stained for PO-activity representative for neutrophils, but
not for mast cells. Indeed, mast cells were observed in +/+ and BMMC→W/Wv mice using
CAE staining (figure 4b,c,e,f). Serial sections revealed no overlap between PO and CAE
positive staining, demonstrating that the CAE-positive cells were no neutrophils (data not
shown). The number, morphology and anatomical distribution of mast cells in trachea of
+/+ mice differ from mast cells in mast cell-reconstituted mice. It seems that latter mast
cells are more mucosal-like: located in the mucosa, being smaller in size and having lower
granular density (figure 4).
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Figure 3. Mast cells are activated shortly after intranasal DNS challenge in DNFB-sensitized +/+ mice, but not
in two strains mast cell-deficient mice. Mast cell protease (mMCP-1) levels in serum of vehicle- and DNFB-
sensitized mast cell deficient W/Wv, mast cell deficient Sl/Sld and their respective normal littermate (+/+) and
mast cell-reconstituted BMMC→W/Wv mice 30 min after intranasal DNS challenge. a) Results presented are
obtained from 8 weeks old mice. b) Results presented are obtained from 40 weeks old mice. Results are
expressed as mean (ng mMCP-1/ml serum) ± SEM, * p<0.05, n=6-12 mice per group.
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Figure 4. BMMC transplantation reconstitutes mast cells in trachea of mast cell-deficient W/Wv mice. BMMCs
were injected intravenously into W/Wv mice. After reconstitution mice were housed for 20 weeks before being
subjected to DNFB-sensitization and intranasal DNS challenge. At the time of experiment all mice were 40-
weeks-old. Serial sections of GMA-embedded trachea from vehicle-sensitized +/+ (a-c) and BMMC→W/Wv
mice (d-f) were stained with Heaths Aluminium Toluidin Blue (TB, a and d) and the chloro-acetate esterase
reaction (CAE, b,c,e and f). The high magnification pictures (c and f) reveal a granular structure of CAE-
positive mast cells. Arrows denote TB or/and CAE-positive mast cells. Arrowheads denote CAE-stained mast
cells photographed at high magnification. Note the difference in size and granular density of CAE-stained mast
cells in the wild-type and reconstituted animals (c and f).
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As shown in Figure 5, DNFB-sensitization
and DNS challenge resulted in a profound
bronchoconstriction in 40 weeks old +/+
and BMMC→W/Wv mice, but mast cell
deficient W/Wv mice failed to exhibit a
bronchoconstrictive response directly
after challenge. Although this response
was associated in +/+ mice with a
significant rise of mMCP-1 serum levels,
no such changes were observed in W/Wv
and BMMC→W/Wv mice (figure 3b).
Nevertheless, an early phase-associated
increase in tracheal vascular permeability
observed in +/+ mice, that was absent
in DNFB-sensitized W/Wv mice 30 min after
challenge, could be completely restored
after mast cell reconstitution (figure 6).
Examination of BAL fluid of age-matched
W/Wv, +/+, BMMC→ W/Wv mice, indicated
that the presence of  mast cells in the
lung is important for the infiltration of
neutrophils (table 2). Note that the total
cell number of BAL cells is markedly risen
in 40 weeks old mice compared to 8
weeks old mice (table 2). We were
unable to assess mucosal exudation upon
DNFB sensitization in 40 weeks old +/+
and BMMC→ W/Wv mice 24 h after
intranasal challenge. The mucosal
exudation values observed in +/+, W/Wv
mice and BMMC→W/Wv mice after DNFB-
sensitization and DNS challenge did not
significantly differ from basal values in
non-treated +/+ mice (table 1). Finally,
reconstitution of mast cells in W/Wv mice
restored the DNFB-induced tracheal
hyperreactivity found 48 hours after the
challenge (figure 7). The extent of
tracheal hyperreactivity to carbachol in
mast cell-reconstituted W/Wv mice was
comparable to that observed in age-
matched +/+ mice (table 3).
0 5 10 15 20 25 30
0
1
2
3
4
*
A  +/+
time (min)
Pe
nH
0 5 10 15 20 25 30
0
1
2
3
4
time (min)
Pe
nH
B  W/Wv
0 5 10 15 20 25 30
0
1
2
3
4
time (min)
Pe
nH
C  BMMC→W/Wv  *
Figure 5. Acute bronchoconstriction is found in DNFB-
sensitized +/+ and BMMC→ W/Wv  mice, but not in mast
cell deficient W/Wv mice. After reconstitution mice were
housed for 20 weeks before being subjected to DNFB-
sensitization and intranasal DNS challenge. At the time
of experiment all mice were 40 weeks old.
Bronchoconstriction is characterized by increases in PenH
values, which were recorded in vehicle- and DNFB-
sensitized mice 5 min before until 25 min after the
challenge. For each mouse max PenH readings were taken
over 1 min time windows at -5 min, 0 min, 2 min 30'
sec, 5, 7 min 30 sec, 10, 12 min 30 sec, 15, 17 min 30
sec, 20, 22 min 30 sec and 25 min and 30 min. * p<0.05,
n=5-6 mice per group.
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Figure 6. Tracheal vascular hyperpermeability is found in DNFB-sensitized +/+ (a,b) and BMMC→W/Wv mice
(e,f), but not in mast cell deficient W/Wv mice (c,d). After reconstitution mice were housed for 20 weeks before
being subjected to DNFB-sensitization and intranasal DNS challenge. At the time of experiment all mice were
40 weeks old. Typical individual samples of Monastral blue labeled blood vessels in trachea of DNFB- or vehicle-
sensitized mice 30 min after DNS challenge.
A     +/+: veh/DNS B     +/+: DNFB/DNS
C     W/Wv: veh/DNS D     W/Wv: DNFB/DNS
E     BMMC → W/Wv: veh/DNS F     BMMC → W/Wv: DNFB/DNS
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Discussion
Mast cell mediators are known to contribute to the pathogenesis of asthma. Increased
numbers of pulmonary mast cells have been demonstrated in atopic as well as in non-
atopic asthmatic patients (8). The presence of increased mast cell numbers in non-atopic
asthma focuses attention on the role of non-IgE mediated mast cell activation in asthma.
In the present experiments, we describe a murine model for non-atopic asthma and
examine the putative role of mast cells. Cutaneous sensitization with the low molecular
weight hapten DNFB, followed by an intranasal challenge with DNS, resulted in early and
late phase hypersensitivity responses. An acute bronchoconstriction, tracheal vascular
hyperpermeability and mucosal exudation characterized the early phase (within 1 h after
hapten challenge). These responses were associated with mast cell activation shortly after
the challenge. For each of these features, responses to intranasal DNS in DNFB-sensitized
mast cell deficient mice were significantly lower or absent when compared to normal
congenic +/+ mice. Similar results were found for the late phase responses of this murine
model for non-atopic asthma, such as mucosal exudation, cellular infiltration and tracheal
hyperreactivity. Moreover, DNFB-induced pulmonary hypersensitivity responses in mast
cell reconstituted BMMC→W/Wv mice were indistinguishable from age-matched normal +/
+ mice.
Figure 7. Tracheal hyperreactivity is found in DNFB-sensitized
+/+ (a) and BMMC→W/Wv (c) mice, but not in mast cell
deficient W/Wv mice (b). After reconstitution mice were
housed for 20 weeks before being subjected to DNFB-
sensitization and intranasal DNS challenge. At the time of
experiment all mice were 40-weeks-old. Concentration-
response curves to carbachol were measured in trachea
obtained from DNFB- or vehicle-sensitized mice 48 h after
DNS challenge. Results are expressed as mean (mg
contraction) ± SEM. * p<0.05, n=5-6 mice per group.
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These data extend previous work performed by Garssen and coworkers and other
investigators, which indicated that mast cells are involved in the elicitation of hapten-
induced T cell-mediated responses in the airways of actively immunized mice (16, 18).
There are several lines of evidence that favor a role for the mast cell in the early phase of
hapten-induced hypersensitivity reactions. Firstly, these reactions are elicited preferentially
at sites enriched with mast cells, such as lung, gastrointestinal tract, buccal mucosa and
skin (12, 27, 28). Studies have reported the release of the mast cell mediator serotonin
during contact sensitization in skin and lung early after the challenge (12, 29-31). This
vaso-active amine can act locally by increasing vascular permeability and inducing
vasodilatation, thereby facilitating cellular infiltration (29, 31). In addition, corticosteroid-
induced mast cell depletion and treatment with mast cell stabilizers or serotonin receptor
antagonists suppressed hapten-induced hypersensitivity reactions in lung, gastrointestinal
tract and skin of mice and rat (12, 29, 31). Defective mucosal pulmonary hapten-induced
hypersensitivity responses have been found in strains of mast cell deficient mice (12). This
finding seems in contrast with hapten-induced contact hypersensitivity reactions at
cutaneous sites, where skin responses were found in mast cell deficient mice (32). It was
suggested that other cell types, such as the platelet, could be involved. However, very
recently Biedermann and coworkers (33) have demonstrated, using mast cell-deficient
mice and mast cell-reconstituted mice, that mast cells are necessary for the full development
of a cutaneous hapten-induced delayed type hypersensitivity reaction.
No reports have described direct assessment of mast cell activation during the early
phase of pulmonary hapten-induced hypersensitivity reactions in the mouse. In this study
we have monitored in vivo mast cell activation up to 3 h after the challenge by means of
measurement of histamine and mMCP-1. Our results demonstrate that mast cells are
activated directly after the intra-airway DNS challenge of DNFB-sensitized mice. This early
mast cell activation was associated with acute bronchoconstriction and mucosal exudation,
which occurred within 1 h after the challenge indicating that an increase in vascular
permeability had taken place. The latter feature was indeed demonstrated in trachea.
The role of the mast cell in DNFB-induced pulmonary hypersensitivity reaction was
further evaluated using mast cell deficient W/Wv and Sl/Sld mice. No early phase
bronchoconstriction, mast cell activation or increased vascular permeability, nor late phase
infiltration of inflammatory cells into the airways nor tracheal hyperreactivity at 24 to 48 h
were found in these mice. In +/+ littermate control mice normal hapten-induced early and
late phase events were observed. In a previous study examining picryl chloride-induced
pulmonary hypersensitivity reaction, no inflammatory infiltrates were found in the lungs
of W/Wv mast cell deficient mice 48 h after the challenge (12). Tracheal reactivity during
the late phase of this hypersensitivity reaction was not assessed. However, treatment with
the mast cell stabilizer, nedocromil, resulted in an inhibition of the picryl chloride-induced
tracheal hyperreactivity observed at 48 h after the challenge of BALB/c mice (12).
To provide more definitive evidence for the role of mast cells in this murine model for
non-atopic asthma, we reconstituted mast cells in W/Wv mice by i.v. injection of in vitro
cultured mast cells obtained from bone marrow of +/+ mice. Mast cell reconstitution
restored the acute bronchoconstriction, tracheal vascular hyperpermeability, BAL neutrophilia
and tracheal hyperreactivity observed after DNFB sensitization and intranasal DNS challenge.
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However, the early phase mast cell activation as assessed by rises in serum mMCP-1 could
be detected in +/+ but not in BMMC→W/Wv mice. One possible explanation could be that
only a few pulmonary mast cells need to be activated in mice undergoing a DNFB-induced
hypersensitivity reaction. Du and coworkers have described that in W/Wv mice that have
been infused with bone marrow cell or BMMC, the density of pulmonary mast cells is 5 to
15-fold lower than in age-matched +/+ mice, suggesting minimal reconstitution (34). It has
been demonstrated that only minimal reconstitution of a relatively small number of mast
cells can restore IgE-mediated hypersensitivity reactions in the lung (35). It could be
possible that the number of mast cell activated in reconstituted mice is too low to detect
mMCP-1 levels in serum. In our study, however, tracheal mast cell counts did not indicate
differences in the number of mast cells comparing +/+ and BMMC→W/Wv mice.  A more
plausible explanation could be that mMCP-1 may not be the right marker for mast cell
activation in mast cell reconstituted W/Wv. Galli stressed that appropriate studies should
be done to assess the number, phenotype and anatomical distribution of mast cells which
develop in W/Wv recipients of BMMC (36). Indeed, histological examination of mast cells in
trachea obtained from +/+ and BMMC→W/Wv mice showed differences in staining-sensitivity,
morphology (granular density and size) and anatomical distribution. It was beyond the
scope of this study to in-depth investigating this phenomenon.
The mechanism by which mast cells are activated in this murine model is currently
under investigation. Mast cell activation can also be elicited via IgG1 in the mouse and low
local levels of IgE, that are not detectable in serum, could result in mast cell sensitization.
However, we have demonstrated that upon contact sensitization with low molecular weight
haptens, hapten-specific proteins are produced. These hapten-specific proteins were devoid
of IgG, IgE and IgM (unpublished observations). Purified hapten-specific proteins are able
to passively sensitize naive mice. Intranasal challenge results in an acute
bronchoconstriction, plasma leakage and mast cell activation. These features are similar
as observed in the early phase of the hapten-induced asthma model described in this
study. In addition, our studies indicate that hapten-specific proteins bind to mast cells and
upon second contact with the hapten mast cells degranulate and thereby initiating a cascade
resulting in hapten-induced hypersensitivity reaction in lung or skin.
In conclusion, our findings are confirmatory for the hypothesis of the initiating role of
the mast cell in the cellular cascade leading to a hapten-induced hypersensitivity reaction
as postulated earlier (12, 27, 30, 33, 37). Evidence from this study consistent with the
hypothesis that mast cells significantly contribute to the initiation of non-IgE-mediated
hypersensitivity responses in airways. Although the importance of mast cells in murine
models for atopic asthma remains controversial, we are the first to demonstrate an essential
role for mast cells in a murine model for non-atopic asthma.
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Abstract
Mast cell activation, bronchoconstriction, inflammation and airway hyperreactivity are
prominent features of dinitrofluorobenzene (DNFB)-induced hypersensitivity reactions in
the mouse airways, a murine model for non-atopic asthma. We studied the role of the
tachykinin receptors in the development of non-atopic asthma using specific NK-1 (RP67580)
or NK-2 (SR48968) receptor antagonists and genetically NK-1 receptor-deficient animals.
NK-1 receptor blockade strongly reduced the DNFB-induced tracheal hyperreactivity and
the accumulation of neutrophils and mononuclear cells in the bronchoalveolar lavage (BAL)
fluid in DNFB-sensitized mice at 48 h after dinitrosulfonic acid (DNS) challenge. Treatment
with the NK-2 receptor antagonist did not affect the DNFB-induced hypersensitivity reaction.
The role for the NK-1 receptor was further confirmed in NK-1 receptor knockout mice. In
previous studies, we have shown that mast cells played a crucial role in the development
of non-atopic asthma. Although mast cell activation may be induced by stimulation of
neurokinin receptors, we did not find an inhibitory effect of the tachykinin receptor
antagonists or genetic absence of NK-1 receptors on the release of mast cell protease in
serum of asthmatic animals. In conclusion, present study shows that, distal from mast cell
activation, the NK-1 receptor is crucial for the development of tracheal hyperreactivity and
pulmonary leukocyte accumulation in non-atopic asthma.
Introduction
Asthma and chronic obstructive pulmonary diseases are among the worlds most prevalent
airway diseases. Asthma patients can roughly be divided in two groups. In most cases,
asthma is associated with atopy. Atopic asthma refers to the genetic predisposition of
individuals expressing immunoglobulin E (IgE) specific for certain allergens. The second
group of patients comprises patients in which asthma is not associated with atopy. In
these patients no allergen-specific IgE can be detected in the blood. Non-atopic asthma,
accounting for 5% to 15% of all new cases of asthma (1), is an increasing problem in the
developed world. Low molecular weight substances (<5000 Da) are the most common
agents causing occupational asthma without producing specific IgE (1). Sensitization and
local challenge with the low molecular weight compound dinitrofluorobenzene (DNFB) has
been shown to induce bronchoconstriction, airway hyperreactivity, cellular accumulation,
mast cell activation and increased vascular permeability in the mouse airways. Sensitization
is not associated with an increase in hapten-specific IgE. Therefore, this murine model is
useful to study mechanisms of non-atopic asthma. Buckley and coworkers showed that
DNFB-induced tracheal hyperreactivity and cellular infiltration were inhibited by capsaicin-
induced depletion of excitatory non-adrenergic non-cholinergic (NANC) neuropeptides (2).
From this study we hypothesize that sensory nerves play a role in the pathogenesis of
non-atopic asthma.
Excitatory NANC pathway innervate the airways of human and other mammalian
species (3). The excitatory NANC nerves can be activated by different stimuli, that affect
the chemosensitive C-fiber afferents in the airways and lead to the local release of
neuropeptides (4). Tachykinins and calcitonin gene-related peptide are the predominant
excitatory NANC-neuropeptides in the airways (5). The tachykinins, substance P and
neurokinin A, have various proinflammatory effects that could contribute to changes
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observed in asthmatic airways such as smooth muscle contraction, vasodilatation, an
increase in vascular permeability and infiltration and stimulation of inflammatory cells (3).
Most of the effects have been observed in human and animal tissue and are mediated by
specific tachykinin receptors. Two receptor types, neurokinin 1 (NK-1) and neurokinin 2
(NK-2), mediate the biological actions of tachykinins in the airways. The preferred ligand
for these receptors are substance P and neurokinin A, respectively (6). Stimulation of the
NK-1 receptor induces vasodilatation, plasma protein extravasation, mucus secretion,
upregulation of adhesion molecules and stimulation of inflammatory cells such as
mononuclear cells, neutrophils and mast cells (4). The NK-1 receptor is present on the
surface of these effector cells and it has been shown to play a role in many inflammatory
diseases including asthma, inflammatory bowel disease and experimental arthritis (7).
Stimulation of the NK-2 receptor mediates a major part of the tachykinin-induced airway
smooth muscle contraction (8, 9). Tachykinin effects on immune cells can also be non-
receptor mediated. Substance P can cause degranulation of mast cells through direct
activation of G proteins in the inner surface of the plasma membrane (10).
It is well appreciated that mast cells play a critical role in immediate hypersensitivity
reactions, involving IgE. However, mast cells also play a prominent role in non-atopic
hypersensitivity reactions (11,12,13). Firstly, mast cell degranulation is observed in DNFB-
sensitized mice directly after DNS challenge (12,14,15). Furthermore, non-IgE
hypersensitivity responses such as tracheal hyperreactivity and neutrophil infiltration are
absent in WBB6F1-W/Wv and Sl/Sld mast cell deficient mice (14). As mast cells are in close
proximity to excitatory NANC-nerves, the mast cell is thought to be an important mediator
cell in neuroimmune interactions (16,17).
In the present study, we investigated the role of the neurokinin receptors in the
non-atopic hypersensitivity reactions in the mouse airways leading to tracheal
hyperreactivity and cellular accumulation in mice. Furthermore, mast cell activation was
measured early after hapten challenge. The involvement of the tachykinin receptors in the
development of airway hyperresponsiveness, pulmonary cellular influx and mast cell
activation, was studied by using  specific NK-1 and NK-2 receptor antagonists and NK-1
receptor knockout mice.
Methods
Animals. Male BALB/c mice were obtained from Charles River, Someren, the Netherlands.
Neurokinin 1 receptor knockout mice (back-crossed to BALB/c) were developed and bred
by Dr. N. Gerard, Harvard, Boston, USA (16). All mice used were 6-8 weeks of age. The
experiments were conducted in accordance with the Animal Care Committee of the Utrecht
University (Utrecht, The Netherlands).
Sensitization and experimental procedure. Mice were skin-sensitized on day 0 and 1 with
dinitrofluorobenzene (DNFB, 50 µl 0.5 %) or vehicle (acetone:olive oil, 4:1). On day 5 the
animals were intranasally challenged with dinitrobenzene sulfonic acid (DNS, 50 µl 0.6%
in PBS). DNFB- or vehicle-sensitized mice were intravenously (i.v.) injected with the
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neurokinin 1 (NK-1) receptor antagonist RP67580 (10-9 mol/mouse) or the neurokinin 2 (NK-
2) receptor antagonist SR48968 (10-9 mol/mouse) at indicated times after the sensitization.
As a control group, DNFB and vehicle sensitized mice were i.v. injected with RP65681, the
inactive enantiomer of RP67580 (10-9 mole/mouse) or saline in the SR48968 study. The
concentration SR48968 used in this study showed to be effective since this NK-2 receptor
antagonist was capable of significantly inhibiting ear swelling in NK-1 receptor knockout
mice caused by intradermal application of neurokinin A (100 pmol/site) (Saline/Saline:
94±22 µm; NKA/Saline: 218±22 µm, n=4; p<0.05. Saline/SR48968: 105±13 µm; NKA/SR48968:
134±16 µm, n=6; ns). Previous studies have shown that the mentioned dose RP67580 has
been effective in inhibiting NK-1 receptor-mediated responses in the mouse (18,19). The
NK-1 receptor antagonist and its inactive enantiomer were administered i.v. using four
treatment regimes:
I. 10 min before and 1 h after the challenge
II. 46 and 47 h after the challenge
III. 10 min before and 1 h, 24, 46 and 47 h after the challenge
IV. 10 min before challenge.
The NK-2 receptor antagonist, or saline as its control, was administered according to
regime III and IV.
Tracheal reactivity in vitro.  Mice were killed with an overdose of  pentobarbitone 48 h after
intranasal DNS challenge. The trachea, which was resected in toto, was carefully cleaned
of connective tissue using a binocular microscope. A nine ring piece of trachea (taken from
just below the larynx) was then transferred to a 10 ml organ bath containing a modified
oxygenated Krebs solution (118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 0.5 mM MgCl2, 25
mM NaHCO3, 1 mM NaHPO4 and 11.1 mM glucose), aerated with 95% O2: 5% CO2, 37ºC.
Measurements were expressed as changes in milligram (mg) force. An optimal preload,
determined to be 1 g, was placed on the tissue at the beginning of the experiment. The
trachea was allowed to equilibrate for at least 1 h before contractile effects were elicited.
During this period, the bath fluid was exchanged every 15 min. At the end of the equilibrium
phase, tracheal contractile reactivity was measured by recording cumulative concentration
response-curves to carbachol (10-8 to 10-4 M).
Leukocyte accumulation in bronchoalveolar lavage fluid. Bronchoalveolar lavages (BAL)
were taken from vehicle and DNFB-sensitized mice 48 h after the challenge. After sacrificing
the animals, the trachea was carefully intubated and the catheter was secured with ligatures.
The chest cavity was exposed for expansion. Saline (37ºC) was slowly injected via the
catheter into the lung and withdrawn in 4 x 1 ml aliquots. The aliquots were pooled and
maintained at 4ºC. The lavage fluids were centrifuged (1500 rpm, 10 min., 4ºC) to isolate
the BAL cells. The cell pellet was resuspended in 150 µl PBS. Total cells were counted using
a haemocytometer and expressed as cells/lung. The BAL cell preparations were analyzed
morphologically after centrifugation on microscopic slides. Air dried preparations were
fixed and stained with hematoxylin and eosin to ascertain the leukocyte populations. Results
are expressed as leukocytes/lung for neutrophils and mononuclear cells in the airway
lumen.
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Mast cell activation in vivo. Blood samples of DNFB- and vehicle-sensitized mice were
taken 30 min after intranasal DNS challenge. Blood samples were collected and after
centrifugation sera were stored at 70o C until use. Levels of mouse mast cell protease 1
(mMCP-1), a selective marker for mast cell degranulation, were measured using a
commercially available ELISA assay. Results were expressed as ng mMCP-1 per ml serum.
Materials. DNFB and olive oil were purchased from Sigma Chemical Co., St. Louis, USA.
RP67580 and RP65681 were generous gifts from Rhône-Poulenc Rorer, Dr. C. Garrett in
France. SR48968 was a generous gift from Dr. X. Emonds-Alt (Sanofi Research France).
Carbachol was purchased from Onderlinge Farmaceutische Groothandel, Utrecht, The
Netherlands. Sodium pentobarbitone was obtained from Sanofi, Maassluis, The Netherlands.
The mMCP-1 ELISA was from Moredun Scientific Ltd., Midlothian, UK. Maxisorp surface 96
well plates were purchased from Nunc Immuno plate, Roskilde, Denmark.The force
displacement transducer was purchased from Harvard Bioscience, Boston, MA, USA and
the two channel recorder (Servogar type SE-120) from Plato BV, Diemen, the Netherlands.
Data analyses. Data are expressed as mean and standard error of the mean (SEM). EC50-
and Emax-values for the carbachol-induced tracheal contractions were calculated by non-
linear least-squares regression analysis of the measured contractions versus carbachol
concentration using the sigmoid concentration-response relationship. The data were
analyzed by performing a two way analysis of variance (ANOVA). Data on the cellular
accumulation were studied by a distribution free Kruskal-Wallis ANOVA. mMCP-1 data
were analyzed by using a one-tailed unpaired t-test. Probability values of P<0.05 were
considered significantly different. Analyses were performed by the usage of Graphpad
Prism (version 2.01, San Diego, U.S.A.).
Results
Effect of NK receptor antagonists on DNFB-induced tracheal hyperreactivity.
Intranasal hapten application in DNFB-sensitized mice resulted in the development of a
tracheal hyperreactivity to carbachol at 48 h (Figures 1a and 2a). In previous studies, we
have shown that neuropeptide depletion prevented the development of DNFB-induced
tracheal hyperreactivity (8). We now further focussed on the role of NK receptors 1 and 2
in the development of this hyperreactivity. Mice were i.v. injected with the NK-1 receptor
antagonist RP67580 or the NK-2 receptor antagonist SR48968 at indicated times after the
sensitization. RP67580 had no effect on the DNFB-induced tracheal reactivity when
administered 10 min before and 1 hr after the challenge (regimen I) or at 46 and 47 h
after the challenge (regimen II) (table 1). Previously, it was demonstrated that it is important
to have a sustained concentration of the antagonist present to inhibit the NK-1 receptor in
vivo (20). After pretreatment with the NK-1 receptor antagonist RP67580 10 min before
and 1 h and 24, 46 and 47 h after the challenge (regimen III) the development of tracheal
hyperreactivity was abolished in DNFB-sensitized animals (Figure 1b, table 1). Pretreatment
with the inactive enantiomer RP65681 according to all treatment regimens did not affect
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the tracheal hyperreactivity observed in DNFB-sensitized mice 48 h after the DNS challenge
(table 1). In vehicle-sensitized animals, treatment with RP67580 or RP65681 did not affect
basal tracheal reactivity (figure 1b, table 1). Pretreatment with the NK-2 receptor antagonist
SR48968, using regimen III, did not influence the tracheal hyperreactivity (figure 2b,
table I) suggesting that only the NK-1 receptor played a role in the induction of non-atopic
airway hyperreactivity.
Table 1. Effect of NK-1 or NK-2 receptor
inhibition on the development of tracheal
hyperreactivity. Emax and EC50 values
are derived from concentration-response
curves to carbachol (10-8-10-4 M). Mice
were skin-sensitized with DNFB and
challenged intranasally with DNS. Mice
were i.v. injected with RP67580, the
inactive enantiomer RP65681, SR48968
or saline following indicated treatment
regimes (see Methods).Results are
expressed as mean ± sem (n=6).
Significant differences are denoted by (*)
or (**) for p<0.05, p<0.01 between the
vehicle-sensitized and the DNFB-
sensitized group, respectively.
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Figure 1. Effect of NK-1 receptor blockade on the development of tracheal hyperreactivity to carbachol 48 h
after intranasal DNS challenge in DNFB-sensitized BALB/c mice. Concentration-response curves were measured
in DNFB- (closed circles) or vehicle- (open circles) sensitized mice treated i.v. with 10-9 mol/mouse
RP65681(control, a) or RP67580 (NK-1 receptor antagonist, b) at 10 min before, 1 h, 24, 46 and 47 h after the
DNS challenge. Results are expressed as mean ± SEM (n=6). Significant differences (p<0.01) between curves
are denoted by (**).
Sensitization Treatment Regimes Emax (mg) pD2
Vehicle RP65681 I 1593 ± 98 6.9 ± 0.0
DNFB RP65681 I  2334 ± 196**  6.8 ± 0.0*
Vehicle RP67580 I 1384 ± 100 6.9 ± 0.0
DNFB RP67580 I  2372 ± 167*** 6.8 ± 0.1
Vehicle RP65681 II 1736 ± 67 6.8 ± 0.1
DNFB RP65681 II 2544 ± 368** 6.8 ± 0.1
Vehicle RP67580 II 1533 ± 221 6.7 ± 0.1
DNFB RP67580 II 2484 ± 173 6.8 ± 0.1
Vehicle RP65681 III 1755 ± 185 6.6 ± 0.0
DNFB RP65681 III  3368 ± 110*** 6.9 ± 0.1
Vehicle RP67580 III 1760 ± 247 6.7 ± 0.0
DNFB RP67580 III 2070 ± 166 6.8 ± 0.1
Vehicle Saline III 1696 ± 157 6.9 ± 0.1
DNFB Saline III  3012 ± 202***  6.7 ± 0.0*
Vehicle SR48968 III 1872 ± 359 6.7 ± 0.1
DNFB SR48968 III  3292 ± 298** 6.8 ± 0.1
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No development of DNFB-induced tracheal
hyperreactivity in NK-1 receptor knockout
mice.
To further confirm the role for the NK-1
receptor, we studied the development of
hyperreactivity in the airways of NK-1
receptor knockout mice. The animals were
DNFB-sensitized and DNS-challenged and
tracheal responses were measured 48 h
after DNS challenge. In contrast to control
BALB/c mice, in the NK-1 receptor knockout
animals no hapten-induced development of
tracheal hyperreactivity was observed in
DNFB-sensitized mice compared to vehicle-
sensitized animals (Emax: Con 1720 mg ±
113 mg, DNFB 1762 mg ± 118 mg. n=6;
ns) (figure 3). Moreover, vehicle-sensitized
and hapten-challenged NK-1 receptor
knockout mice demonstrated a similar
tracheal reactivity response upon
stimulation with carbachol as vehicle-
sensitized and DNS-challenged BALB/c mice
(Emax: BALB/c mice 1752 mg ± 179 mg,
NK-1 receptor knockout mice 1720 mg ±
113 mg. n=6; ns).
Figure 2. Effect of NK-2 receptor blockade on the development of tracheal hyperreactivity to carbachol 48 h
after intranasal DNS challenge in DNFB-sensitized BALB/c mice. Concentration-response curves were measured
in DNFB- (closed circles) or vehicle- (open circles) sensitized mice treated i.v. with saline (control, a) or with
10-9 mol/mouse SR48968 (NK-2 receptor antagonist, b) at 10 min before, 1 hr, 24, 46 and 47 h after the DNS
challenge. Results are expressed as mean ± SEM (n=6). Significant differences between the vehicle-sensitized
and the DNFB-sensitized group are denoted by (*) or (**) for p<0.05 or p<0.01, respectively.
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Figure 3. Effect of NK-1 receptor deficiency on
tracheal hyperreactivity to carbachol 48 h after
intranasal DNS challenge in DNFB-sensitized mice.
Control Balb/c mice (a) and NK-1 receptor knock-
out mice (b) were DNFB- (closed circles) or vehicle-
(open circles) sensitized and DNS-challenged.
Results are expressed as mean ± SEM (n=6).
Significant differences (p<0.05) between curves
are denoted by (**).
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Tachykinin receptors in DNFB-induced
leukocyte accumulation in bronchial
alveolar lavage fluid.
An increase in mononuclear cells and
neutrophils was found in DNFB-sensitized
mice 48 h after DNS challenge (figure 4,
table 2) compared to vehicle-sensitized
mice. A separate set of mice were injected
with the NK-1 or NK-2 receptor antagonist
10 min before and 1 h, 24, 46 and 47 h
after DNS challenge (regimen III). The
NK-1 receptor antagonist, RP67580, did
significantly inhibit the accumulation of
mononuclear cells and neutrophils in the
airway lumen of DNFB-sensitized mice
(figure 4a, table 2). In contrast, treatment
with the NK-2 receptor antagonist
SR48968 showed no significant decease
in cellular accumulation associated with
the pulmonary hypersensitivity response
(figure 4b, table 2). In NK-1 receptor
knockout mice, no significant differences
in the accumulation of mononuclear cells
and neutrophils were found comparing
DNFB- and vehicle-sensitized animals 48
h after challenge (figure 4c, table 2).
Figure 4. Effect of NK-1 or NK-2 receptor inhibition
or deficiency of the NK-1 receptor on neutrophil
accumulation in bronchoalveolar fluid. BALB/c mice
were DNFB- or vehicle-sensitized, DNS-challenged
and: (a) treated with RP67580 or the inactive
enantiomer RP65681 at 10 min before and 1 h, 24,
46 and 47 h after challenge. (b) treated with SR48968
or the inactive control at 10 min before and 1 h, 24,
46 and 47 h after challenge. (c) NK-1 receptor
knockout mice were DNFB- or vehicle-sensitized and
DNS challenged. Open symbols represent vehicle-
sensitized and closed symbols DNFB-sensitized mice.
Results are expressed as mean number of neutrophils/
lung ± SEM (n=6). Significant differences between
the vehicle-sensitized and the DNFB-sensitized group
are denoted by (*) or (**) for p<0.05 or p<0.01,
respectively.
Sensitization Treatment Regimes Median (min-max) of
mononuclear cell (x1000)
Vehicle RP65681 III 23.5 (15.8-36.4)
DNFB RP65681 III 44.2 (26.4-48.6)
*
Vehicle RP67580 III 22.1 (19.1-25.7)
DNFB RP67580 III 26.2 (14.7-33.1)
Vehicle Saline III 18.7 (10.0-26.7)
DNFB Saline III 29.2 (18.9-52.4)
Vehicle SR48968 III 19.5 (11.9-29.4)
DNFB SR48968 III 29.5 (18.9-39.9)
Vehicle NK-1 receptor -/- mice 70.5 (29.4-85.3)
DNFB NK-1 receptor -/- mice 52.1 (32.3-58.2)
Table 2.  Effect of NK-1 or NK-2 receptor inhibition or deficiency of the NK-1 receptor on mononuclear cell
number in bronchoalveolar fluid. Mice were skin sensitized with DNFB and challenged intranasally with DNS.
Mice were i.v. injected with RP67580, the inactive enantiomer RP65681, SR48968 or saline following
indicated treatment regimes (see Methods).
Results are expressed as mean ± sem (n=6). Significant differences are denoted by (*) for p<0.05 between the
vehicle-sensitized and the DNFB-sensitized group.
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No involvement of tachykinin receptors in mast cell activation in vivo.
mMCP-1 levels in serum were measured to monitor mast cell activation. Previously, it was
demonstrated that in mice the DNFB/DNS-induced hypersensitivity was associated with
rapid mast cell activation as assessed by elevated serum levels of mMCP-1 at 30 min after
challenge (15). Indeed, in our study, serum mMCP-1 levels were increased 30 min after-
DNS challenge in DNFB-sensitized animals when compared to vehicle-sensitized mice (figure
5). The NK-1 receptor antagonist RP67580 nor the NK-2 receptor antagonist SR48968
were able to block early mast cell activation (Figure 5). Similar mast cell activation was
found in DNFB-sensitized NK-1 receptor knockout mice compared to DNFB-sensitized BALB/
c mice 30 min after hapten challenge (figure 5).
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Figure 5. No effect of NK-1 or NK-2 receptor inhibition
or deficiency of the NK-1 receptor on mast cell activation
induced by intranasal hapten challenge of DNFB-sensitized
mice. BALB/c mice were vehicle- or DNFB-sensitized, DNS
challenged and: (a) treated with RP67580 or the inactive
enantiomer RP65681 10 min before challenge. (b) treated
with SR48968 or the inactive control 10 min before
challenge. (c) NK-1 receptor knockout mice were DNFB-
or vehicle-sensitized and DNS challenged. mMCP-1 levels
in seum were measured 30 min after challenge. Open
bars represent vehicle-sensitized and closed bars DNFB-
sensitized mice. Results are expressed as mean ± SEM
(n=6). Significant differences between the vehicle-
sensitized and the DNFB-sensitized group are denoted by
(**) for p<0.01, respectively.
Discussion
The present study provides evidence for the involvement of the NK-1 receptor in the
pathogenesis of non-atopic asthma. To investigate the role of the NK-1 receptor, we induced
non-atopic asthma in mice by DNFB skin-sensitization and intranasal DNS challenge.
Blockade of the NK-1 receptor with a specific antagonist or the genetic absence of the NK-
1 receptor prevented the development of tracheal hyperreactivity and cellular accumulation
in the mouse airways. These results are in concord with our previous studies showing that
neonatal neuropeptide depletion prevented the induction of tracheal hyperreactivity and
cellular accumulation (21) and indicate that neuropeptide stimulation of the NK-1 receptor
plays a crucial role in the development of this airway disease.
It has been demonstrated that, in the mouse adult lung, substance P-like
immunoreactive nerve fibers are located in the smooth muscle of the airways, surrounding
bronchi and bronchioli (22). Ek and coworkers (23) demonstrated that substance P and
neurokinin A are released in response to epicutaneous application of the allergen oxazolone,
a hapten known to cause hypersensitivity reactions in skin and airways. From our results,
we hypothesize that intranasal DNS challenge causes tachykinin release from the sensory
nerve endings in DNFB-sensitized airways.
The tachykinins substance P and neurokinin A, locally released from excitatory
NANC nerves upon activation by different stimuli, have been shown to elicit inflammatory
71               The NK-1 receptor in non-atopic asthma
airway responses, collectively referred to as neurogenic inflammation (24,25). These
responses include bronchoconstriction, mucus secretion, vascular leakage, upregulation
of adhesion molecules and recruitment and activation of inflammatory cells. These
inflammatory responses are predominantly mediated by tachykinin receptors (26-30).
Despite the evidence for the involvement of excitatory NANC neuropeptides in non-
atopic airway inflammation (12,21), it remained unclear which tachykinin receptors are
implicated in the development of tracheal hyperreactivity and cellular accumulation. The
present study shows that development of tracheal hyperreactivity and cellular accumulation,
associated with DNFB-induced hypersensitivity reactions in the mouse, were inhibited by
the selective NK-1 receptor antagonist RP67580. The NK-2 receptor antagonist SR48968
did not affect the non-atopic tracheal hyperreactivity and cellular accumulation. The role
for the NK-1 receptor was further confirmed in NK-1 receptor knockout mice. Therefore, it
can be concluded that the NK-1 receptor, but not the NK-2 receptor, plays an important
role in the induction of tracheal hyperreactivity and cellular accumulation in the mouse
lung.
Several studies have reported that exposure of guinea pigs to substance P elicited
airway hyperresponsiveness to bronchoconstrictor agents. In the rat, a significant increase
of airway responsiveness to acetylcholine was found after substance P pretreatment in the
presence of a NEP inhibitor (31). Until now, no reports have described substance P-induced
tracheal hyperreactivity in murine airways. Preliminary experiments in BALB/c mice have
demonstrated that intranasal administration of substance P resulted in the induction of a
profound tracheal hyperreactivity to carbachol (data not shown).
Excitatory NANC neuropeptides do not act only on bronchial smooth muscle, but it
has recently become evident that neuropeptides are modulators of immune cells such as
mast cells, eosinophils, neutrophils and lymphocytes. From these immune cells, mast
cells, neutrophils and lymphocytes have been shown to be involved in this murine model
for non-atopic asthma (14,32). In the skin and airways, it has been demonstrated that
substance P is able to induce infiltration and activate lymphocytes and neutrophils to
release their mediators such as cytokines, oxygen radicals and myeloperoxidase (MPO)
(28). Furthermore, substance P can cause degranulation of mast cells in the respiratory
system (11,12,16,17,28,33). Therefore, it is possible that excitatory NANC neuropeptides
modulate smooth muscle activity indirectly via stimulation of infiltrating or resident immune
cells.
Using a NK-1 receptor antagonist and NK-1 receptor knockout mice, we have shown
that the antigen-induced infiltration of neutrophils is dependent on the presence of NK-1
receptors (Figure 4). These results correlate with the study of Bozic and coworkers (34), in
which they have demonstrated that neutrophil accumulation was not found in NK-1 receptor
knockout mice undergoing an immune-complex reaction. Moreover, studies have reported
that substance P or specific NK-1 receptor agonists injected locally in skin or airways, was
able to induce neutrophil infiltration (35-38). Potent inhibitory effects of NK-1 receptor
antagonists on substance P induced neutrophil infiltration point out to an important role
for the NK-1 receptor. The local microenvironment in the tissue seems te be important,
because injection of substance P in normal rat and mouse skin did not induce neutrophil
infiltration (39), but in inflamed skin the NK-1 receptor was involved in mediating neutrophil
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accumulation (40). A possible mechanism of action of substance P in inducing infiltration of
neutrophils, could be the upregulation of the expression of intracellular adhesion molecule
(ICAM-1). Previously, we have demonstrated a prominent role for ICAM-1 in the development
of tracheal hyperreactivity and cellular infiltration in DNFB-sensitized and DNS-challenged
mice (41). Nakagawa and coworkers have shown that substance P is able to upregulate
the expression of ICAM-1 on human endothelial cells (42). Besides the substance P-induced
infiltration of neutrophils, it has been shown that substance P activates neutrophils, an
effect that could be mediated by the NK-1 receptor. Stimulation of human PMN cells by
substance P leads to superoxide anion production, IL-8 or MPO release (43). This mediator
release in turn could lead to the development of tracheal hyperreactivity.
NK-1 receptor blockade or NK-1 receptor deficiency also prevented the DNFB/DNS-
induced increased number of mononuclear cells in BAL fluid. An increase in lymphocytes
mainly accounted for this rise in mononuclear cells in the airway. Tachykinin NK-1 receptors
have been demonstrated on human and murine lymphocytes (44). Furthermore, substance
P has been shown to stimulate chemotaxis (45), proliferation and activation of these cells
(46). T-lymphocyte proliferation induced by substance P occurred both in the absence and
presence of other stimuli and was mediated via the NK-1 receptor. Kaltreider and coworkers
(47) have shown that mice undergoing a pulmonary immune reaction demonstrated a
significant rise of BAL fluid lymphocytes expressing NK-1 receptor mRNA. Systemic treatment
of mice with a selective NK-1 receptor antagonist reduced significantly the total number of
lymphocytes, leukocytes and granulocytes retrieved in BAL fluid on day 5 of the pulmonary
immune response (47). Taken together, we propose that DNFB/DNS-induced release of
substance P and subsequent stimulation of the NK-1 receptor results in the infiltration and
activation of neutrophils and lymphocytes. Besides the neutrophil and lymphocyte, the
mast cell has been shown to be an essential immune cell in pulmonary hypersensitivity
reactions (14,32). Mast cells and macrophages lining the mucosal layer of the respiratory
tract, have been found in close vicinity of substance P- and CGRP-immunoreactive nerves
(12,16,17). It has been shown that excitatory NANC nerves can modulate the activation
state of mast cells. Stimulation of nerve fibers induces mast cells to degranulate and
release histamine and other mediators such as serotonin and TNF-α in the respiratory tract
of humans and animals (13). Mediator release from mast cells can be induced by
neurotrophic factors such as NGF (48) and neuropeptides (49,50). Recently, Forsythe and
coworkers (51) have demonstrated that substance P and neurokinin A induce histamine
release from human airway mast cells. Activation of mast cells by substance P has been
reported to be NK-1, NK-2 receptor mediated as well as non-receptor mediated, e.g. via
direct activation of G-proteins (52,53). Whether NK receptors are involved or not in mediator
release from mast cells, may be dependent on agonist concentration and mast cell origin.
The interaction between mast cells and excitatory NANC nerves is bidirectional. Many
studies have shown that mast cell derived mediators, such as histamine, serotonin,
prostaglandins and leukotrienes, can modulate NANC neurotransmission. Moreover, NANC
nerve endings express receptors for histamine (H1 and H3) and serotonin (5-HT2A) (33,54,55).
Under inflammatory-like conditions, it has been shown that primary NANC nerves show an
upregulation of histamine H1 receptor expression (56). Mast cell mediators can sensitize
and cause release of substance P and CGRP from unmyelinated C-fibers (57,58). One of
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the major cytokines released by mast cells under inflammatory conditions is tumor necrosis
factor α (TNF-α). Very recently, we showed that mast cell-derived TNF-α has a priming
effect on excitatory NANC nerves in (32). Thus, not only can tachykinins induce mast cell
degranulation but also mediators released from mast cells cause the release of neuropeptides
from sensory nerve endings. In our study, the NK-1 or NK-2 receptor blockade nor deficiency
of the NK-1 receptor could inhibit mast cell activation associated with a pulmonary non-
atopic response, which suggests that mast cells are activated by non-receptor mediated
mechanisms or by other stimuli.
In conclusion, our study points to a role for excitatory NANC nerves in non-atopic
asthma. The NK-1 receptor is crucial for the development of tracheal hyperreactivity and
leukocyte accumulation, which occurs parallel to or distal from mast cell activation.
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Abstract
Tumor necrosis factor alpha (TNF-α) is a multifunctional proinflammatory cytokine, rapidly
released by mast cells, that elicits a large number of biological effects, including
inflammatory and immuno-regulatory responses. The present study shows that TNF-α is
an important mediator in the pathogenesis of non-atopic asthma. Non-atopic asthma was
induced in mice by skin sensitization with dinitrofluorobenzene (DNFB) followed by intranasal
challenge with dinitrobenzene sulfonic acid (DNS). Features of this pulmonary reaction
include acute bronchoconstriction, tracheal hyperreactivity, cellular infiltration and an
increase in mucosal exudation in the alveolar lumen, not characterized by an elevation of
total and allergen-specific IgE in serum. Intranasal DNS challenge of DNFB-sensitized
mice was accompanied with rapid mast cell activation as measured by increase in serum
mast cell protease-1 (mMCP-1) compared to vehicle sensitized animals. Significantly
increased levels of TNF-α were found in the bronchoalveolar lavage (BAL) fluid BAL fluid of
DNFB-sensitized mice, 30 min to 3 h after DNS challenge (30 min DNFB/DNS: 147±27 pg/ml;
vehicle/DNS 72±10 pg/ml: p<0.05. 3 h DNFB/DNS: 122±19 pg/ml; vehicle/DNS 77±11 pg/ml:
p<0.05, n=3-6). Neutralizing anti-TNF-α antibodies did not affect mast cell activation.
However, neutralizing anti-TNF-α antibodies strongly reduced the tracheal hyperreactivity
and the accumulation of neutrophils and mononuclear cells in the BAL fluid in DNFB-
sensitized mice at 48 h after DNS challenge. Pretreating animals with an antagonist for the
TNFR1 receptor inhibited the development of tracheal hyperreactivity, whereas blockade
of the TNFR2 receptor had no effect. These findings indicate that TNF-α and its TNFR1
contribute to the induction of airway hypersensitivity reactions in a murine model for non-
atopic asthma.
Introduction
Tumor necrosis factor alpha (TNF-α) is a multifunctional proinflammatory cytokine that
elicits a large number of biological effects such as hyperresponsiveness, vascular
permeability, vasodilatation and the influx and accumulation of neutrophils (1-3).
A variety of cells such as alveolar macrophages, fibroblasts, monocytes, endothelial
cells and neutrophils produce and release TNF-α upon stimulation (4-8). Moreover, the
mast cell, a tissue resident inflammatory cell,  contains immunologically inducible TNF-α
and, in contrast to many other cell types, has a storage of preformed TNF-α (9). TNF-α is
identified to be one of the main preformed mediators immediately released by the mast
cell after cellular activation (10, 11). Furthermore, mast cells secrete newly synthetized
TNF-α within 30 min following certain stimuli such as specific allergen and LPS (9).
Increased concentrations of TNF-α, in response to local injury, can play a role in
cellular activation and the proliferation of the inflammatory response. Several investigators
have shown increased amounts of TNF-α in BAL fluid of asthmatic patients (12, 13). In
patients with toluene diisocyanate-induced asthma, a form of non-atopic asthma, TNF-α
immunoreactivity was enhanced compared to control patients and the localization of the
cytokine was predominantly to mast cells (14). These results indicate a possible role for
mast cell-derived TNF-α in the pathogenesis of non-atopic asthma.
TNF-α has been demonstrated to upregulate the expression of adhesion molecules,
effecting the neutrophil infiltration into the airways (15). Infiltration with neutrophils and
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other inflammatory cells can subsequently lead to tissue destruction in the course of
chronic inflammatory diseases such as asthma (16).
Biological activities of TNF-α are mediated by two distinct receptors, the p55 type 1
receptor (TNFR1) and p75 type 2 receptor (TNFR2). TNFR1 is associated with inflammation
(1, 17) and neutrophilic infiltration (18), while TNFR2 seems to play a role in cell proliferation,
the induction of tissue necrosis (1) and initiation of cutaneous immune responses (19,
20). The majority of cell types and tissues appear to express both receptors (1, 21).
In the present study, we investigated the role of TNF-alpha in pulmonary non-IgE-
mediated hypersensitivity reactions in the mouse, a murine model for non-atopic asthma.
It is currently accepted that asthma can roughly be divided into two categories. The majority
of patients have atopic asthma, which is characterized by an elevation of total and allergen-
specific IgE in serum (22). The second category comprises the non-atopic asthmatics.
Non-atopic asthmatics are skin test negative to common allergens and there is no evidence
of allergen-specific serum IgE (23, 24). Amin and coworkers recently showed that besides
the difference in serum IgE levels, atopic and non-atopic patients had different pathological
changes present in their airways despite their similar clinical respiratory symptoms (25).
Atopic patients had increased numbers of eosinophils in their airway tissue, whereas non-
atopic asthma is dominated by the infiltration of neutrophils. The number of mast cells
showed a similar increase in both of the groups. Many studies have focused on the role of
the mast cell in atopy showing that TNF-α released from the mast cell plays a role in the
pathogenesis of atopic asthma (3, 26).
In our laboratory, a murine model for non-atopic asthma has been developed and
characterized (27, 28). In this model, mice were skin sensitized with the low molecular
weight compound dinitrofluorobenzene (DNFB) followed by an intra-airway challenge with
dinitrobenzene sulphonic acid (DNS). Features of this pulmonary reaction included acute
bronchoconstriction and mast cell activation shortly after challenge, and tracheal
hyperreactivity, mononuclear and neutrophilic cell infiltration and an increase in mucosal
exudation in the alveolar lumen 24 to 48 h after the challenge. This hypersensitivity reaction
was not associated with an increase in hapten specific IgE (27, 28).
 Previous studies in our laboratory have pointed to an important role for the mast
cell in non-atopic pulmonary hypersensitivity reactions (29, 30). In this study, we report
on the role of TNF-α in the airway hyperreactivity response and cellular infiltration observed
in this murine model for non-atopic asthma.
Methods
Animals.  Male BALB/c mice were obtained from the Central Animal Laboratory (GDL),
Utrecht University, Utrecht, The Netherlands. All mice used were 6-8 weeks of age. Animal
studies were approved by the Animal Care Committee of the Utrecht University (Utrecht,
The Netherlands).
Sensitization and experimental procedure. Mice were sensitized on day 0 with either
DNFB (0.5% dissolved in acetone: olive oil [4:1]) or vehicle control, both of which were
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applied epicutaneously to the shaved thorax (50 µl) and all four paws (50 µl). On day 1,
DNFB or vehicle control (50 µl) was applied to the thorax alone. DNFB- and vehicle-
sensitized mice were intranasally challenged with dinitrobenzene sulphonic acid (DNS,
50 µl 0.6 % in PBS, pH 7.2) on day 5. The sensitization and challenge were performed
under light anesthesia (pentobarbitone, 40 mg/kg i.p.). In stated experiments,
neutralizing anti-TNF-α antibodies (XT22, 1 mg/mouse), anti-TNF R1 and R2 antibodies
(50 µg/mouse) or control antibodies were injected i.v. 1 hr before and 24 h after DNS
challenge.
Measurement of TNF-α in BAL fluid. Bronchoalveolar lavages (BAL) were taken from vehicle-
or DNFB-sensitized animals at different time points after DNS challenge. After sacrificing
the animals, the trachea was intubated and 1 ml saline (37o C) was slowly injected into the
lung and withdrawn. The lavage fluids were centrifuged (1500 rpm, 10 min., 4ºC) to
isolate the BAL cells. The concentration of TNF-α in BAL fluid was measured via ELISA.
Plates were coated with anti-TNF-α antibody (4 µg/ml rat anti-mouse TNF-α) at 4ºC. The
next day, plates were washed 5 times with 0.1% Tween 20 in PBS. Non-specific binding
was prevented by incubating plates with 0.5% BSA in PBS for 2 h at room temperature.
After washing, BAL fluid and standards were loaded on the plates together with biotinylated
rabbit anti-mouse TNF-α antibody (1.25 µg/ml, 100 µl) and incubated for 2 h on an orbital
shaker. Thereafter, plates were washed and streptavidin-poly-HRP (1:25000, 100 µl) was
added and incubated for 1 h at room temperature on the shaker. Plates were washed and
a solution of chromogen tetramethyl benzidine (TMB) 100 µl 1% TMB in DMSO, 10 ml 0.1
M sodium acetate buffer and 10 µl 3% H2O2) was added to each well. The plates were
incubated for 15-30 min protected from light on an orbital shaker. The reaction was stopped
with 100 µl 0.9 M H2SO4. The optical density was measured at a wavelength of 595 nm with
a Benchmark microplate reader. Results are expressed as pg TNF-α per ml BAL fluid.
Mast cell activation in vivo. Blood samples of DNFB- and vehicle-sensitized mice were
taken 30 min after intranasal DNS challenge. Blood samples were centrifuged and sera
were stored at -70ºC until use. Levels of mouse mast cell protease-1 (mMCP-1), a selective
marker for mast cell degranulation, were measured using a commercially available ELISA
assay. Results were expressed as ng mMCP-1 per ml serum.
Leukocyte accumulation in bronchoalveolar lavage fluid. Bronchoalveolar lavages (BAL)
were taken from vehicle and DNFB-sensitized mice 48 h after the challenge. After sacrificing
the animals, the trachea was carefully intubated and the catheter was secured with ligatures.
The chest cavity was exposed for expansion. Saline (37ºC) was slowly injected via the
catheter into the lung and withdrawn in 4 x 1 ml aliquots. The aliquots were pooled and
maintained at 4ºC. The lavage fluids were centrifuged (1500 rpm, 10 min, 4ºC) to isolate
the BAL cells. The cell pellet was resuspended in 150 µl PBS. Total cells were counted using
a haemocytometer and expressed as cells/lung. The BAL cell preparations were analyzed
morphologically after centrifugation on microscopic slides. Air dried preparations were
fixed and stained with hematoxylin and eosin to ascertain the leukocyte populations. Results
are expressed as leukocytes/lung for neutrophils and mononuclear cells in the airway
lumen.
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Tracheal reactivity in vitro. Mice were killed with an overdose of pentobarbitone 48 h after
intranasal DNS challenge. The trachea, which was resected in toto, was carefully cleaned
of connective tissue using a binocular microscope as described before (27). A nine ring
piece of trachea (taken from just below the larynx) was then transferred to a 10 ml organ
bath containing a modified oxygenated Krebs solution (118 mM NaCl, 4.7 mM KCl, 2.5 mM
CaCl2, 0.5 mM MgCl2, 25 mM NaHCO3, 1 mM NaHPO4 and 11.1 mM glucose), aerated with
95% O2: 5% CO2, 37ºC. Measurements were expressed as changes in milligram (mg)
force. An optimal preload, determined to be 1 g, was placed on the tissue at the beginning
of the experiment. The trachea was allowed to equilibrate for at least 1 h before contractile
effects were elicited. During this period, the bath fluid was exchanged every 15 min. At the
end of the equilibrium phase, tracheal contractile reactivity was measured by recording
cumulative concentration response-curves to carbachol (10-8 to 10-4 M).
Materials. DNFB and olive oil were purchased from Sigma Chemical Co., St. Louis, USA.
DNS was obtained from Eastman Kodak Company (Rochester, New York, USA). Hamster
anti-mouse TNFR1 and TNFR2 antibodies were purchased from Genzyme (R&D systems,
Inc., Minneapolis, USA). Hamster serum, used as a control for the TNFR1 and R2 antibodies,
was obtained from the Central Animal Laboratory (Utrecht, The Netherlands). Rat anti-
mouse TNF-α antibodies and biotinylated rabbit anti-mouse TNF-α antibodies were obtained
from Pharmingen (San Diego, USA). Sodium barbitone was purchased from Sanofi BN
(Maassluis, The Netherlands). Carbachol was purchased from Onderlinge Pharmaceutische
Groothandel, Utrecht, The Netherlands. Hematoxylin and eosin were obtained from Sigma
Aldrich, St.Louis, MO, USA. The TNF-α ELISA kit was obtained from BioSource, Nivelles,
Belgium and the mMCP-1 ELISA from Moredun Scientific Ltd., Midlothian, UK. Maxisorp
surface 96 well plates were purchased from Nunc Immuno plate, Roskilde, Denmark. The
Benchmark microplate reader came from Biorad, California, USA.  The force displacement
transducer was purchased from Harvard Bioscience, Boston, MA, USA and the two channel
recorder (Servogar type SE-120) from Plato BV, Diemen, the Netherlands.
Statistical analysis.  Data are expressed as mean and standard error of the mean (SEM).
EC50- and Emax-values for the carbachol-induced tracheal contractions were calculated
by non-linear least-squares regression analysis of the measured contractions versus
carbachol concentration using the sigmoid concentration-response relationship. The data
were analyzed by performing a two-way analysis of variance (ANOVA). Data on the cellular
accumulation were studied by a distribution free Kruskal-Wallis ANOVA. mMCP-1 data
were analyzed by using a one-way ANOVA followed by the Bonferronis multiple comparison
test. Probability values of P<0.05 were considered significantly different. Analyses were
performed by the usage of Graphpad Prism (version 2.01, San Diego, U.S.A.).
Results
TNF-α levels in BAL fluid of DNFB-sensitized and DNS-challenged mice.
TNF-α was detectable in the BAL fluid of both vehicle- and DNFB-sensitized mice. At 30 min
and 3 h after DNS challenge, the amount of TNF-α in the BAL fluid of DNFB-sensitized
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animals was significantly increased compared to vehicle-sensitized animals. At later time
points after challenge, the amount of TNF-α in BAL fluid of DNFB-sensitized animals declined
to basal levels as found in vehicle-sensitized mice (figure 1).
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Figure 1.  TNF-α levels (pg/ml) in BAL fluid of DNFB- and
vehicle-sensitized mice at different time points after DNS
challenge. Open bars represent vehicle-sensitized and
closed bars DNFB-sensitized mice. Data are expressed as
mean ± SEM, 3-6 animals per group, Significant differ-
ences are denoted by (*) for p<0.05 as compared to
vehicle-sensitized animals at the same time point.
Effect of anti-TNF-α treatment on
mast cell activation in vivo.
mMCP-1 levels in serum were measured
to monitor mast cell activation.
Previously, it was demonstrated that
in mice the DNFB/DNS-induced
hypersensitivity was associated with
rapid mast cell activation as assessed
by elevated serum levels of mMCP-1
at 30 min after challenge (31). Indeed,
in our study, serum mMCP-1 levels were
increased 30 min after-DNS challenge
in DNFB-sensitized animals when
compared to vehicle-sensitized mice
(figure 2). No effects of anti-TNF-α
antibodies on basal mMCP-1 levels were
observed. Neutralizing anti-TNF-α did
not affect the mMCP-1 release in DNFB-
sensitized mice (figure 2).
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Figure 2. No effect of anti-TNF-α-antibodies on mast cell
activation induced by intranasal hapten challenge of DNFB-
sensitized mice. Mice were vehicle- or DNFB-sensitized, DNS
challenged and treated with anti-TNF-α-antibodies (XT22, 1
mg/mouse) or rat IgG (control, 1 mg/mouse) 10 min before
challenge. mMCP-1 levels in serum were measured 30 min
after challenge. Open bars represent vehicle-sensitized and
closed bars DNFB-sensitized mice. Results are expressed as
mean ± SEM (n=6). Significant differences between curves
are denoted by (**) for p<0.01.
Effect of anti-TNF-α antibody treatment in DNFB-induced leukocyte accumulation in
bronchoalveolar lavage fluid.
An increase in cellular accumulation of mononuclear cells and neutrophils was found in
DNFB-sensitized animals 48 h after DNS challenge (table 1). The neutralizing TNF-α-antibody
significantly inhibited the accumulation of mononuclear cells and neutrophils in DNFB-
sensitized mice (table 1).
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Effect of anti-TNF-α antibody treatment on DNFB-induced tracheal hyperreactivity.
Intranasal DNS application in DNFB-sensitized animals resulted in the development of tracheal
hyperreactivity to carbachol 48 h after challenge (figure 3a). To study the role of TNF-α in
the development of tracheal hyperreactivity, neutralizing anti-TNF-α antibodies were i.v.
injected 1 h before and 24 h after challenge. Figure 3 shows that anti-TNF-α treatment
abolished the development of tracheal hyperreactivity in DNFB-sensitized mice. Anti-TNF-
α itself did not affect basal reactivity as measured in vehicle-sensitized, hapten challenged
mice (figure 3, table 2).
Sensitization Treatment Leukocyte accumulation in BAL fluid (cells/lung x 103)
total cells        mononuclear cells neutrophils
Vehicle IgG  22.5 (12.0-42.0)      24.5 (12.0-32.7) 0.2 (0.0-1.0)
DNFB IgG  40.5 (37.5-55.5)      38.5 (34.5-52.2)* 3.0 (2.0-3.3)*
Vehicle anti-TNF-α  24.0 (19.5-30.0)      25.3 (19.3-33.0) 0.3 (0.0-0.5)
DNFB anti-TNF-α  21.8 (19.5-22.5)     21.4 (18.3-22.3) 1.1 (0.2-1.7)
Table 1.  Effect of neutralizing anti-TNF-α antibodies on mononuclear and neutrophil cell numbers in
bronchoalveolar fluid. Mice were skin sensitized with DNFB and challenged intranasally with DNS and studied
48 h after the challenge. Mice were i.v. injected with neutralizing TNF-α antibodies or IgG 1 h before and 24 h
after challenge (see Methods).
Results are expressed as median (min-max) (n=5-6 animals/group). Significant differences are denoted by (*)
for p<0.05 between the vehicle-sensitized and the DNFB-sensitized group and by () for p<0.05 between the
control (IgG) and the anti-TNF-α-treated group.
Table 2. Effect of neutralizing anti-TNF-α antibodies and R1/R2 receptor inhibition on the development of
tracheal hyperreactivity. Emax and pD2 values are derived from concentration-response curves to carbachol
(10-8-10-4 M). Mice were skin-sensitized with DNFB and challenged intranasally with DNS. Mice were i.v. injected
with anti-TNF-α, anti-R1, anti-R2 or hamster serum as a control (see Methods).
Sensitization Treatment Emax (mg)               pD2
  Vehicle      IgG 1756 ± 201 6.7 ± 0.1
   DNFB      IgG 2896 ± 143** 6.9 ± 0.1
  Vehicle anti-TNF-α 1780 ± 240 6.7 ± 0.1
   DNFB anti-TNF-α 2213 ± 186 6.7 ± 0.0
  Vehicle             hamster serum 1760 ± 186 6.7 ± 0.1
   DNFB             hamster serum 2848 ± 216** 6.7 ± 0.1
  Vehicle anti-TNFR1 1731 ± 157 6.6 ± 0.1
   DNFB anti-TNFR1 1923 ± 218 6.7 ± 0.1
  Vehicle             hamster serum 1885 ± 211 6.6 ± 0.0
   DNFB             hamster serum 2973 ± 182** 6.7 ± 0.1
  Vehicle anti-TNFR2 1812 ± 83 6.6 ± 0.0
   DNFB anti-TNFR2 2515 ± 162* 6.7 ± 0.0
Results are expressed as mean ± sem (n=6). Significant differences are denoted by (*) or (**) for p<0.05,
p<0.01 between the vehicle-sensitized and the DNFB-sensitized group, respectively and by () for p<0.05
between the control (IgG) and the anti-TNF-α-treated group.
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Effect of anti-TNFR1 and anti-TNFR2
antibody treatment on DNFB-induced
tracheal hyperreactivity.
In a second set of experiments, we
neutralized TNF-α by treatment with
TNF-α receptor-specific antibodies. In
previous studies, it has been shown
that TNFR1 and R2-specific antibodies
inhibited TNF-α induced activation of
the receptors. Both receptor antibodies
do not activate the receptor by itself
(32). The role of TNFR1 and TNFR2 was
studied by i.v. injection of antagonists
against the R1 and R2 receptor 1 h
before and 24 h after challenge. Figure
4 and 5 respectively, show that anti-
TNFR1, but not anti-TNFR2, inhibited
the development of tracheal
hyperreactivity in DNFB-sensitized,
DNS-challenged mice (table 2).
Figure 3. Effect of anti-TNF-α-antibodies on the development of tracheal hyperreactivity to carbachol 48 h
after intranasal DNS challenge in DNFB-sensitized mice. Concentration-response curves were measured in
DNFB- (closed circles) or vehicle- (open circles) sensitized mice treated i.v. with rat IgG (control, 1 mg/mouse,
a) or anti-TNF-α-antibodies (XT22, 1 mg/mouse, b) at 10 min before and 1 h after the DNS challenge. Results
are expressed as mean ± SEM (n=6). Significant differences (p<0.01) between curves are denoted by (**).
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Figure 4. Effect of TNFR1 receptor blockade on the development of tracheal hyperreactivity to carbachol 48 h
after intranasal DNS challenge in DNFB-sensitized BALB/c mice. Concentration-response curves were measured
in DNFB- (closed circles) or vehicle- (open circles) sensitized mice treated i.v. with rat IgG (control, 1 mg/
mouse)  (a) or with 1 mg/mouse anti-TNFR1 (b) at 10 min before and 1 h after the DNS challenge. Results are
expressed as mean ± SEM (n=6). Significant differences (p<0.01) between curves are denoted by (**).
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Discussion
The present study shows that TNF-α is an important mediator in the pathogenesis of non-
atopic asthma. Neutralizing antibodies for TNF-α completely prevented the development
of tracheal hyperreactivity and airway inflammation in mice.
 TNF-α is increased in the sputa of patients with bronchial asthma (33) and several
studies have shown that BAL fluid from atopic asthmatics contains increased amounts of
TNF-α (34, 35). Workers with confirmed diiocyanate-induced occupational asthma,
comprising of both atopic and non-atopic patients, showed increased levels of TNF-α in
BAL fluid (36). To date no studies clearly report on changed TNF-α levels specifically in
non-atopic asthma patients. In the present study, TNF-α levels in BAL fluid of non-atopic
mice were significantly increased in sensitized animals shortly after challenge. This suggests
that TNF-α is released by cells that contain prestored TNF-α leaving the mast cell as a
potential source (11). Previous studies in our laboratory confirm this hypothesis. Van
Houwelingen and coworkers (30) found that mast cell deficient mice failed to show an
increase in TNF-α BAL levels 30 min after challenge in the murine model presented in this
study. These data point to an important role of mast cell-derived TNF-α in mice undergoing
a non-atopic asthmatic reaction.
TNF-α released from storage granules of mast cells appears to play a prominent
role in neutrophil recruitment. For instance, neutrophil influx during IgE-dependent
cutaneous inflammation is dependent on mast cells. TNF-α was identified as an important
mediator involved in this response (37). In the present study, neutralizing TNF-α antibodies
were capable of significantly diminishing the number of neutrophils and mononuclear cells
in the BAL fluid of mice during a pulmonary hypersensitivity reaction. In accordance,
neutralization of TNF-α in vivo has been shown to decrease the influx of neutrophils and
subsequently suppress tissue injury in several models of inflammation. Furuta and coworkers
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Figure 5. No effect of TNFR2 receptor blockade on the development of tracheal hyperreactivity to carbachol 48
h after intranasal DNS challenge in DNFB-sensitized mice. Concentration-response curves were measured in
DNFB- (closed circles) or vehicle- (open circles) sensitized mice treated i.v. with rat IgG (control, 1 mg/
mouse)(a) or with 1 mg/mouse α−TNFR2 (b) at 10 min before and 1 h after the DNS challenge. Results are
expressed as mean ± SEM (n=6). Significant differences between curves are denoted by (*) or (**) for p<0.05
and p<0.01, respectively.
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(38) found that the local administration of anti-TNF-α antibodies resulted in the inhibition
of neutrophil accumulation in all layers of the stomach. In the airways, neutralization of
TNF-α  in vivo also affected the neutrophil infiltration, decreasing the percentage of cells
by 50% (39). Kips and coworkers showed that anti-TNF-α antibodies partly diminished the
influx of neutrophils into BAL fluid occurring after LPS exposure (2). In addition, they
demonstrated that the increase in bronchial hyperresponsiveness after LPS exposure, was
significantly diminished when pretreating rats with anti-TNF-α antibodies. This is in line
with our study where anti-TNF-α antibodies diminished the development of tracheal
hyperreactivity reaction in the murine model for non-atopic asthma.
The mechanisms of TNF-α involvement in the neutrophil response and tracheal
reactivity reaction may center around the induction of adhesion molecules and leukocyte-
specific chemokines, with the ability to participate in inflammatory responses (39). TNF-α
has been shown to upregulate endothelial adhesion molecules, such as ELAM-1 and VCAM-
1. The induction of these adhesion molecules has been shown to be essential for the
migration of the neutrophil (40, 41). Moreover, monoclonal antibodies against adhesion
molecules were able to block the occurrence of airway hyperresponsiveness in rat, sheep
and guinea pig models (42-46). In the present model for non-atopic asthma, it was
demonstrated that treatment with anti-LFA-1 or anti-ICAM-1 resulted in the abolishment
of the accumulation of neutrophils into the airway lumen and a total suppression of the
development of tracheal hyperreactivity (47, 48). These results suggest a relation between
the migration of neutrophils into BAL fluid and the development of tracheal hyperreactivity.
Biological activities of TNF-α can be mediated by the TNFR1 and TNFR2 receptor.
We demonstrated that the induction of tracheal hyperreactivity is abolished after treatment
with α-TNFR1 but not after treatment with TNFR2 antibodies. Selective deficits in several
host defense and inflammatory responses are observed in mice lacking the TNFR1 or both
R1 and R2 receptor, but not in mice lacking only the R2 receptor. In the skin, Kondo and
Sauder show that the inflammation induced by TNF-α in TNFR1 -/- mice is less than in
TNFR2 -/- or control mice (1). This may be explained by the lack of induction of adhesion
molecules as TNFR1-/- mice failed to show any upregulation of ICAM-1. In the presented
study, the mechanism may involve the TNF-α R1 receptor-induced upregulation of adhesion
molecules, facilitating the migration of neutrophils eventually leading to tracheal
hyperreactivity. However, TNF-α may also directly modulate airway smooth muscle
contractility by directly inducing calcium sensitization of intracellular contractile elements
(49).
Taken together, we show that TNF-α is present in the BAL fluid shortly after challenge,
probably released by mast cells. Additionally, we propose that TNF-α plays a central role in
the development of airway hypersensitivity reactions in a murine model for non-atopic
asthma.
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Abstract
Previously, we and other investigators have demonstrated that TNF-α and substance P are
involved in the inflammatory process associated with airway diseases. In the present
study we examined the effects of TNF-α and substance P on tracheal hyperreactivity and
cellular accumulation and activation by intranasal application of TNF-α (250 pg/mouse),
substance P (10-10mol/mouse) or a combination of TNF-α and substance P to BALB/c mice
on 2 consecutive days. Hyperreactivity occurred 24 h after the second treatment in all
thee groups of mice compared to the PBS-treated group. Mice treated with the combination
of TNF-α and substance P showed a more profound development of tracheal hyperreactivity
than mice injected with TNF-α or substance P alone. TNF-α-treated animals, in contrast to
the substance P-treated group, demonstrated a significant increase in the number of
neutrophils in the bronchoalveolar lavage (BAL) fluid compared to the PBS-treated group.
Neutrophil depletion caused a significant decrease in the TNF-α-induced hyperreactivity
reaction, supporting the role of the neutrophil in the development of tracheal hyperreactivity
by TNF-α. A significant increase in the number of neutrophils was also seen in the substance
P/TNF-α-treated group compared to the PBS-treated group. Moreover, TNF-α- and TNF-α/
substance P-induced increase in BAL neutrophils was accomponied by a rise in
myeloperoxidase levels in the BAL fluid, indicative for neutrophil activation. In summary,
TNF-α and substance P both can induce tracheal hyperreactivity via possibly different
pathways. Substance P amplifies the TNF-α-induced infiltration and subsequent activation
of neutrophils.
Introduction
A close anatomical relationship between mast cells and nerves has been reported in virtually
all tissues of the body including the airways (1-3). Close proximity to nerves, mostly of
sensory origin, allows a bidirectional communication between mast cells and the nervous
system (4, 5). Sensory neurons play an important role in neurogenic inflammation and it
is becoming apparent that the mast cell may also play a role in this process (6, 7). Its
inflammatory mediators can affect neuronal functioning by inducing an enhanced release
of neuropeptides from the sensory nerve endings, a process that could be involved in the
pathogenesis of asthma.
TNF-α, a major mast cell mediator, has been shown to be involved in the inflammatory
process in asthma. Several investigators have shown increased amounts of TNF-α in BAL
fluid of asthmatic patients (8, 9). In the airways, neutrophils, alveolar macrophages, airway
epithelial cells, T lymphocytes and mast cells are all potential sources of TNF-α (10, 11).
However, the mast cell is the only cell containing prestored TNF-α in its granules (12)
which can be released by mast cells shortly after activation.
The airways are innervated with C-fiber terminals containing tachykinins, that are
able to cause neurogenic inflammation (7, 13, 14).  Substance P is a neuropeptide belonging
to the family of tachykinins. It is stored in a subpopulation of afferent nerves characterized
by their sensitivity to capsaicin. The release of tachykinins from sensory nerves can be
evoked by a variety of stimuli such as capsaicin, electrical nerve stimulation, temperature,
low pH, toluene diisocyanate, methacholine, leukotrienes, and prostaglandins (15).
Subsequent to its release from nerve endings, substance P can increase microvascular
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permeability, contract smooth muscle and stimulate immune cells such as the mast cell.
Substance P showed to play an inflammatory role in several animal models for airway
diseases (16, 17). In humans, BAL fluid and sputum samples taken from asthmatics after
antigen challenge show an increase in substance P immunoreactivity (18). In addition, in
asthmatic patients, an increase in both the number and the length of substance P-containing
nerve fibers are found compared to subjects without asthma (19). These findings suggest
a role for substance P in asthma.
Substance P and TNF-α are two important mediators which may link the neurologic
and the immune system. Several studies have shown that mast cell mediators such as
TNF-α can sensitize sensory neurons and cause the release of tachykinins such as substance
P from unmyelinated C-fibers (20-22). Substance P is an important stimulus for cytokine
expression in mast cells and can for instance selectively modulate mast cell TNF-α production
(23). In the present study, the direct effects of TNF-α, substance P and the combination of
TNF-α/substance P on tracheal hyperreactivity and neutrophil accumulation and activation,
were studied by intranasal application of TNF-α and/or substance P to BALB/c mice.
Methods
Animals.  Male BALB/c mice were obtained from the Central Animal Laboratory (GDL),
Utrecht University, Utrecht, The Netherlands. All mice used were 6-8 weeks of age.
Experiments were conducted in accordance with the Animal Care Committee of the Utrecht
University (Utrecht, The Netherlands).
Intranasal treatment with TNF-α and substance P. Naïve mice were anesthetized with
sodium pentobarbitone (50 mg/kg i.p.). The animals received TNF-α (250 pg/mouse),
substance P (5x10-10mol/mouse), a combination of TNF-α and substance P, or PBS as a
control, intranasally, in a volume of 50 µl on day 0 and day 1. On day 2, mice were killed
by an overdose of pentobarbitone and experiments were conducted.
Neutrophil depletion. In stated experiments, neutrophils were depleted from the circulation,
diluted rabbit anti-PMN antiserum (1:10 in sterile saline, 12 ml/g body weight) or control
serum (rabbit serum) was injected i.p. 1 day before starting TNF-α treatment and at day 0,
together with intranasal TNF-α treatment. In a pilot study performed in naïve mice (n=3
mice/group), the effective neutropenia was approximately 98% with the total neutrophil
count decreasing from 143.2 ± 12.1 x 104 cells/ml in the control serum treated mice to 4.7
± 0.4 x 104 cells/ml in the anti-PMN antibody treated animals.
Tracheal reactivity in vitro.  Mice were killed with an overdose of pentobarbitone at day 2
after starting the treatment of the mice. The trachea, which was resected in toto, was
carefully cleaned of connective tissue using a binocular microscope as described before
(24). A nine ring piece of trachea (taken from just below the larynx) was then transferred
to a 10 ml organ bath containing a modified oxygenated Krebs solution (118 mM NaCl, 4.7
mM KCl, 2.5 mM CaCl2, 0.5 mM MgCl2, 25 mM NaHCO3, 1 mM NaHPO4 and 11.1 mM
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glucose, aerated (95% O2: 5% CO2, 37ºC)). An optimal preload, determined to be 1 g, was
placed on the tissue at the beginning of the experiment. The trachea was allowed to
equilibrate for at least 1 h before contractile effects were elicited. During this period, the
bath fluid was exchanged every 15 min. At the end of the equilibrium phase, airway
reactivity was measured by recording cumulative concentration response-curves to carbachol
(10-8 to 10-4 M).
Leukocyte accumulation in bronchoalveolar lavage fluid. Bronchoalveolar lavages (BAL)
were performed 24 h after the final treatment with either PBS, TNF, substance P or a
combination of TNF-α and substance P. After sacrificing the animals, the trachea was
carefully intubated and the catheter was secured with ligatures. The chest cavity was
exposed for expansion. Saline (37ºC) was slowly injected via the catheter into the lung
and withdrawn in 4 x 1 ml aliquots. The aliquots were pooled and maintained at 4ºC. The
lavage fluids were centrifuged (1500 rpm, 10 min, 4ºC) to isolate the BAL cells. The cell
pellet was resuspended in 150 µl PBS. Total cells were counted using a haemocytometer
and expressed as cells/lung. The BAL cell preparations were analyzed morphologically
after centrifugation on to microscopic slides. Air dried preparations were fixed and stained
with hematoxylin and eosin to ascertain the leukocyte populations. Results are expressed
as leukocytes/lung for neutrophils and mononuclear cells in the airway lumen. The remainder
of the cell suspension (approximate 80 µl of the original 150 µl) was kept at 20ºC for
myeloperoxidase activity of the BAL cells.
Myeloperoxidase in BAL fluid and BAL fluid cells. MPO activity, a marker for neutrophil
activation, was measured in the BAL fluid and in the BAL fluid cells according to a standard
spectrophotometrical technique (25). BAL cells samples were centrifugated and the
supernatants were used to measure MPO activity. Both BAL fluid and BAL cell supernatant
samples were diluted 1:1 in MPO dilution buffer (10 mM citratebuffer pH 5.0). Aliquots of
50 µl of each sample were pipetted into a 96-wells plate and 50 µl of substrate solution
(0.46 mM tetramethylbenzidene, 0.88 mM H202, and 120 µM resorcinol) was added to each
well. The samples were incubated with substrate solution at protected from light at room
temperature on a orbital shaker. The reaction was stopped after 15 min with a stop solution
(4N H2SO4). The optical density (OD) at 450 nm was determined. As an additional control,
50 µl of citratebuffer + 50 µl of substrate solution with resorcinol was pipetted into 4 wells,
followed by stop solution. Results were expressed as OD/ml BAL fluid or OD/ cells.
Furthermore, the OD was corrected for the total amount of neutrophils in the BAL fluid
samples and results were expressed as OD/neutrophil.
Materials. Substance P was purchased from Calbiochem-Novabiochem, Lufelfingen,
Switzerland and TNF-α from PeproTech Inc. (Rocky Hills, USA). Sodium barbitone was
purchased from Sanofi BN (Maassluis, The Netherlands). Carbachol was purchased from
Onderlinge Pharmaceutische Groothandel, Utrecht, The Netherlands. Rabbit anti-PMN
antiserum was obtained from Accurate Chemical & Scientific Corp., Westbury, New York,
USA. Control rabbit serum was purchased from Central Animal Laboratory, Utrecht, The
Netherlands. Hematoxylin and eosin (Diff-Quick) were purchased from Merz & Dade A.G.,
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Dubingen, Switzerland. The force displacement transducer was purchased from Harvard
Bioscience, Boston, MA, USA and the two channel recorder (Servogar type SE-120) from
Plato BV, Diemen, the Netherlands.
Statistical analysis. Data are expressed as mean and standard error of the mean (SEM).
EC50- and Emax-values for the carbachol-induced tracheal contractions were calculated
by non-linear least-squares regression analysis of the measured contractions versus
carbachol concentration using the sigmoid concentration-response relationship. The data
were analyzed by performing a two-way analysis of variance (ANOVA). Data on the cellular
accumulation were analyzed by a distribution free Kruskal-Wallis ANOVA followed by Dunns
multiple comparison test. MPO data were analyzed by using a one-way ANOVA followed by
the Bonferronis multiple comparison test. Probability values of P<0.05 were considered
significantly different. Analyses were performed by the usage of Graphpad Prism (version
2.01, San Diego, U.S.A.).
Results
Effect of TNF-α  and/or substance P on the development of tracheal hyperreactivity.
Mice were intranasally treated with TNF-α, substance P, or a combination, on day 0 and
day 1. On day 2, a significant tracheal hyperreactivity occurred in mice treated with TNF-
α or with substance P compared to PBS-treated animals. Mice treated with a combination
of TNF-α and substance P showed a more profound development of tracheal hyperreactivity
than mice injected with TNF-α or substance P alone. This increase was significantly different
from the reactivity in substance P treated mice, but not from the TNF-α treated group.
When ∆Emax values of the different treatment groups were compared, it can be concluded
that the effect of substance P and TNF-α were additive (figure 1 and table 1).
Treatment Emax ∆ Emax pD2
PBS 1997  133 0 6.8 ± 0.1
TNF-α 2805 ± 122* 808 ± 179.7* 6.7 ± 0.1
Substance P 2553 ± 132* 556 ± 187.4* 6.9 ± 0.1
TNF-α/substance P 3436 ± 137* 1438 ± 190.0* 6.8  ± 0.1
Table 1. Effect of TNF-α, substance P or TNF-α/substance P on the development of tracheal
hyperreactivity. Mice were i.n. treated with TNF-α, substance P, TNF-α/substance P or PBS. Emax and
pD2 values are derived fromconcentration-response curves to carbachol (10
-8-10-4 M).
Results are expressed as mean ± sem (n=6). Significant differences (p<0.05) denoted by (*)
compared to  the PBS and () to the substance P group.
Effect of TNF-α and/or substance P on leukocyte accumulation in bronchalveolar lavage
fluid. A significant increase in the number of neutrophils in the TNF-α treated group compared
to control PBS-treated mice was observed (table 2). No significant differences in the
number of neutrophils were seen in the substance P-treated mice compared to control
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Figure 2. Effect of TNF-α, substance P or the combination of TNF-α and substance P on myeloperoxidase levels
in: A. BAL fluid and B. neutrophils. All animals were treated on 2 consecutive days. Reactivity was measured 24
h after the last treatment. Results are expressed as mean ± SEM (n=6). Significant differences (p<0.05)
denoted by (*) compared to the PBS group and () to the substance P group.
Table 2. Effect of TNF-α, substance P or TNF-α/substance P on leukocyte accumulation and differentiation.
Mice were i.n. injected with TNF-α, substance P, TNF-α/substance P or PBS as a control.
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Results are expressed as median (min-max). Significant differences (p<0.05) are denoted by (*) compared
to the PBS group and ()  to the substance P group.
Treatment Leukocyte accumulation in BAL fluid (cells/lung x 103)
Total cells Mononuclear cells Neutrophils
PBS 28.5 (21.0-45.0) 25.9 (19.9-42.3) 1.8 (1.1-2.7)
TNF-α 48.0 (33.0-60.0) 31.7 (20.5-49.1) 15.4 (7.6-19.8)*
Substance P 27.8 (19.5-45.0) 24.4 (16.6-36.5) 3.5 (2.7-8.6)
TNF-α/Substance P 56.3 (37.5-76.5) 34.8 (23.6-40.0) 21.8 (12.2-38.2)*
Figure 1. Effect of TNF-α, substance P or the
combination of TNF-α and substance P on the
development of tracheal hyperreactivity to
carbachol. Concentration-response curves were
measured in substance P- (closed squares), TNF-
α (open squares), TNF-α/substance P- (closed
circles) and PBS-treated mice (open circles). All
animals were treated on 2 consecutive days.
Reactivity was measured 24 h after the last
treatment. Results are expressed as mean ± SEM
(n=6). Significant differences (p<0.05) are denoted
by (*) compared to the PBS group and by ()
compared to the substance P group.
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animals (table 2). Mice treated with the combination of TNF-α and substance P showed a
significant increase in the number of neutrophils in the BAL Fluid (table 2). The neutrophil
increase as seen in the TNF-α/substance P group is more profound although not significantly
higher than in mice treated with TNF-α.
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Effect of TNF-α and substance P on myeloperoxidase levels in BAL fluid and neutrophils.
Treatment with substance P did not change the MPO content in the BAL fluid when compared
to PBS-treated mice (figure 2a). However, TNF-α treatment did significantly increase the
MPO levels in the BAL fluid. A combination of TNF-α and substance P led to a profound
increase in the MPO levels in the BAL fluid. This increase was significant compared to the
PBS-treated group(p=0.002) as well as to the substance P-treated animals (p=0.04).
However, the increase was not significantly different from treatment with TNF-α alone
(p=0.08). The amount of MPO per neutrophil was significantly decreased in the TNF-α and
the TNF-α/substance P- treated groups suggesting that the neutrophils had released their
MPO (figure 2b). This finding is consistent with the significant increase in MPO levels in the
BAL fluid supernatant in both groups.
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Figure 3. Effect of α-PMN antibody on the TNF-α-
induced development of tracheal hyperreactivity to
carbachol. Animals were treated with TNF-α on 2
consecutive days. a-neutrophil antibodies (300 ul/
mouse) or rabbit serum (control) were injected i.p.
1 day before TNF-α treatment and at day 0, together
with intranasal TNF-α treatment. Reactivity was
measured 24 h after the last TNF-α treatment.
Concentration-response curves were measured in
PBS/rabbit serum- (closed squares), PBS/α-PMN
(open squares), TNF-α/rabbit serum (closed circles)
and TNF-α/α-PMN-treated mice (open circles). Results
are expressed as mean ± SEM (n=6). Significant
differences (p<0.05) from the PBS group are denoted
by (*).
Effect of anti-PMN antibody on the TNF-α-induced development of tracheal hyperreactivity.
As is described above, TNF-α treatment caused a significant infiltration and activation of
neutrophils, presumably followed by the development of tracheal hyperreactivity. To study
this, an antiserum causing the depletion of neutrophils, was administered before and together
with TNF-α treatment. Neutrophil depletion induced a significant inhibition of TNF-α-induced
tracheal hyperreactivity. The reactivity of tracheas obtained from TNF-α/α-PMN-treated
animals did not significantly differ from the reactivity of tracheas obtained from PBS/
control or PBS/α-PMN-treated mice (figure 3).
Discussion
As mast cells are in close proximity to excitatory NANC-nerves, the mast cell is thought to
be a pivotal cell in neuroimmune interactions (2, 4, 5, 26). TNF-α and substance P are two
important mediators in the link between the neurologic and the immune system. In this
study we investigated the potential role of TNF-α and substance P in the development of
tracheal hyperreactivity, cellular accumulation and neutrophil activation.
TNF-α showed to significantly induce the development of tracheal hyperreactivity.
This is in accordance with earlier studies which show that application of TNF-α in vivo
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causes bronchial hyperresponsiveness in rats (27, 28). In addition, inhaled TNF-α is able to
increase the responsiveness of normal human subjects to methacholine (29). Indeed,
neutralizing antibodies for TNF-α completely prevents the development of tracheal
hyperreactivity in our murine model for non-atopic asthma (chapter 5 of this thesis).
TNF-α injection in human skin has been shown to induce neutrophil accumulation
within a few hours (30). We found that TNF-α was able to increase the number of neutrophils
in the BAL fluid of mice. In several models of acute inflammation, TNF-α has been
demonstrated to play a role in neutrophil infiltration (31-33). Neutralization of TNF-α in
vivo has also been shown to decrease the influx of neutrophils and subsequently suppress
tissue injury in several models of airway inflammation (27, 32). In chapter 5 of this thesis,
it was also shown that neutralizing TNF-α antibodies prevented the accumulation of
neutrophils in a murine model for non-atopic asthma. Summarized, TNF-α is a potent
inducer of neutrophil infiltration. However, TNF-α per se is a weak chemoattractant. The
chemotactic effect of TNF-α on tissue trafficking of neutrophils appears to be dependent on
the induction of cell adhesion molecules and the release of chemokines in the vascular
endothelium (32, 34-37). The murine CXC chemokines involved in neutrophil attraction
comprises macrophage inflammatory protein-2 (MIP-2) and cytokine-induced neutrophil
chemoattractant (KC). Selectins are another prerequisite for neutrophil adhesion and
subsequent migration. Mercer-Jones and coworkers demonstrated that TNF-α derived from
the mast cell is an important factor to induce endothelial selectins (38).
In the present study in mice, substance P is shown to cause tracheal hyperreactivity
after repeated substance P treatment. Substance P is one of the important tachykinins
released from the sensory nerve endings. It has been suggested that tachykinins, and
substance P in particular, can contribute to the inflammatory response in asthma (1, 7,
39). Exposure of guinea pigs to substance P elicited airway hyperresponsiveness (16, 40).
In the rat, a significant increase of airway responsiveness to acetylcholine was found after
substance P pretreatment in presence of a neural endopeptidase inhibitor (41).
Substance P-induced development of tracheal hyperreactivity could have been
mediated by an increased neutrophil influx. Serra and coworkers (42) indicated that
substance P can stimulate the synthesis and direct release of the chemotactic cytokine IL-
8 from polymorphonuclear cells. In this way, substance P may influence neutrophil adhesion
and subsequent migration towards lung inflammatory sites as has been described in various
studies (43-45). Moreover, substance P can increase the permeability of bloodvessels by
the activation of NK-1 receptors, thereby facilitating the movement of neutrophils into the
tissue compartment (46-48). A study by Tomoe and coworkers (49) demonstrated that
substance P induces neutrophil infiltration in a concentration-dependent way in the skin,
which was mediated though degranulation of mast cells. It can be speculated that substance
P induces neutrophil infiltration via the release of TNF-α from mast cells in the present
study. However, intranasal application of substance P showed only a minor, not significant
effect on the infiltration of neutrophils. Possibly, the concentration of substance P used in
this study, was not high enough to effect neutrophil infiltration or to evoke TNF-α release
from mast cells. Yet, substance P did amplify TNF-α-induced neutrophil infiltration and
activation suggesting that a treshold is passed by the effect of TNF-α.
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The results obtained from this study suggest that TNF-α and substance P both
affect airway hypersensitivity reactions. Application of the two compounds together  leads
to more profound effects. It is not clear what exact mechanisms are involved. The present
report demonstrates that neutrophil migration is involved in the development of TNF-α-
induced tracheal hyperreactivity as it could be significantly reduced by neutrophil depletion.
Amrani and coworkers (50, 51) showed that TNF-α can modulate airway smooth muscle
contractility by directly inducing calcium sensitization of intracellular contractile elements.
This might not be the mechanism involved in the development of tracheal hyperreactivity
by TNF-α in our study. Also, TNF-α can affect a subpopulation of C fibers resulting in the
release of substance P (52).  In turn, substance P could contribute to the induction of
hypersensitivity reactions in the mouse and can induce TNF-α release from mast cells (53-
56). Further research is needed to dissect the mechanimsms involved in substance P and
TNF-α-induced airway hyperreactivity and neutrophil infiltration.
The results from this study show that TNF-α and substance P are both able to
induce tracheal hyperreactivity via possible different pathways. Combination of both results
in a profound tracheal hyperreactivity. We can conclude that the infiltration and activation
of neutrophils is in turn, at least partly involved in the development of tracheal
hyperreactivity (scheme 1).
Scheme 1. Proposed model for the effects of TNF-α and substance P on airway function. TNF-α and
substance P both can induce tracheal hyperreactivity via different pathways. Substance P amplifies (as
denoted by +) the TNF-α-induced infiltration and subsequent activation of neutrophils.
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Abstract
It is widely accepted that NK-1 receptors are not generally expressed on mast cells but
little is known about their expression in inflammation. The present study shows expression
of NK-1 receptors on bone-marrow-derived mast cells (BMMC) under the influence of IL-4
or SCF. Highest expression was found when both cytokines are present. Six days of co-
culture with the cytokines IL-4 and SCF showed significant expression of NK-1 receptors
(NK-1 receptor+/c-kit+ BMMC; control: 8 %, IL-4/SCF: 16 %), while 12 days of cytokine-
co-culture increased this expression to 38 % positive mast cells. A longer co-culture with
IL-4 and SCF did not show an additional effect. Furthermore, we demonstrated the functional
relevance of NK-1 receptor expression for the activation of BMMC resulting in an enhanced
degranulation upon stimulation by substance P. This mast cell activation was significantly
diminished by the NK-1 receptor antagonist RP67580 (10  µM) when stimulated with low
concentrations of substance P. The inactive enantiomer RP65681 had no effect. In addition,
BMMC cultured from bone marrow of NK-1 receptor knockout mice showed significantly
decreased exocytosis to low concentrations of substance P. The present study clearly shows
that NK-1 receptor-induced activation contributes significantly at low physiological substance
P concentrations (<100  µM). At higher concentrations, activation of BMMC was largely
due to receptor-independent mechanisms. In conclusion, BMMC were shown to express
NK-1 receptors upon IL-4/SCF co-culture. This expression of NK-1 receptors has been
demonstrated to be of functional relevance and leads to an increase in the sensitivity of
BMMC to substance P.
Introduction
Mast cells are often found in the proximity of nerve endings, and may be activated by a
number of neuropeptides, including tachykinins such as substance P. This close anatomical
relationship in various tissues including skin (1), intestine (2), dura mater (3, 4) and
airway mucosa (1) suggests the involvement of mast cells in the neurogenic component of
inflammatory conditions. Furthermore, substance P can induce the release of histamine
from certain types of mast cells such as peritoneal and mucosal mast cells (5, 6), human
mast cells (7) and human pulmonary mast cells (8), further supporting the functional
interaction between mast cells and substance P-containing nerves.
         Mast cells can be divided into various subpopulations with distinct phenotypes. Two
main subsets, connective tissue type mast cells (CTMC) and mucosal mast cells (MMC) are
recognized as distinct mast cell populations with different phenotypical and functional
characteristics (9, 10). However, environmental factors such as cytokines, may induce
differentiation in various subsets (11). In spite of their differences, both CTMC and MMC
are considered to be derived from a common precursor in the bone marrow. Mast-cell
progenitor cells translocate from bone marrow to mucosal and connective tissues to locally
undergo differentiation into mature forms. They possess a remarkable degree of plasticity,
so that even apparently fully differentiated CTMC will transform their phenotype in MMC if
transplanted into a mucosal environment (12). Their development and survival essentially
depends on stem cell factor (SCF) and its receptor c-kit (13). Besides SCF, cytokines such
as IL-3, IL-4 and IL-10 influence mast cell growth and differentiation (14), as does nerve
growth factor (15, 16).
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          Classically, mast cells are associated with hypersensitivity reactions, involving the
interaction with IgE (17). However, mast cells also play a prominent role in non-IgE mediated
hypersensitivity reactions (18, 19). The sensitivity of mast cells to activation by non-
immunological stimuli such as polycationic compounds, complement proteins, superoxide
anions or neuropeptides is dependent on the subset of the mast cells examined (20).
           Basic secretagogues trigger mast cell exocytosis though a mechanism called
the peptidergic pathway. Instead of interacting with a membrane bound receptor, they
appear to directly activate and bind to pertussis toxin-sensitive GTP-binding proteins (G-
proteins) through the N-terminal domain located in the inner surface of the plasma
membrane (21, 22). Stimulation of G-proteins will activate a signal transduction pathway
eventually leading to mast cell mediator production and release.
It has been proposed that tachykinins like substance P can also induce mast cell
activation via a receptor-dependent mechanism (23-25). Activation of the neurokinin
receptors is dependent on the C-terminal domain of the tachykinins. C-terminal fragments
of substance P cause histamine release from the mouse mast cell line MC/9 via an NK-2
receptor mediated pathway (26). Cooke and coworkers (25) demonstrated that RBL-2H3
cells, a rat mast cell line homologous to MMC, express the NK-1 receptor for substance P
on their surface. However, it is widely accepted that mast cells do not express NK receptors
under normal physiological conditions. The observation that mast cell lines express NK-1
receptors could represent an aberrance of these cell lines.
Most reports reveal that neuropeptides only cause degranulation at relatively high
concentrations (>10-5 M). However, some researchers have shown that physiological
concentrations of substance P can have biological consequences under some conditions
(27). Therefore, we wondered if NK-1 receptors might be expressed on mast cells cultured
from bone marrow under different conditions involving co-culture with SCF and IL-4. We
examined the expression of NK-1 receptors on mast cells by fluorescence activated cell
sorting (FACS), and functionally by examining the release of ß-hexosaminidase in the
presence or absence of NK-1 inhibitors and the NK-1 receptor itself.
Previously, we have shown that substance P causes dose-dependent degranulation
in BMMC co-cultured with IL-4 and SCF for 6 days (28, 29). In this report, we have found
that BMMC express functional NK-1 receptors under the influence of IL-4 or SCF but are
expressed in highest numbers when IL-4 and SCF are both present. The IL-4/SCF-induced
upregulation of the NK-1 receptor on BMMC was associated with an increased response to
substance P.
Methods
Pokeweed mitogen-stimulated spleen cell conditioned medium (PWM-SCM).
Spleen cells from BALB/c mice (Charles River, Someren, the Netherlands or Harlan, Indianapolis,
Indiana, USA) were cultured at density of 2x106 cells/ml in RPMI 1640 medium containing 4
mmol/l L-glutamine , 5x10-5 mol/l 2-mercaptoethanol, 1 mmol/l sodium pyruvate, 100 U/ml
penicillin, 100 µg/ml streptomycin and 0.1 mmol/l nonessential amino acids (complete RPMI)
containing lectin (8 µg/ml) and placed in 75-cm2 tissue-culture flasks. The cells were
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incubated at 37o C in a 5% CO2 humidified atmosphere. After 5-7 days, medium was
collected, centrifuged for 15 min. at 4000 RPM, filtered through a 0.22 µm millipore filter
and used as PWM-SCM.
Mouse bone marrow cultures. BALB/c mice, in stated experiments NK-1 receptor knockout
mice (a generous gift from Dr. N. Gerard, Harvard, Boston, USA), were killed by cervical
dyslocation and bone marrow was aseptically flushed from femurs into complete RPMI
1640. The cell suspension was washed twice in complete RPMI by centrifugation at 400 g
for 10 min and finally resuspended in complete RPMI containing 10% vol/vol FCS and
placed in 75-cm2  tissue culture flasks at density of 1-2x105 cells/ml. PWM-SCM, 20% vol/
vol was added to the culture medium. Flasks were incubated at 37oC in a 5% CO2 humidified
atmosphere. Cells were centrifuged and resuspended in fresh media every week to achieve
a final concentration of 1-2x105 cells/ml. After 3-4 weeks, the BMMC were resuspended in
complete RPMI and cultured with IL-4 (300 U/ml), SCF (50 ng/ml) or IL-4 plus SCF. Cytokine-
treated BMMC were centrifuged and resuspended in fresh medium every three days to
achieve a final concentration of 2x105 cells/ml.
FACS analysis for NK-1 receptor expression. Immunofluorescence analysis was performed
to determine the presence of NK-1 receptors on BMMC positive for c-kit. Therefore BMMC
were monitored by double staining with the antibodies against the NK-1 receptor and c-
kit. RBL-2H3 cells were used as a positive control as these cells are known to express NK-
1 receptors. Cell staining analysis was performed on BMMC cultured under different culture
conditions : BMMC,  IL-4 co-cultured BMMC at 6 and 12 days of co-culture, SCF co-cultured
BMMC at 6 and 12 days of co-culture, IL-4/SCF co-cultured BMMC at 6, 12 and 18 days of
co-culture. Cells were harvested and resuspended at a concentration of 1x106 cells/ml. 105
cells were aliquoted per tube and cells were washed using ice-cold staining buffer (PBS
supplemented with 1% BSA, 0.02% EDTA and 0.02% NaN3). Cells were centrifuged at
1000 rpm for 5 min at room temperature and resuspended in staining buffer with the
primary rabbit antibody against either the NK-1 receptor (1:100) or rabbit IgG (isotype
control) was added. Biotin conjugated c-kit or isotype control (rat IgG) was added to the
designated tubes at a final concentration of 1 µg/ml and incubated for 30 min at room
temperature. Next, cells were centrifuged, washed twice and resuspended in blocking
buffer (staining buffer containing 5% goat serum). FITC-conjugated goat anti-rabbit IgG
was used for the detection of the NK-1 receptor, PE-conjugated streptavidin was used for
detection of c-kit, incubated for 30 min. Again, cells were centrifuged, washed twice and
resuspended in 500 µl FACS buffer per tube. Cells were analyzed using FACS WinList
(version 5.0).
Activation of cells. Bone marrow cells from BALB/c mice or NK-1 receptor knockout mice
were cultured for 3 to 4 weeks to develop into BMMC. At 3 to 4 weeks, these cells were
cultured with SCF and IL-4 as described above. Cells were washed twice with Tyrodes
buffer supplemented with 0.1% BSA and resuspended in Tyrodes buffer at density of
0.6x106 cells/ml. 2-3x104 cells were aliquoted in 96 well plates. In stated experiments
cells were pretreated with RP67580, a specific NK-1 receptor antagonist or its inactive
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enantiomer RP65681 (10-6 M) for 10 min. Cells were activated with different concentrations
of substance P (0-200  µM) for 30 min. Total release was established by adding NP40 to get
complete lysis of cells. After one hour incubation of the supernatant with assay solution
containing 4-methylumbelliferyl glucosaminide in 0.1 M citrate buffer (pH=4.5), the reaction
was stopped by adding 0.2 M glycine buffer, pH 10.7. Fluorescence was measured using a
multi-well plate reader at an emission wavelength y= 360 nm and excitation wavelength
y= 450 nm. The percentage of degranulation was calculated as: [(a-b)/(t-b)]x100, where
a is the amount of  ß-hexosaminidase released from stimulated cells, b is that released
from unstimulated cells and t is total cellular content.
Reagents. RPMI 1640, fetal calf serum and nonessential amino acids were purchased from
GibCo BRL Life Technologies, Paisley Scotland. Penicillin, streptomycin, L-glutamine, sodium
pyruvate, 2-mercaptoethanol were obtained from Sigma, St. Louis, MO, USA and lectin
from Phytocalla Americana. Murine recombinant SCF came from PeproTech, London, England.
Murine recombinant IL-4 was kindly provided by W.E. Paul NIH, USA. Substance P was
purchased from Novabiochem, Laufelfingen, Switzerland. Rabbit anti-NK1 was obtained
from Chemicon International, Temecula, Canada and rabbit IgG from DAKO Diagnostics,
Missisauga, Ontario, Canada. Goat anti-rabbit-FITC was purchased from Vector Lab,
Burlingame, Canada. Streptavidin-PE conjugate was from Becton Dickinson, USA. Biotin
anti-mouse CD117 (c-kit) was from PharmaMingen, San Diego, CA, USA. RP67580 and
RP65681 were generous gifts from Rhône-Poulenc Rorer, Dr. C. Garrett in France.
Results
NK-1 receptor expression on BMMC
Previously we have shown that co-culture of BMMC in presence of IL-4 and SCF increased
the sensitivity to stimulation by substance P (29).
To investigate if co-culture was paralleled by an increase in expression of the NK-1 receptor,
we analyzed binding of an NK-1 receptor specific antibody using flow cytometry. Cells
were double stained for NK-1 and c-kit to show the population of mature mast cells positive
for the NK-1 receptor. As a positive control, we first studied RBL-2H3 cells, which were
known to express NK-1 receptors on their surface (25). These cells indeed showed NK-1
receptor expression (NK-1 receptor+: 18.5%, table 1). To further confirm specificity, bone
marrow from NK-1 receptor knockout mice were cultured and studied for NK-1 receptor
expression. These NK-1 receptor cells were negative for the expression of the NK-1 receptor
(figure 1a). Additionally, NK-1 receptor knockout BMMC cells co-cultured with IL-4 and
SCF were also negative for the expression of the NK-1 receptor (figure 1b). We next
analyzed NK-1 receptor expression on BMMC cultured in PWM-SCM. On these cells, only
8.1 % of the cells showed expression of the NK-1 receptor (figure 2a). BMMC were now
studied after 6, 12 and 18 days of treatment with IL-4 and/or SCF. These levels of NK-1
receptor positive mast cells represent significant increases compared to untreated cells.
After 6 days of cytokine treatment, the percentage of cells expressing c-kit and the NK-1
receptor, increased significantly compared to non-treated BMMC. IL-4 by itself (figure 2b)
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showed no effect on the expression of the NK-1 receptor compared to non-treated cells
BMMC at this time of culture, whereas treatment with SCF displayed a slight increase
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Figure 1. FACS analysis of expression of NK-1 receptor on NK-1 receptor knockout BMMC in different culture
conditions. Mouse bone marrow cells were cultured for 28 days in the presence of PWM-SCM (A) or for 22 days
with PWM-SCM plus 6 days of IL-4/SCF co-culture (B) as described in methods. Cells were stained with anti-
NK-1 receptor antibody and analyzed by flow cytometry. Isotype controls are represented by the shaded
histograms. The clear histograms represent NK-1 receptor+ cells. Both untreated and IL-4/SCF treated cells
showed negative for NK-1 receptor expression.
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Figure 2. FACS analysis of NK-1 receptor+-c-kit+ cells in different culture conditions. Mouse bone marrow
cells were cultured for 28 days in the presence of PWM-SCM (A) or for 22 days with PWM-SCM plus 6
days with IL-4 alone (300 U/ml)(B), SCF alone (50 ng/ml)(C) or a combination of IL-4 and SCF (D).
Different cell populations were double stained with FITC-conjugated anti-NK-1 receptor (1:100) and
streptavidin PE-conjugated c-kit specific biotinylated Ab (1 ìg/ml) and analyzed by flow cytometry.
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compared to non-treated mast cells (figure 2c). Combining IL-4 and SCF demonstrated an
additional increase in NK-1 receptor expression (figure 2d). After 12 days of co-culture,
the percentage NK-1 receptor positive cells further increased (figure 3). No difference in
fluorescence background at 12 days was observed (figure 3). Treatment for 12 days with
IL-4 resulted in an increased number of positive mast cells compared to 6 days treatment
(figure 3b). The percentage of positive mast cells after single SCF treatment was also
increased at day 12 (figure 3c). IL-4/SCF co-cultured BMMC showed a percentage of 37.9
% positive cells for the expression of the NK-1 receptor (figure 3d).
Figure 3. FACS analysis of NK-1 receptor+-c-kit+ cells in different culture conditions. Mouse bone marrow
cells were cultured for 28 days in the presence of PWM-SCM (A) or for 16 days with PWM-SCM plus 12
days with IL-4 alone (300 U/ml)(B), SCF alone (50 ng/ml)(C) or a combination of IL-4 and SCF (D).
Different cell populations were double stained with FITC-conjugated anti-NK-1 receptor (1:100) and
streptavidin PE-conjugated c-kit specific biotinylated Ab (1 ìg/ml) and analyzed by flow cytometry.
Isotype controls are represented by the shaded histograms. The clear histograms represent NK-1 recep-
tor+-c-kit+
18 Days of IL-4 and SCF treatment did not further increase the percentage of positive
mast cells (NK-1 receptor+/c-kit+ BMMC; 12 days IL-4/SCF: 37.9 % vs 18 days IL-4/SCF:
38.6 %, data not shown), indicating a plateau level. Taken together, these data suggest
that IL-4 and SCF individually promote the expression of the NK-1 receptor on BMMC, but
together their effects are synergistic. An overview of all the experiments, with their respective
numbers of NK-1 receptor positive and NK-1 receptor/c-kit double positive cells is summarized
in table 1.
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Table 1. Percentage of cells positive
for the NK-1 receptor and cells double
positive for the NK-1 and c-kit receptor.
Different mast cell populations were
stained with FITC-conjugated anti-NK-
1 receptor (1:100) or double stained
with FITC-conjugated anti-NK-1
receptor and streptavidin PE-conjugated
c-kit specific Ab (1 µg/ml). Cells were
analyzed by flow cytometry.
Substance P-induced mast cell activation.
In the next set of experiments, we studied whether the increased NK-1 receptor expression
on BMMC was accompanied by enhanced sensitivity to stimulation by substance P.
IL-4/SCF co-culture increased substance P-induced mast cell activation.
BMMC showed only minor degranulation upon stimulation with substance P (figure 4). In
comparison, BMMC co-cultured for 6 days with SCF and IL-4 showed significant dose-
dependent degranulation upon substance P stimulation (figure 4). A significant increase in
responsiveness was seen at all concentrations of substance P used to stimulate mast cells
(10-200 µM). Moreover, continued co-culture with IL-4/SCF for 12 days increased the
response to substance P significantly (figure 4). The increased responsiveness was seen
at all substance P concentrations but was more marked in the lower concentration range.
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Figure 4. BMMC activation. Short term co-culture with
IL-4 and SCF increases the responsiveness of BMMC to
substance P. BMMC were cultured for 6 and 12 days in
presence of IL-4/SCF. Grey bars represent non-treated
BMMC, white bars represent IL-4/SCF co-cultured BMMC
for 6 days and black bars represent BMMC co-cultured
for 12 days. Results are expressed as mean ± SEM of
quadruplicate samples. Significant differences (p<0.05)
between the 6 days co-culture group and the non-treated
group are denoted by (+) and by (*)  between the 12
days co-culture group and both other groups.
NK-1 receptor antagonist RP67580 affects
substance P-induced mast cell activation.
We addressed whether stimulation of BMMC
was NK-1 receptor-dependent. Therefore,
IL-4/SCF BMMC co-cultured for 12 days
were incubated with RP67580, a specific
NK-1 receptor antagonist, before
activation with substance P. Blockade of
the NK-1 receptor resulted in a significant
decrease of substance P-induced β-
hexosaminidase release at low
concentration range (10 -75 µM, figure 5).
Stimulation at higher concentrations of
substance P (100-200 µM) was not
significantly affected by RP67580 (figure
5). The inactive enantiomer RP65681, used
as a control for specificity, did not affect
the dose-dependent release of β-
hexosaminidase (figure 5).
Day 6 Day 12
BMMC NK1-R+/c kit+ NK1-R+ NK1-R+/c-kit+ NK1-R+
untreated 8.1 9.1 11.4 13.6
IL-4 6.2 8.0 19.2 22.4
SCF 12.9 15.2 28.3 34.2
IL-4+SCF 16.0 18.9 37.8 45.4
NK1-R KO
untreated c-kit+  74.9 0
IL-4+SCF c-kit+  77.3 0
RBL-2H3 18.5
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NK-1 receptor knockout BMMC show a
decreased response to low substance P
concentrations.
In addition, BMMC were grown from NK-1
receptor knockout mice and were co-
cultured with IL-4/SCF. At high
concentrations (100-200 µM), the release
of β-hexosaminidase by substance P was
comparable in BMMC from BALB/c mice and
BMMC grown from NK-1 receptor knockout
mice (figure 6). However, NK-1 receptor
knockout BMMC released significantly less
β-hexosaminidase in the lower
concentration range (0-75 µM) than did
normal BMMC (figure 6). These results
suggest that at lower concentrations of
substance P, both a receptor-dependent and
independent mechanism are involved in the
induction of mast cell degranulation. At
higher concentrations, the contribution of
the receptor-dependent pathway seems to
be insignificant.
Figure 5. Effect of NK-1 receptor blockade on BMMC
activation by substance P. All cells were co-cultured
with IL-4 and SCF. Cells were pretreated with the
NK-1 receptor antagonist RP67580 (10-3 M) or its
inactive enantiomer RP65681(10-3 M) 10 min before
activation with substance P (10-200 µM) for 30 min.
White bars represent BMMC pretreated with
RP67580, hatched bars represent BMMC pretreated
with RP65681 and black bars BMMC not pretreated
with an antagonist. Results are expressed as mean
± SEM of quadruplicate samples. Significant
differences (p<0.05) compared to BMMC pretreated
with RP67580 are denoted by (*).
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Figure 6. BMMC activation. BMMC were grown from
NK-1 receptor knockout mice and were co-cultured
with IL-4/SCF. Cells were incubated with different
concentrations of substance P (10-200 mM) for 30
min and degranulation was assessed by the release
of b-hexosaminidase. White bars represent BMMC
grown from BALB/c mice and black bars represent
BMMC grown from NK-1 receptor knockout mice.
Results are expressed as mean ± SEM of
quadruplicate samples. Significant differences
(p<0.05) between groups are denoted by (*).
Discussion
The present study investigated functional expression of the NK-1 receptor on BMMC. Our
study clearly shows increased time dependent NK-1 receptor expression on BMMC after
co-culture with the cytokines IL-4 and SCF. In addition, we show that the expression of the
NK-1 receptor is of functional relevance for the activation of mast cells.
            In previous work, we have shown that BMMC gained sensitivity to substance P
in the presence of IL-4 and SCF (28, 29). Tsai and coworkers (30) showed that SCF
induces proliferation of mouse mast cells in vitro and in vivo. However, optimal murine
mast cell proliferation and differentiation in response to SCF may require cofactors such
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as IL-4 (14). IL-4 synergistically enhanced the proliferation of various mast cell lines in
the presence of IL-3 or SCF (31-34). In the present study, IL-4 functioned as an
efficient cofactor for SCF to induce the expression of NK-1 receptors on BMMC.  A
combination of IL-4 and SCF is sufficient to induce stable expression of the NK-1
receptor on primary cultured mast cells. However, in time IL-4 and SCF alone also
induced a significant increase in expression of NK-1 receptors
            Mast cells may exhibit enhanced expression of NK receptors in certain
pathophysiological conditions. In line with our results, it has been shown that in murine
peritoneal macrophages the level of expression of the NK-1 receptor can be increased
following exposure to IL-4 (35). This suggests an increased expression of NK-1 receptors
in inflammatory conditions. In vivo, several investigators have discussed the increased
expression of the NK-1 receptor during inflammation. Mantyh and coworkers (36, 37)
have shown that NK-1 receptors were significantly upregulated in inflamed tissues, on
epithelium, blood vessels and in lymphoid accumulations. Pothoulakis and coworkers (38)
provide evidence for increased NK-1 receptor expression in the intestinal epithelium
shortly after exposure to Clostridium Toxin A. Furthermore, increased levels of BAL
lymphocyte mRNA encoding NK-1 receptors were found in a murine model of immune
inflammation in the lung (39). Upregulation of NK-1 receptors on cultured macrophages
following exposure to lipopolysaccharide in rats and salmonella in mice has been reported
(40). However, in vivo no studies have been reported on the increased expression of the
NK-1 receptor on the mast cell.
SCF and IL-4 have been implicated to play an important role in the pathogenesis of
inflammatory diseases including atopic dermatitis (41, 42) and asthma (43). We hypothesize
that elevated levels of IL-4 and SCF in tissues undergoing inflammation could result in the
enhanced expression of NK-1 receptors on inflammatory tissue resident cells, such as
mast cells.
           Substance P can induce histamine release from several types of mast cells such as
rat peritoneal mast cells, dural mast cells (44), human skin mast cells (45) and mucosal
mast cells (6). Since high concentrations of substance P (micromolar) are required to
induce mast cell activation, and dependent on the positively charged N-terminal amino
acid residues of the substance P molecule (46, 47), the mechanism of degranulation by
substance P is believed to be the result of a direct G-protein activation rather than a
specific receptor-mediated process (48). However, several studies support the hypothesis
that neurokinins can activate mast cells via a specific receptor-dependent pathway. Ogawa
and coworkers (5) showed on rat peritoneal mast cells that substance P stimulated NK-1
receptors to release histamine. This was significantly blocked by the NK-1 receptor antagonist
CP96345. Okada and coworkers (49) demonstrated that peritoneal mast cells of rats express
functional NK-1 receptors but this is, so far, the only report of NK-1 receptor expression on
mast cells in vitro.
In this study, we show for the first time inducible expression on primary cultured
mast cells. Co-culture of BMMC with SCF and IL-4 results in a time-dependent increased
expression of the NK-1 receptor and leads to an increased sensitivity to degranulation by
substance P. Several lines of evidence indicate that substance P can stimulate BMMC by a
receptor-dependent route. First, an NK-1 receptor antagonist was able to partially block
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mast cell activation by substance P. Secondly, BMMC cultured from NK-1 receptor knockout
mice show significant exocytosis but only upon exposure to high concentrations of substance
P. Therefore, the data presented in this study clearly show a receptor-dependent mast cell
activation. However, since mast cell activation is not completely blocked, other pathways
must also be involved. Furthermore, decreased exocytosis induced by inhibition or absence
of the NK-1 receptor was only found at lower concentrations of substance P. Thus, at low
(physiological) concentrations substance P induced degranulation in a receptor-dependent
manner. However, at high concentrations substance P effected mast cell degranulation in a
receptor-independent way since substance P-induced degranulation was not altered in the
higher concentration range. Several mechanisms for substance P action on mast cells have
been suggested. Previously in our laboratory, we showed that the IL-4/SCF-induced response
to substance P was partially blocked by the G-protein inhibitors pertussis toxin and
benzalkonium chloride (unpublished observations). Furthermore, substance P-induced
activation of BMMC is blocked by specific tyrosine kinase and protein kinase C inhibitors
(unpublished observations). These results delineate a pathway for substance P-induced
secretion via G-protein(s), phospholipase C, calcium, and protein kinase C and are in
accordance with data in the literature. For instance, Mousli and coworkers demonstrated
the involvement of pertussis toxin-sensitive G proteins and phospholipase C as targets for
substance P in rat peritoneal mast cells (50) and human skin mast cells (51), without
requiring substance P specific membrane receptors.
           In conclusion, the present study provides clear evidence for the inducible expression
of functional NK-1 receptors on BMMC in response to co-culture with IL-4 and SCF. Increased
expression of the NK-1 receptor is accompanied by enhanced sensitivity of the mast cells
to stimulation by substance P. Our data suggest that under specific conditions in vivo such
as those accompanying inflammation, mast cells could gain increased responsiveness to
substance P, which may propagate and enhance neurogenic inflammatory responses. In
turn, we suggest that NK-1 receptor antagonists may be partially effective in minor
inflammatory conditions, but are less likely to be effective when inflammation is more
severe.
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Abstract
Mast cells may play a role in neurogenic inflammation. Close proximity to nerves, mostly
of sensory origin, allows direct communication between mast cells and the nervous system.
By electron microscopy we showed that substance P in vivo is capable of inducing mast cell
degranulation. However, it is not clear if this is a direct response. To date, very few studies
report on co-cultures of mast cells and neurons. To study functional interactions between
mast cells and peripheral nerves, a tissue culture model of murine neurons and mast cells,
was developed. Bone marrow-derived mast cells (BMMC) and superior cervical ganglia
(SCG) were co-cultured to study bidirectional interaction using a fluorescent calcium indicator
as an index of cellular activation. Scorpion venom, a stimulus for SCG, did not have an
effect on BMMC by itself. Scorpion venom caused an increase in neurite fluorescence within
10 sec after addition of the venom. Neurite activation is subsequently followed by activation
of the mast cell approximately 5 sec after the signal appeared in the neurite, presumably
by substance P release from the neurite. We proceeded to assess the role of substance P,
the preferred ligand for the neurokinin 1 (NK-1) receptor, as the mediator responsible for
the direct neurite-mast cell communication. Therefore, BMMC cultured from bone marrow
of NK-1 receptor knockout mice, were studied for their response to neurite stimulation in
the co-culture system. Preliminary results show that mast cells cultured from the NK-1
receptor knockout mice did not respond to neurite activation as elicited by scorpion venom.
These data suggest an NK-1 receptor dependent process. We demonstrate that mast cell
activation can occur as a direct response to the release of presumably substance P from
neurites.
Introduction
Mast cells are often found in the proximity of nerve endings, and may be activated by a
number of neuropeptides including tachykinins such as substance P and neurokinin A. It
has been postulated that mast cells may play a role in neurogenic inflammation for example
in asthmatic disease (1). Neurogenic inflammation involves changes in function of the
sensory neurons due to inflammatory mediators which results in an enhanced release of
tachykinins from the nerves (2). Indeed, mast cell mediators such as serotonin, histamine
and nerve growth factor have been suggested to influence neuronal function (3, 4). Moreover,
mediators released by nerves, such as acetylcholine and substance P can induce the
activation of mast cells resulting in mediator release (4-7).
Close proximity to nerves, mostly of sensory origin, allows a bidirectional
communication between mast cells and the nervous system (8, 9). A close anatomical
relationship between mast cells and substance P-containing sensory nerve endings has
been reported in various tissues including skin (10), intestine (11), dura mater (9, 12) and
airway mucosa (10). Morphometric analysis has shown mast cells associated with nerves
along their axial path, for example in the intestine (13, 14). Burnstock and coworkers have
shown that cells within 200 nm of a nerve can be affected by an action potential moving
down a nerve fiber. This lends more meaning to the likelihood of two-way communication.
Mast cell-nerve interaction has been shown in infected/inflamed tissue as well as in
healthy tissue. Increased numbers of mast cells are seen in inflammatory or allergic
conditions. Additionally, enhanced mast cell-nerve contacts appear in the infected/inflamed
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areas. For instance, rats infected with nematodes have been shown to have more frequent
mast cell nerve associations in the intestinal mucosa than normal counterparts (11).
To date, very few studies report on co-cultures of mast cells and neurons. In vivo
studies only revealed possible interactions between both cell types (15). Most in vitro
studies demonstrate the effect of single mediators, released by either neurons or mast
cells, on the other cell type (5, 16). To study functional interactions between mast cells
and peripheral nerves, a tissue culture model of murine neurons and rat basophilic leukemia
cells (RBL-2H3), was developed (17). Results from this study demonstrate direct
communication between mast cells and superior cervical neurites in co-culture. In the
present study, we examined the direct communication of co-cultured primary murine bone
marrow-derived mast cells (BMMC) and neurite-sprouting murine superior cervical ganglia
(SCG). BMMC and SCG were co-cultured to study direct mast cell-to-neuron communication
measuring calcium-fluorophores as an index of cellular activation.
Methods
Animals. For the culture of BMMC, 6-8 weeks old male BALB/c mice were used. To grow
SCG, 0-48 h old BALB/c mice were used. Mice were obtained from Harlan, Indianapolis,
Indiana, USA. Neurokinin 1 receptor knockout mice (back-crossed to BALB/c) were a
generous gift from Dr. N. Gerard, Harvard, Boston, USA
Electron microscopy. Mice were intranasally treated with substance P (3x10-9mol) for 10
min. Ultrastructural changes in mast cells as a sign for mast cell activation was studied by
performing electron microscopy of murine tracheal mast cells after exposure to substance
P. Mice were killed with an overdose of pentobarbitone, the trachea was isolated and fixed
in Karnovsky. Samples were cut and washed with osmium tetroxide, dehydrated and
embedded on epoxy resin. Ultrathin sections were contrasted with aqueous uranyl acetate
and Reynolds lead citrate and examined in an electron microscope.
Mouse bone marrow cultures. Bone marrow cells were isolated according to a standard
protocol, as described in chapter 7 of this thesis. Cells were centrifuged and resuspended
in fresh media every week to achieve a final concentration of 1-2x105 cells/ml. After culturing
the cells for 3-4 weeks, the BMMC were co-cultured for 6 days with SCF (50 ng/ml) plus IL-
4 (300 U/ml). Cytokine-treated BMMC were centrifuged and resuspended in fresh medium
plus IL-4 and SCF every three days to achieve a final concentration of 2x105 cells/ml.
Nerve-mast cell co-culture. SCG were dissected from newborn (0-48 h old) BALB/c mice
and rinsed in HBBS containing 10 mM HEPES (pH 7.4). Each ganglion was divided in 2
pieces and incubated for 60 minutes in at 37o C in 2 ml of HEPES containing 0.125%
trypsin. The resultant cell suspension was plated at a density of 0.5-1x104 nerve cells onto
matrigel-coated 35-mm diameter glass dishes. The neurons were grown in RPMI medium
enriched with 0.2 mM L-glutamine, 1% Pen/strep, 10% FBS,10 ng/ml nerve growth factor,
and cytosine-β-d-arabinofuranoside (Ara-C, 10-6 M) to kill nonganglionic cells in the culture.
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For co-culture, BMMC (2x104 cells/dish) were added to 48 h old cultures of SCG-neurites
and incubated for another 72 h in the presence of IL-4 (300 U/ml) and SCF (50 ng/ml).
Cellular activation. After 72 h of co-culture, cells were loaded with Fluo-3-AM (2.5 µM, 30
min, 37ºC), and washed 3 times with HEPES buffer. Cells were examined using confocal
microscopy to study calcium mobilization by activation of fluorophores as index of cellular
activation (18, 19). A special computer program was developed capable of measuring the
fluorescence of an indicated area during time. Neurite activation was evoked by scorpion
venom.
Reagents. RPMI 1640, fetal calf serum and nonessential amino acids were purchased from
GibCo BRL Life Technologies, Paisley Scotland. Penicillin, streptomycin, L-glutamine, sodium
pyruvate, 2-mercaptoethanol, pokeweed, trypsin, scorpion venom were obtained from
Sigma, St. Louis, MO, USA and lectin from Phytocalla Americana. Murine recombinant SCF
came from PeproTech, London, England. Murine recombinant IL-4 was kindly provided by
W.E. Paul NIH, USA. Matrigel was purchased at Becton Dickinson, Bedford, MA.
Results
1. Electron microscopy: the effect of substance P on mast cell in vivo
Substance P affects mast cells in vivo. Figure 1a shows an intact control mast cell from the
trachea of a mouse. Figure 1b depicts a tracheal mast cell of a mouse after intranasal
treatment with substance P. Substance P induced marked morphological changes to mast
cells located in the mouse trachea. The plasma membrane is intact however, granular
swelling and loss in electron density were observed as indicated with arrows.
Figure 1. Substance P induces marked morphological changes in mast cells located in the mouse
trachea. A. Control mast cell (x12740). Note the close proximity of the unmyelinated nerve to the
mast cell membrane (arrow). B. Intranasal application of substance P (3x10-9mol; 10 min)(x16100;
trachea preparation). Plasma membrane is intact however, a high proportion of granules are less
electron dense and/or oedematous.
128 Chapter 8
2. Confocal laser scanning microscopy: BMMC-SCG co-culture
Previously, a tissue culture model of murine neurons and rat basophilic leukemia cells
(RBL-2H3), was developed. This tissue culture system was used to study functional
interaction between BMMC and sympathetic neurons. Unlike RBL-2H3 cells, BMMC do not
adhere to the laminin coated wells. These primary mast cells normally grow in suspension.
From the BMMC-neurite co-culture we can conclude that BMMC specifically adhere to
neurites. Adhered cells, in contrast to non-adhered cells, were not removed from the
culture after washing the dishes before conducting the experiments.
Scorpion venom selectively induces an increase in calcium mobilization in the neurite.
Activation of the neurite was measured by calcium mobilization by activation of fluorophores
using confocal fluorescence microscopy. Scorpion venom showed an almost instantaneous
increase in neurite fluorescence, which was maximal within 10 sec after addition of the
venom (figure 2a). The neurite activation peaked at 15 sec and returned to basal levels
again at 30 sec after addition of the venom. In a BMMC culture scorpion venom did not
have any effect meaning that scorpion venom exclusively affects the neurite in vitro (data
not shown).
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Effect of neurite stimulation on BMMC calcium mobilization.
BMMC were co-cultured with SCG. Scorpion venom caused an increase in neurite
fluorescence, maximal within 10 sec after addition of the venom (figure 2a and 3). The
increase in neurite activation was followed by a rise in BMMC calcium mobilization (figure
2b and 3). Calcium levels in the BMMC slowly increased 10 sec after addition of scorpion
venom and reached its maximum at 25 sec after addition of the venom to the co-culture.
After 25 sec, calcium levels slowly decreased but remained elevated till the end of the
Figure 2. A representative trace illustrating the sequential increase in fluorescence evoked by
scorpion venom (100 pg/ml) in BMMC-SCG co-cultures. A. Increase in fluorescence in neurite after
addition of scorpion venom to the co-culture. B. Increase in fluorescence in the BMMC in response
to the neurite activation.
experiment (40 sec)(figure 2b and 3). In all co-culture experiments examined, scorpion
venom-evoked neurite activation preceded BMMC activation.
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Discussion
Considerable evidence exists for a consistent anatomical association between mast cells
and nerves in tissues throughout the body (4, 20). Several studies in vivo show a functional
and morphological relationship between mast cells and capsaicin-sensitive sensory neurons
(8-10, 12). In vivo studies only demonstrated possible interactions between mast cells
and tachykinins (15). In the present report, we show that substance P in vivo, at low dose,
has profound stimulatory effects on pulmonary mast cells (figure 1). Electrical stimulation
of nerves has been shown to either cause ultrastructural changes in associated mast cell
granules or actual degranulation. Dimitriadou and colleagues (21) found that electrical
nerve stimulation caused mast cell degranulation in the dura matter. Gottwald and coworkers
(22) have presented morphological and histochemical evidence of mast cell activation in
the gut following electrical stimulation in vivo. These data provide evidence for the functional
importance of communication between nerves and mast cells. Yet, electrical stimulation is
not always associated with mast cell activation (23, 24).
Figure 3. Fluorescence images of a BMMC-SCG co-culture in time. A. Basal fluorescence image
of a co-culture. B. Fluorescence image showing the increase in the neurite (11 sec) evoked by
scorpion venom (100 pg/ml). C. Image showing the sequential effect of neurite activation on
the BMMC (25 sec after scorpion venom addition). D. 40 sec; end of the time course. Fluorescence
is still elevated in the BMMC but is slowly returning to basal level.
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It proved to be very difficult to directly link substance P release to mast cell
activation and release of bioactive mediators in vivo. Although several studies suggest
direct communication between mast cells and neurons, they do not exclude the possibility
of an intermediate cell facilitating this functional cross-talk. Using an in vitro co-culture
system, we examined direct communication between mast cells and neurites. We have
shown that scorpion venom stimulates the neurite followed by activation of the mast cell,
possibly induced by substance P release from the neurite.
Previously, we have demonstrated that substance P caused mast cell degranulation
at least partly via the NK-1 receptor (chapter 7). Enhanced expression of the NK-1 receptor
was induced by short time treatment with IL-4 and SCF and resulted in a significantly
increase in responsiveness to substance P. The enhanced sensitivity to substance P could
be decreased by blockade or deficiency of the NK-1 receptor. In conclusion, substance P
can stimulate BMMC by a receptor (NK-1) dependent route.
We proceeded to assess the role of substance P and its NK-1 receptor in neuron-
to-mast cell communication in this tissue culture system. First, BMMC, which were not
treated with IL-4 and SCF, were studied in our tissue culture model. Neurite activation did
not show to affect these mast cells (preliminary results, data not shown). IL-4 and SCF
treatment of BMMC, knowing to enhance the expression of  NK-1 receptors on mast cells,
therefore seems necessary to achieve communication from neuron-to mast cell. Secondly,
BMMC cultured from NK-1 receptor knockout mice were studied for their response to
neurite stimulation. In preliminary experiments, we demonstrated that mast cells cultured
from the NK-1 receptor knockout mice (treated with IL-4 and SCF) did not respond to
neurite activation as elicited by scorpion venom (data not shown). These data are in line
with the data in chapter 7 of this thesis and suggest an NK-1 receptor dependent pathway.
We have demonstrated that mast cell activation can occur as a direct response to the
possible release of substance P from neurites.
Acknowlegements
The authors would like to thank Gudrun Goettsche for expert technical assistance.
  Direct neurite-mast cell communication in vitro   131
References
1. Barnes, P. J. 1991. Neuropeptides and asthma. Am Rev Respir Dis 143:S28.
2. Barnes, P. J. 1991. Neurogenic inflammation in airways. Int Arch Allergy Appl Immunol
94:303.
3. Bienenstock, J., G. MacQueen, P. Sestini, J. S. Marshall, R. H. Stead, and M. H. Perdue.
1991. Mast cell/nerve interactions in vitro and in vivo. Am Rev Respir Dis 143:S55.
4. Purcell, W. M., and C. K. Atterwill. 1995. Mast cells in neuroimmune function:
neurotoxicological and neuropharmacological perspectives. Neurochem Res 20:521.
5. Janiszewski, J., J. Bienenstock, and M. G. Blennerhassett. 1994. Picomolar doses of substance
P trigger electrical responses in mast cells without degranulation. Am J Physiol 267:C138.
6. Karimi, K., F. A. Redegeld, R. Blom, and F. P. Nijkamp. 2000. Stem cell factor and interleukin-
4 increase responsiveness of mast cells to substance P. Exp Hematol 28:626.
7. Silver, R., A. J. Silverman, L. Vitkovic, and Lederhendler, II. 1996. Mast cells in the brain:
evidence and functional significance. Trends Neurosci 19:25.
8. Botchkarev, V. A., S. Eichmuller, E. M. Peters, P. Pietsch, O. Johansson, M. Maurer, and R.
Paus. 1997. A simple immunofluorescence technique for simultaneous visualization of mast
cells and nerve fibers reveals selectivity and hair cycle dependent changes in mast cell
nerve fiber contacts in murine skin. Arch Dermatol Res 289:292.
9. Dimitriadou, V., A. Rouleau, M. D. Trung Tuong, G. J. Newlands, H. R. Miller, G. Luffau, J. C.
Schwartz, and M. Garbarg. 1997. Functional relationships between sensory nerve fibers and
mast cells of dura mater in normal and inflammatory conditions. Neuroscience 77:829.
10. Alving, K., C. Sundstrom, R. Matran, P. Panula, T. Hokfelt, and J. M. Lundberg. 1991.
Association between histamine-containing mast cells and sensory nerves in the skin and
airways of control and capsaicin-treated pigs. Cell Tissue Res 264:529.
11. Stead, R. H., M. Tomioka, G. Quinonez, G. T. Simon, S. Y. Felten, and J. Bienenstock. 1987.
Intestinal mucosal mast cells in normal and nematode-infected rat intestines are in intimate
contact with peptidergic nerves. Proc Natl Acad Sci U S A 84:2975.
12. Rozniecki, J. J., V. Dimitriadou, M. Lambracht-Hall, X. Pang, and T. C. Theoharides. 1999.
Morphological and functional demonstration of rat dura mater mast cell-neuron interactions
in vitro and in vivo. Brain Res 849:1.
13. Stead, R. H., M. F. Dixon, N. H. Bramwell, R. H. Riddell, and J. Bienenstock. 1989. Mast cells
are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology
97:575.
14. Blennerhassett, M. G., J. Janiszewski, and J. Bienenstock. 1992. Sympathetic nerve contact
alters membrane resistance of cells of the RBL-2H3 mucosal mast cell line. Am J Respir Cell
Mol Biol 6:504.
15. Bienenstock, J., M. Tomioka, H. Matsuda, R. H. Stead, G. Quinonez, G. T. Simon, M. D.
Coughlin, and J. A. Denburg. 1987. The role of mast cells in inflammatory processes: evidence
for nerve/mast cell interactions. Int Arch Allergy Appl Immunol 82:238.
16. Nicol, G. D., J. C. Lopshire, and C. M. Pafford. 1997. Tumor necrosis factor enhances the
capsaicin sensitivity of rat sensory neurons. J Neurosci 17:975.
17. Suzuki, R., T. Furuno, D. M. McKay, D. Wolvers, R. Teshima, M. Nakanishi, and J. Bienenstock.
1999. Direct neurite-mast cell communication in vitro occurs via the neuropeptide substance
P. J Immunol 163:2410.
18. Furuno, T., T. Hamano, and M. Nakanishi. 1993. Receptor-mediated calcium signal playing
a nuclear third messenger in the activation of antigen-specific B cells. Biophys J 64:665.
132 Chapter 8
19. Okabe, T., R. Teshima, T. Furuno, C. Torigoe, J. Sawada, and M. Nakanishi. 1996. Confocal
fluorescence microscopy for antibodies against a highly conserved sequence in SH2 domains.
Biochem Biophys Res Commun 223:245.
20. Arizono, N., S. Matsuda, T. Hattori, Y. Kojima, T. Maeda, and S. J. Galli. 1990. Anatomical
variation in mast cell nerve associations in the rat small intestine, heart, lung, and skin.
Similarities of distances between neural processes and mast cells, eosinophils, or plasma
cells in the jejunal lamina propria. Lab Invest 62:626.
21. Dimitriadou, V., M. G. Buzzi, M. A. Moskowitz, and T. C. Theoharides. 1991. Trigeminal
sensory fiber stimulation induces morphological changes reflecting secretion in rat dura
mater mast cells. Neuroscience 44:97.
22. Gottwald, T. P., B. R. Hewlett, S. Lhotak, and R. H. Stead. 1995. Electrical stimulation of the
vagus nerve modulates the histamine content of mast cells in the rat jejunal mucosa.
Neuroreport 7:313.
23. Miura, M., H. Inoue, M. Ichinose, K. Kimura, U. Katsumata, and T. Takishima. 1990. Effect of
nonadrenergic noncholinergic inhibitory nerve stimulation on the allergic reaction in cat
airways. Am Rev Respir Dis 141:29.
24. Baraniuk, J. N., M. L. Kowalski, and M. A. Kaliner. 1990. Relationships between permeable
vessels, nerves, and mast cells in rat cutaneous neurogenic inflammation. J Appl Physiol
68:2305.
9
Summarizing discussion
134 Chapter 9
135               Summarizing discussion
1. Introduction
Mast cells are located in close proximity to neurons in the peripheral and central nervous
system (1-4). In various studies, tissue mast cells invariably show ultrastructural evidence
of activation even in normal healthy conditions, suggesting that these cells are constantly
providing information to the nervous system. Neuronal mechanisms are involved in mast
cell activation and mast cells act as principle transducers of information between peripheral
nerves and local inflammatory events (5).
In virtually all tissues of the body, mast cells are closely associated with nerve fibers.
Besides activation in normal healthy conditions, the mast cell-nerve communication pathway
has been implicated as an important element in the pathology of various diseases including
asthma (6). Mast cells lining the mucosal layer of the respiratory tract, have been found in
close vicinity of substance P- and CGRP-immunoreactive nerves of rat trachea and peripheral
lung tissue (3).
Asthma is characterized by a chonic inflammatory reaction in the airways. Roughly, asthma
can be subdivided into atopic asthma involving elevated levels of serum IgE and a less
familiar form, non-atopic asthma. Non-atopic asthma, accounting for 5% to 15% of all
new cases of asthma (7), is an increasing problem in the developed world. Low molecular
weight substances (<5000 Da) are the most common agents causing occupational asthma
without producing specific IgE (7). Although the number of non-atopic asthmatics is
increasing, the mechanisms involved in the induction and on-going respiratory impairments
associated with non-atopic asthma are unknown and poorly investigated. From previous
studies, it is recognized that mast cells and sensory neurons may play a role in non-atopic
asthma (8-10). It is our aim to gain a deeper understanding of this immune-nerve interaction
in non-atopic asthma. In this thesis mast cell and nerves were studied in vitro using
primary cultured mast cells and neurons and in vivo, in a murine model for non-atopic
asthma.
2. In vivo studies
Non-atopic asthma was induced  in mice by skin-sensitization with the low molecular
weight compound dinitrofluorobenzene (DNFB) followed by intranasal intra-airway challenge
with a water-soluble dinitrobenzene derivate, dinitrobenzene sulphonic acid (DNS). Features
of this pulmonary reaction included acute bronchoconstriction and mast cell activation
shortly after challenge, and tracheal hyperreactivity, mononuclear and neutrophilic cell
infiltration and an increase in mucosal exudation in the alveolar lumen 24 to 48 h after the
challenge. This hypersensitivity reaction was not associated with an increase in hapten
specific IgE (8, 11).
Mast cells
In the employed model for non-atopic asthms, the early phase reaction is associated with
mast cell activation (chapter 2). mMCP-1 is present in the serum of DNFB-sensitized mice
directly after challenge (chapter 2-5). Very recently, it is demonstrated that during
sensitization mast cells are armed with hapten-specific immunoglobulin kappa light chains
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(IgLC) (12). Upon challenge, the hapten will multivalent crosslink IgLC bound to the mast
cell, causing activation and subsequent release of mediators starting the whole inflammatory
response (chapter 2).
Thus far no direct proof for the involvement of mast cells in hapten-induced
pulmonary hypersensitivity reaction in the mouse has been presented. In chapter 3,
genetically mast cell-deficient and congenic normal mice were used to further establish
the role of the mast cell in this murine model for non-atopic asthma. DNFB-sensitization
was applied to mast cell-deficient W/Wv and Sl/Sld mice, their respective normal (+/+)
littermate mice and mast cell-reconstituted W/Wv mice (BMMC→ W/Wv). In BALB/c and +/
+ mice, an early phase mast cell activation was found accompanied by bronchoconstriction
and increased vascular permeability. The late phase was associated with mucosal exudation,
infiltration of neutrophils in bronchoalveolar lavage fluid and tracheal hyperreactivity. Both
mast cell-deficient strains failed to show any features of this hypersensitivity response.
Mast cell reconstitution restored the acute bronchoconstriction, tracheal vascular
hyperpermeability, BAL neutrophilia and tracheal hyperreactivity observed after DNFB
sensitization and intranasal DNS challenge. These findings clearly demonstrate a key role
for mast cells in the regulation of pulmonary hypersensitivity responses associated with
non-atopic asthma.
Tumor necrosis factor alpha
TNF-α is a multifunctional proinflammatory cytokine that is produced and released by a
variety of cells such as alveolar macrophages, fibroblasts, monocytes, endothelial cells,
neutrophils and mast cells (13-17). TNF-α levels in BAL fluid of non-atopic mice were
significantly increased shortly after challenge (chapter 5). This suggests that TNF-α is
released by cells that contain prestored TNF-α leaving the mast cell as potential source
(18). This hypothesis is confirmed by a another study performed in our laboratory (19)
demonstrating that mast cell-deficient mice failed to show an increase in TNF-α BAL levels
30 minutes after challenge in the murine model presented in this thesis. These data point
to an important role of mast cell-derived TNF-α in mice undergoing a non-atopic asthmatic
reaction.
An important role for TNF-α in pulmonary hypersensitivity reactions is demonstrated
in chapters 5 and 6. Intra-airway application of TNF-α to non-treated mice resulted in the
infiltration of a significant number of neutrophils (chapter 6). Other animal models confirmed
this role for TNF-α in the recruitment of neutrophils into inflammatory tissue (20, 21).
However, TNF-α per se is a weak chemoattractant. The chemotactic effect of TNF-α is
dependent on the induction of cell adhesion molecules and the release of chemokines (22,
23). Intra-airway application of TNF-α also results in the development of tracheal
hyperreactivity (chapter 6). Neutrophil depletion prevented this induction. Furthermore,
in the employed model, DNFB-sensitization and intra-airway DNS challenge causes
neutrophil infiltration and tracheal hyperreactivity, both strongly reduced by neutralizing
anti-TNF-α antibodies (chapter 5). Together, these results provide evidence of a relationship
between the migration of neutrophils into BAL fluid and the development of tracheal
hyperreactivity. Furthermore, TNF-α seems a crucial mediator released by mast cells after
challenge.
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Substance P
A role for substance P was reported in animal models for airway inflammation (24, 25).  In
the employed model for non-atopic asthma, blockade of the NK-1 receptor with a specific
antagonist or the genetic absence of the NK-1 receptor prevented the development of
tracheal hyperreactivity and cellular (neutrophil) accumulation in the mouse airways (chapter
2). Since mast cell activation was still observed in these mice, the role for the NK-1
receptor/substance P is downstream from mast cell activation. It is hypothesized that
upon DNFB-sensitization and DNS challenge, mast cells will be activated and mast cell
mediators such as TNF-α will affect NANC nerves to release their tachykinins. In turn,
tachykinins will activate NK-1 receptors possibly on endothelial cells inducing
vasodilatation, vascular exudation and upregulation of adhesion molecules leading to
the infiltration of leukocytes, especially neutrophils. This cellular infiltration leads to the
induction of tracheal hyperreactivity. Indeed, in chapter 6 it is demonstrated that TNF-α-
induced tracheal hyperreactivity is diminished after neutrophil depletion. Furthermore,
unpublished observations (van Houwelingen et al., submitted) also showed inhibition of
tracheal hyperreactivity in the DNFB model after neutrophil depletion.
In chapter 6 it is shown that intra-airway application of substance P in non-treated
mice results in the development of tracheal hyperreactivity. This suggests a causal relation
between substance P and the induction of tracheal hyperreactivity. In contrast to the
results in chapter 2, no neutrophil accumulation was detected in these mice. This suggests
that substance P can induce tracheal hyperreactivity via different pathways depending
on the local microenvironment in the tissue. For instance, injection of substance P in
normal rat and mouse skin did not induce neutrophil infiltration (26), but in inflamed
skin the NK-1 receptor was involved in mediating neutrophil accumulation (27). This
could explain why neutrophil infiltration is found in DNFB-sensitized mice and is not
significantly increased in animals treated with substance P intranasally.
We do not exclude a direct role of substance P on tracheal smooth muscle cells
inducing tracheal hyperreactivity to carbachol. Substance P has a facilitatory role in the
release of acetylcholine from cholinergic nerves in guinea pigs (28) and rabbits (29).  In
mice, electrical field stimulation induced a significant lower contraction of the trachea in
NK-1 receptor knockout mice compared to wild type (30). This provides evidence for a
direct role of the NK-1 receptor in the augmentation of cholinergic neurotransmission in
the mouse trachea.
3. In vitro mast cell studies
NK-1 receptor expression
Mast cells are ubiquitous in the body and often found close to neurons. They can be
activated by a number of neuropeptides, including tachykinins such as substance P.
There are different opinions about the pathways involved in mast cell activation by non-
immunological stimuli like neuropeptides. Although it has been suggested that functional
NK-1 receptors are expressed on mast cells (31-33), most investigators support non-
receptor mediated activation induced via direct interaction with pertussis toxin-sensitive
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G proteins though the N-terminal domain located in the inner surface of the plasma membrane
(34, 35).
In vivo, several investigators have discussed the increased expression of the NK-1
receptor in inflamed tissue (36-38). Therefore, it can be proposed that NK-1 receptor
expression on immune cells such as mast cells is influenced by environmental inflammatory
factors such as cytokines. In previous work, Karimi et al (39) demonstrated the increased
sensitivity of BMMC to substance P, the preferred ligand for the NK-1 receptor, after a short
co-culture with the cytokines IL-4 and SCF. In other studies, it is shown that elevated
levels of SCF and IL-4 both have been implicated to play a role in the pathogenesis of
inflammatory diseases including asthma (40). Indeed, NK-1 receptors are significantly
expressed on BMMC shortly co-cultured with IL-4 and/or SCF in contrast to non-treated
BMMC that barely express NK-1 receptors (chapter 7). Although IL-4 by itself can promote
the expression of the NK-1 receptor on BMMC, it mainly functioned as an efficient cofactor
for SCF to induce the expression of NK-1 receptors on BMMC. This is in line with literature
data demonstrating that optimal murine mast cell proliferation and differentiation in response
to SCF may require cofactors such as IL-4 (41-43). The increase in NK-1 receptor expression
induced by IL-4 and SCF is time dependent. The number of positive cells increases with
the length of co-culture although a plateau level is reached.
The traditional classification of mast cells into two main subsets, CTMC and MMC,
based on different phenotypical and functional characteristics is unsufficient (44). Mast
cells are highly influenced by their environment resulting in functionally different subtypes.
In vivo and in vitro studies have shown that mast cells can fully transform their phenotype,
if transplanted into a different environment (45, 46). Indeed, a short-term culture of
BMMC with IL-4 and SCF resulted in a mast cell population with an altered phenotype
(47). The cell environment has been suggested as a critical regulatory factor in the
responsiveness of mast cells to basic secretagogues (48). The data in chapter 7 show that
mast cells increase their responsiveness to substance P by an increased expression of NK-
1 receptors.
Nerve-mast cell interaction in vitro
The effect of a single mediator, substance P, on mast cells was investigated in chapter 7. In
vitro, substance P is able to activate mast cells. Furthermore, by electron microscopy we
were able to show that substance P in vivo is capable of inducing mast cell activation
(chapter 8). To directly link substance P release to mast cell activation, the direct
communication of BMMC and neurite-sprouting SCG was examined. It is shown that mast
cell activation can occur as a direct response to the possible release of substance P from
neurites (chapter 8). In general, relatively high concentration of substance P (>10-5 M) are
required to induce mast cells degranulation in vitro. Researchers have argued that these
concentrations are not physiological relevant. However, mast cells and neurites are closely
related in the body. It is postulated that under inflammatory conditions given the close
contact, it is possible that such concentrations of neuropeptides can be obtained locally
within the tissue. In chapter 8, in an in vitro experimental setup, we provide clear evidence
for that mast cell degranulation can occur as a response to neurite activation.
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Priming
Besides direct activation, there is the concept of priming. Priming appears to be a broadly
based biological process and has been reported in several cell types. Mast cells have been
reported to be primed by different cytokine growth factors for activation by different agonists
(49). SCF, for instance, can act as a priming agent in some circumstances (50, 51). In this
thesis, we show that SCF and IL-4 prime BMMC to induce increased responsiveness to
substance P. Mast cells can also be primed by substance P itself. Although relatively high
levels of substance P are to directly induce mast cell degranulation (>10-5M), it has been
demonstrated that repeated doses of very low concentrations (picomolar) of substance P
can induce mast cell degranulation (52). In other words, very low concentrations of substance
P showed to be able to prime mast cells and lower their thesholds to subsequent activation
(52). The concept of priming also applies to neurons. TNF-α may exert a priming, rather
than a direct stimulatory effect on sensory activity (19, 53).
Mast cell activation versus mast cell degranulation
Exocytosis is the most obvious event associated with secretion of the mediator molecules
contained in granules. However, secretion can occur without evidence of degranulation,
and even molecules stored within the same granules can be released and secreted in a
discriminatory pattern.
Serotonin can be released separately from histamine (54). Differential synthesis
and release of arachidonic acid metabolites, prostaglandins and leukotrienes have been
reported (55). Ultrastructurally, a study by Ratliff et al (56) showed mast cells in close
proximity to unmyelinated nerve fibers. These mast cells contained granules showing
ultrastructural features of activation or piecemeal degranulation, which have been associated
with differential secretion.
In the present thesis, mast cell degranulation was measured in vivo via mMCP-1
release and in vitro by the release of β-hexosaminidase. Degranulation might be not the
best marker to monitor mast cell activation but in most cases it is the best available tool.
The observation that mediator release can occur without degranulation is very
interesting, especially in situations where mast cell degranulation was not found and mast
cells were likely to be involved. In chapter 6, mice received substance P and TNF-α on two
consecutive days. Both substance P and TNF-α can cause degranulation of mast cells.
However, no increase in mMCP-1 release was found in these animals (data not shown).
Marshall and coworkers showed that low doses of substance P can cause synthesis and
secretion of TNF-α from mast cells, in the absence of degranulation (57). Therefore, TNF-
α and substance P both could have affected mast cells in this study.
Enhancement mast cell-nerve interaction
Mast cell mediators can cause the release of tachykinins from sensory nerve endings (6,
58, 59). The release of neurotransmitters may exacerbate the inflammatory response.
Neurogenic inflammation has been documented in a number of inflammatory diseases
including asthma. The mast cell-nerve communication pathway has been implicated as an
important element in neurogenic inflammation.
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Mast cells and nerve are in constant contact with each other. An enhanced
interaction can lead to neurogenic inflammation. Inflammatory models have shown a
significant increase in the number of mast cells resulting in the increased release of
inflammatory mediators upon degranulation. This could lead to an enhancement of the
mast cell-nerve association.
Inflammatory mediators may modulate sensory nerves in the airways through the
activation of receptors on nerve terminals. NANC nerve endings express receptors for
histamine (H1 and H3) and serotonin (5-HT2A) (60-62). Under inflammatory-like conditions,
it has been shown that primary NANC nerves show an upregulation of at least histamine H1
receptor expression (63). A recent report by Shubabey and Myers (64) provide evidence of
TNF-α receptor expression TNFR1 and TNFR2 in DRG neutrons in adult rat. Both receptor
subtypes were upregulated in DRG neurons during inflammation. Capsaicin-sensitive nerves
can be altered in this way that could result in an increased release of neuropeptides.
Allergen/hapten challenge can also lead to substance P production in a subset of sensory
nerve fibers that are typically devoid of neuropeptides. In other words, allergen/hapten
challenge leads to a phenotypic switch in the sensory neuropeptide innervation in the
airways probably via mast cell activation (65, 66) again increasing the interaction between
mast cells and substance P-immunoreactive nerves. Thus, mast cell activation is able to
increase the excitability of sensory nerves, the neuropeptide production and secretion.
In summary, the mast cell-nerve communication may amplify and spread the
inflammatory response that may contribute to the pathogenesis of airway diseases.
Figure 1: Mast cell-nerve interactions. Inflammatory mediators may modulate sensory nerves in the
airways through the activation of receptors on nerve terminals. Neuropeptides can stimulate mast cells
via a receptor-dependent and a receptor-independent mechanism. Under inflammatory-like conditions,
receptor expression on nerve endings and on mast cells can be upregulated.
TNFR 1,25HT-2aPAR 1,2
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histamine
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Sensory nerves in human airways
Human airways are found to be less densely innervated with substance P-immunoreactive
nerves compared to rodent airways (67). However, the pattern of innervation might change
during inflammation. A striking increase in substance P-immunoreactive nerves was reported
in the airways of patients with fatal asthma (68). Several human studies suggest that
tachykinins are present in increased amount in asthmatic airways. (68-70). In addition,
tachykinin levels have shown to be elevated during exacerbations of asthma (71). Although
human aiwarys are less densely innervated with substance P-immunoreactive nerves, it is
clear that tachykinins are involved in the pathogenisis of asthma.
Immune cells as a source of substance P
Although classically neuropeptides are released from autonomic and sensory nerves, there
is increasing evidence that they may also be synthesized and released from inflammatory
cells, particularly in disease. Immune cells could represent an additional source of tachykinins
in inflamed tissues, providing a non-neurogenic tachykininergic contribution to the local
inflammatory process (72). Non-neuronal cells of the immune system such as monocytes,
macrophages, T lymphocytes and eosinophils have shown to produce endogenous substance
P (73-76). This alternative source of substance P, although not further addressed in this
thesis, could be involved in the development of both atopic and non-atopic asthma.
Nerve-immune interactions
In this thesis, we mainly discussed nerve-mast cell communication and its relation to
asthma. It should be mentioned that similar pathways may, and likely do exist in which
other cells of the immune system may have analogous modes of interaction. Besides mast
cells, neural contact can also occur between nerves and for instance eosinophils or plasma
cells (4, 77). In addition, neuropeptides from sensory nerves can directly modulate the
function of langerhans cells. Among these neuropeptides, the tachykinins have been shown
to modulate immune functions such as cytokine production and cell proliferation (78, 79).
4. In vivo versus in vitro
The present thesis describes both in vivo and in vitro studies. In vitro findings can be used
to clarify in vivo observations and visa versa. However, in vivo and in vitro observations
may not always be complementary.
In this thesis, the most striking difference between the in vivo and in vitro observations is
the role of the NK-1 receptor in mast cell activation. The studies described in chapter 2
show suggest that the NK receptors were not involved since NK-receptor antagonists were
not able to block mast cell activation. However, chapter 7 provides clear evidence for the
inducible expression of NK-1 receptors on BMMC in response to IL-4 and SCF. Additionally,
this NK-1 receptor expression is accompanied by enhanced sensitivity/activation of the
mast cell to stimulation by substance P. Furthermore, in vitro mast cell activation could be
blocked partially by an NK-1 receptor antagonist. The in vitro data prompted the hypothesis
that proinflammatory conditions could be sufficient to induce NK-1 receptor expression on
mast cells in vivo. The in vivo data, however, do not support this hypothesis. There are
several possible explanations for this.
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Mast cell activation was determined by measuring mMCP-1 in serum and is released
by mast cells throughout the whole body. DNS challenge was applied intranasally and
changes in mast cell activation were expected to occur predominantly in the airway. NK-1
receptor expression, therefore, might be induced only locally in the inflamed area. It is
possible that the mMCP-1 release from the airway mast cells may not be sufficient to
significantly increase serum mMCP-1. This implies that NK receptors may be involved in
the mast cell activation described in chapter 2 of this thesis, but it was not observed due
to a lack of sensitivity in the assay method used.
On the other hand, the NK-1 receptor antagonist could have inhibited the release of
mediators other than mMCP-1 from mast cells. Low doses of substance P can cause the
secretion of TNF-α from mast cells (57), which may have been prevented by the NK-1
receptor antagonist.
Alternatively, mast cells can exist in various phenotypic states and therefore differ
in their response to non-immunological stimuli such as substance P. It is possible that
phenotypic heterogeneity between the mast cells present in the airways of DNFB-sensitized,
DNS challenged mice and the primary cultured BMMC explains the differences in mast cell
responsiveness to substance P.  NK-1 receptor expression can be upregulated in inflamed
conditions when levels of IL-4 and SCF are elevated. It is possible that IL-4 and SCF levels
are not increased in the animal model used for the experiments described in chapter 2.
It is also likely that there are more pathways involved in the in vivo studies in
chapter 2. Possibly, DNS challenge does not just activate mast cells. For instance, DNS
might cause the release of inflammatory mediators from other immune cells or the direct
release of neuropeptides other than only substance P from sensory nerve endings. In this
way mast cells can also be activated by other stimuli that do not activate the cell via the
NK-1 receptor. Therefore, it is postulated that in the employed model, the NK-1 receptor is
crucial but parallel to or downstream from mast cell activation.
Summarizing, the increased expression of NK-1 receptors on mast cells, leading to
an increased sensitivity to substance P, is an interesting in vitro observation that may be
very relevant in inflammatory conditions. A more sensitive detection method for determining
local mast cell activation in vivo is necessary to resolve the discrepancy between in the in
vivo and in vitro observations.
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Samenvatting
Mestcellen en sensorische zenuwuiteinden bevinden zich dicht bij elkaar in het lichaam. Er
is echter nog weinig bekend over de communicatie die tussen deze twee deze celtypen
plaatsvindt. In dit proefschrift is gekeken naar de rol van mestcellen en zenuwen en hun
interactie bij de ontwikkeling van astma.
Astma
Astma is een longaandoening die gepaard gaat met een chronische ontsteking. Dit leidt
tot overgevoeligheid voor specifieke en niet-specifieke prikkels (zoals koude lucht en
tabaksrook). Astmapatiënten zijn grofweg onder te verdelen in twee groepen. Bij de eerste
groep is astma geassocieerd met atopie of allergie. De tweede groep patiënten is niet-
atopisch of niet-allergisch. De aan- of afwezigheid van allergeen-specifieke antistoffen
(Immunoglobuline E: IgE) in het bloed is het belangrijkste criterium van verschil tussen
de twee groepen.
In dit proefschrift is met name gekeken naar de niet-atopische vorm van astma.
Van verbindingen als isocyanaten (verfmiddelen), persulfaat (kappersmiddelen) en houtstof
is bekend dat zij astma kunnen veroorzaken via een IgE-onafhankelijk mechanisme. Deze
verbindingen (zogenaamde haptenen) hebben een laag molecuulgewicht en zijn daardoor
te klein om zelf allergeen te zijn. Door binding aan lichaamseigen eiwitten onstaat een
complex dat een immuunreactie van het afweersysteem teweegbrengt en in staat is astma
te veroorzaken.
Muismodel voor niet-atopisch astma
In ons laboratorium is een muismodel voor astma ontwikkeld op basis van de laag
moleculaire verbinding dinitrofluorobenzeen (DNFB). Via een eerste toediening op de huid
(sensibilisatie) en een tweede toediening via de longen (challenge) wordt een
ontstekingsreactie in de luchtwegen uitgelokt, die veel overeenkomsten vertoont met de
situatie in de mens.
De mestcel in het muismodel voor niet-atopisch astma
Mestcellen bevinden zich in alle weefsels van het lichaam en bevatten een groot aantal
biologisch actieve stoffen waaronder histamine, serotonine en tumor necrosis factor alpha
(TNF-α). In het muismodel vervult de mestcel een centrale rol. Gespecialiseerde witte
bloedcellen, de B cellen, produceren vrije lichte ketens nadat het lichaam in aanraking is
gekomen met het hapteen (in het model is dit DNFB). Dit proces wordt ook wel sensibilisatie
genoemd. Deze vrije lichte ketens hechten aan een specifieke receptor op het celoppervlak
van de mestcel. Na een tweede contact (de challenge) wordt het hapteen herkend door de
lichte ketens, die gebonden zijn aan de mestcel. De mestcel wordt dan geactiveerd waardoor
stoffen worden vrijgezet, die de bloedvaten verwijden (zie figuur 1). Deze biologisch actieve
mestcelmediatoren veroorzaken allereerst een vroege reactie en zetten mede een cascade
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van reacties in werking die uiteindelijk leiden tot een late ontstekingsreactie 24 tot 48 uur
na het tweede contact met het hapteen.
Figure 1: Mestcelactivatie via Ig lichte ketens
In hoofdstuk 2 zijn de reacties op een rij gezet die optreden in het dier na
sensibilisatie en challenge met DNFB. Een niet-specifieke hyperreactiviteit
(overgevoeligheid) van de trachea (luchtpijp) en een ontsteking van de luchtwegen worden
waargenomen. Het laatst genoemde wordt gekarakteriseerd door een toename van het
aantal ontstekingscellen, met name neutrofiele granulocyten.
Vervolgens is gekeken naar deze overgevoeligheidsreacties in mestcel-deficiënte
muizen (deze muizen hebben van nature geen mestcellen). Hoofdstuk 3 laat zien dat in
mestcel-deficiënte muizen geen luchtwegovergevoeligheidsreacties te meten zijn. Door
het inspuiten van mestcellen in deze muizen keert deze overgevoeligheid weer terug.
Samenvattend wordt in hoofstuk 3 aangetoond dat de mestcel een centrale rol speelt in
ontwikkeling van niet-atopisch astma.
Tumor necrosis factor alpha (TNF-α)
TNF-α is een ontstekingscytokine dat geproduceerd en vrijgezet wordt door verschillende
cellen, waaronder de mestcel. TNF-α spiegels zijn verhoogd in de longspoeling van niet-
atopische muizen kort na challenge (hoofdstuk 5) en dit TNF-α is zeer waarschijnlijk
afkomstig van de mestcel. Op verschillende  manieren is aangetoond dat TNF-α een
belangrijke mediator is, die betrokken is bij de pathogenese van astma. Allereerst leidt
rechtstreekse toediening van TNF-α via de neus in de luchtwegen van muizen, tot infiltratie
van neutrofielen en de ontwikkeling van tracheale hyperreactiviteit (hoofdstuk 6). Daarnaast
is gebleken dat toediening van antilichamen tegen TNF-α aan muizen behandeld met DNFB,
de ontwikkeling van astmatische karakteristieken sterk kan reduceren. Deze twee studies
geven duidelijk aan dat TNF-α een cruciale mediator is, die betrokken is bij de pathogenese
van astma.
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Substance P
Sensorische zenuwen geven signalen van de luchtwegen door aan de hersenen. Een bepaald
soort sensorische zenuwen brengen specifieke neuropeptiden tot expressie, de tachykininen.
Substance P is een belangrijk tachykinine waaraan in dit proefschrift aandacht is besteed.
Substance P werkt voornamelijk via de activatie van de neurokinine 1 receptor (NK-1
receptor). Tachykininen kunnen direct luchtwegovergevoeligheid veroorzaken (hoofdstuk
6) of daaraan bijdragen via een indirect mechanisme bijvoorbeeld door de
vaatdoorlaatbaarheid te verhogen. Hoofdstuk 4 laat zien dat blokkade dan wel genetische
afwezigheid van de NK-1 receptor de ontwikkeling van tracheale hyperreactiviteit en de
infiltratie van neutrofielen in de luchtwegen remt. Verder wordt aangetoond dat tachykininen
receptoren niet betrokken zijn bij het activeren van mestcellen.
Na DNFB sensibilisatie en challenge worden mestcellen geactiveerd en
mestcelmediatoren, zoals TNF-α, zouden mogelijk sensorische zenuwen kunnen prikkelen
tot de vrijzetting van tachykininen (substance P). Substance P activeert vervolgens NK-1
receptoren die onder andere aanwezig zijn op endotheelcellen. Endotheelcellen vormen de
bekleding van de bloedvaten. Door het activeren van de NK-1 receptor wordt een cascade
van reacties in gang gezet. Uiteindelijk ontstaan er zowel gaatjes in als tussen
endotheelcellen waardoor plasma zich kan verplaatsen richting het weefsel (vasculaire
oedeemvorming) en ontstekingscellen, zoals neutrofielen, makkelijker infiltreren in het
weefsel. Ook verhogen substance P en TNF-α de aanwezigheid van adhesiemoleculen
waardoor de infiltratie van neutrofielen wordt versterkt. Neutrofielen spelen een belangrijke
rol bij de inductie van tracheale hyperreactiviteit. Wanneer je deze cellen uit het lichaam
verwijdert, leidt dit tot een duidelijke afname in hyperreactiviteit (hoofdstuk 6).
NK-1 receptor expressie in vitro
Substance P kan mestcellen activeren. Door mestcellen kort in kweek te brengen met de
cytokines interleukine 4 (IL-4) en stamcelfactor (SCF) wordt hun gevoeligheid voor
substance P verhoogd. Verschillende onderzoekers hebben laten zien dat substance P direct
aan kan grijpen op G-eiwitten, die zich bevinden aan de binnenkant van de celmembraan
en op deze manier stimulatie van de cel teweeg kan brengen zonder tussenkomst van een
receptor. In hoofdstuk 7 wordt echter beschreven, dat onder invloed van IL-4 en SCF de
expressie van de NK-1 receptor op de mestcel toeneemt. Het aantal NK-1 positieve cellen
neemt toe met de tijdsduur van de cocultuur. De verhoogde gevoeligheid van de mestcel
voor substance P zou dus een gevolg zijn van de toename in NK-1 receptoren. Blokkade
van de NK-1 receptor of  genetische afwezigheid van de NK-1 receptor leidt tot een lagere
gevoeligheid van de mestcel voor substance P. Deze observatie versterkt de bewering dat
de NK-1 receptor van belang is bij het activeren van de mestcel door substance P.
Interactie in vitro: van zenuw naar mestcel
Met behulp van electronenmicroscopie is aangetoond dat substance P ook in vivo in staat
is om mestcellen te activeren (hoofdstuk 8). Mestcellen en neuronen zijn vervolgens samen
gekweekt om hun directe interactie te onderzoeken. Na korte tijd samen in kweek te zijn
(± 2 dagen), hechten de twee aan elkaar. Wanneer de neuron wordt gestimuleerd tot de
afgifte van zijn neuropeptiden, waaronder substance P, reageert de mestcel hierop door
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ook zijn mediatoren vrij te zetten (hoofdstuk 8). Dit bewijst een directe interactie van de
neuron naar de mestcel zonder de tussenkomst van een andere cel of ander mechanisme.
Een belangrijk gegeven is dat de mestcel niet geactiveerd wordt wanneer deze niet in
contact is geweest met de cytokines IL-4 en SCF. Ook vindt er geen activatie plaats in
mestcellen die geen NK-1 receptor bezitten. Ook uit deze studie blijkt dat de NK-1 receptor
belangrijk is bij de interactie tussen mestcellen en sensorische zenuwen.
Figure 2: Interactie tussen de mestcel en de sensorische zenuw. Ontstekingsmediatoren uit de mestcel kunnen
sensorische zenuwen stimuleren via de activatie van receptoren op de zenuwuiteinden. Neuropeptiden vrijgezet
door sensorische zenuwen kunnen mestcellen activeren via een receptor-onafhankelijk en een receptor-afhankelijk
mechanisme. Tijdens ontsteking kan het aantal receptoren op mestcellen en sensorische zenuwen toenemen
waardoor de interactie tussen de twee wordt versterkt.
Conclusie
Samengevat is in dit proefschrift uiteengezet dat de mestcel en de sensorische zenuwen
beide een belangrijke rol spelen in de pathogenese van niet-atopisch astma. TNF-α is een
belangrijke mestcelmediator gebleken, die betrokken bij de ontwikkeling van niet-atopisch
astma. De NK-1 receptor, de receptor voor substance P, is cruciaal bij de ontwikkeling van
deze vorm van astma. De NK-1 receptor is ook belangrijk gebleken bij de interactie tussen
de mestcel en de zenuw. In vitro is aangetoond dat de mestcel NK-1 receptoren tot
expressie brengt onder invloed van de cytyokinen IL-4 en SCF. Dit resulteert in een toename
in gevoeligheid van mestcellen voor de stimulus substance P. Daarnaast is in een in vitro
systeem duidelijk geworden dat de NK-1 receptor op de mestcel belangrijk is bij de
rechtstreekse interactie van de zenuw met de mestcel.
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te noemen danwel te illustreren. Wel wil ik er een aantal
van noemen.....
Allereerst de analysten die hebben geholpen bij het uitvoeren
van experimenten. Corien, Mirjam en Saskia, bedankt voor
jullie hulp. Ook Andrys hoort hierbij maar die wil ik toch
zeker ook bedanken voor zijn gezelligheid en bovenal zijn
friese wijsheden en uitspraken (stoklebberen?). Anneke van
Houwelingen, ik vond het leuk met je  samen te werken en
bedankt ook voor jouw hulp tijdens de schrijfperiode
(pagemaker??). Nog meer computer hulp van Robert en
Joost (voorheen W041A), even thee zetten en meteen nog
even wat dingen vragen. Over computerhulp gesproken:
Martijn Pieck, naast het ontwerpen van de kaft wil ik jou
graag bedanken voor je hulp wanneer het weer eens fout
ging bij het maken en/of printen van pfds.
En verder in het kort: de hele fff bedankt voor inhoudelijke
hulp, discussies, luisterende oren wanneer dat nodig was,
congresplezier, etentjes etc. en natuurlijk de befaamde
borrels. Bedankt voor vele gezellige avonden, vaak weinig
inhoudelijk maar wel leuk.
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John
It was a great experience to work in your
lab. I learned a lot during my stay in
Canada. Thank you for giving me the
opportunity to write the chapter. I enjoyed
working with such a unique person and I
am happy to have you in Utrecht for my
promotion.
In this part of my thesis there is some space to address
my gratitude to everybody in Canada!
3N11B: Donglai and Gudrun for helping me with my
experiments and all the gezelligheid (finally something
really dutch, specially for Bob), Peter, Claire, Michelle,
Sylvia, Ramez. Angie, thank you for everything (from the
little green bike to all the talks we had, you are great).
Furthermore,  the confocal people for their help with my
experiments (finally it worked!). Thanks as well to the
people at St.Joes hospital for their help and the
opportunity to do experiments in their lab.
And not to forget, friends from inside and outside the
university for a terrific time!
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Ale, Abbiamo condiviso insieme una parte
della nostra esperienza
canadese. Mi manchi.
Saad, Thanks
for everything!
Meta. Wanneer gaan            we weer eens
een avondje stappen
in Toronto!
Canada
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(Super) Pap en Mam, jullie staan altijd
voor me klaar. Ik weet hoe trots jullie
op mij zijn en dat ben ik ook op jullie!
Familie
Paranimfen: Huib en Emmeke.
Ik ben blij dat jullie de taak van paranimf zo
enthousiast op jullie wilde nemen.
Huib, naast mijn (grote) broer nu ook mijn
paranimf. Jij hebt niet voor niets een dubbelrol.
Em, niet alleen mijn paranimf maar je bent ook
nog van de catering en mijn persoonlijke kapster
(3-dubbel op!). Veelzijdigheid en vrij gezelligheid
maken jou speciaal!
Esther, Jan en Sjors. Tijdens mijn schrijfperiode
een regelmatige en welkome afleiding.
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Tenslotte
wil ik vrienden, collegas en familie bedanken voor alle nodige ontspanning ...................
etentjes, biertjes/martinis, squashpartijtjes, dansjes, pijltjes gooien, bioscoopbezoeken
etc.
Abbreviations
BAL bronchoalveolar lavage
BMMC bone marrow-derived mast cell
BMMC→W/Wv mice mast cell reconstituted mast cell-deficient mice
CGRP calcitonin gene-related peptide
CTMC connective tissue type mast cells
DNFB dinitrofluorobenzene
DNS dinitrobenzene sulfonic acid
EC50 concentration agonist that induces 50% of the maximal response
ELISA enzyme-linked immunosorbent assay
Emax maximal response
FACS fluorescent adhesion cell sorter
IFN interferon
Ig immunoglobulin
IL interleukin
LC light chain
MMC mucosal mast cells
mMCP-1 mouse mast cell protease 1
NANC non-adrenergic non-cholinergic
NGF nerve growth factor
NK neurokinin
pD2 -log EC50
PenH enhanced pause
SCF stem cell factor
SEM standard error of the mean
TNF-α tumor necrosis factor alpha
TNFR1,2 tumor necrosis factor alpha receptor1,2
